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Abstract 
Ulcerative colitis is a relapsing and remitting inflammatory bowel disease involving 
the large bowel. The current hypothesis on the pathogenesis of UC is that an 
abnormal innate immune response in genetically susceptible individuals, combined 
with environmental factors, result in excessive activation of the adaptive immune 
system within lamina propria. The role of abnormal barrier function is widely 
accepted. Using transcriptomic analysis of punch biopsies of patients with quiescent 
UC, CLDN8 was identified as grossly downregulated in the intestine. In this thesis, 
loss of Cldn8, a tight junction (TJ) molecule, was shown to result in reduced 
susceptibility of mice to DSS-induced colitis. Cldn8 knock out (Cldn98-KO) mice, had 
smaller increase in intestinal permeability to 3H-mannitol, reduced neutrophils and 
macrophages in inflammatory cell infiltrate in lamina propria during the early phase 
of inflammation. The inner layer of mucous is sterile in naïve Cldn8-KO and WT mice, 
and remains sterile after the animals have been exposed to DSS-water for 12 hours. 
Transcriptomic analysis between Cldn8-KO and WT mice did not reveal any 
significant differences between the two groups at different time points. After 
correction for multiple-testing, no differentially-expressed genes remained. These 
results suggest that downregulation of CLDN8 in patients with UC is a physiologic 
response by the intestine to increase local defences against luminal pathogens. 
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1 Introduction 
1.1 NORMAL INTESTINAL HOMEOSTASIS 
The gastrointestinal (GI) tract is a unique organ, responsible for ingesting, digesting 
and absorbing food, followed by excretion of waste as faeces. Along with food mater, 
significant quantities of exogenous microorganisms, such as bacteria, fungi and 
viruses also enter. Over the course of evolution, the GI tracts has developed several 
mechanisms to protect against invasion by pathogens. 
1.1.1 MICROBIOME 
The healthy GI tract is populated by a commensal microbial community known as the 
microbiome. Genome sequencing of the human microbiome has identified 
approximately up to 1,500 species and 3 x 106 genes (1), although on average the 
microbiome of individuals contains only 160 bacterial species, indicating a 
substantially varied microbiome component among individuals (2,3). Environment 
factors play a significant role in different microbiome compositions between 
individuals; even mice with same genetic background, housed in different cages in 
the same facility have different microbiome composition (4). 
The intestine is sterile prior to birth and is colonised afterwards. In adult humans, the 
bacterial load and diversity increases towards the distal intestine, and reaches its 
maximum in the colon, with 1011-1013 organisms per gram of faeces, compared to 
107-108 in the terminal ileum (TI) or 103-104 in proximal bowel (5). 
The host and the microbiota have a mutually beneficial symbiotic relationship that is 
important for development and maintenance of normal gut homeostasis. The host 
provides nutrients and breeding environment, whilst the commensal bacteria support 
host metabolism and the development of the intestinal immune systems. For 
example, commensal bacteria can produce vitamins B and K (6) as well as providing 
the host with a source of energy by digesting dietary fibre to Short Chain Fatty Acids 
(SCFA) such as acetate, propionate and butyrate as end products (7,8). Recent 
evidence indicated that commensal bacteria may also influence host immunity by 
directly interacting with intestinal cells or producing several metabolites, including 
adenosine triphosphate (ATP) (9). 
The commensal microbiota play an essential role in protecting the host from 
pathogenic invaders and limiting the colonisation of the intestine by pathogens 
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(10,11). Many intestinal bacteria not only produce antimicrobial compounds but also 
compete for nutrients and attachment sites in the intestine, thus preventing 
colonisation with pathogenic organisms. There is evidence that commensal bacteria 
compete for attachment sites on epithelial cells with pathogenic entero-invasive 
bacteria, thus preventing the attachment and subsequent entry of such bacteria into 
the host (12). Additionally, because bacteria compete for nutrients in their immediate 
surroundings, the commensal bacteria can outcompete pathogenic bacteria for 
resources by sheer force of numbers (13,14). Moreover, resident non-pathogenic 
bacteria can inhibit the growth of their competitors by producing antimicrobial 
substances known as bacteriocins, and the ability to synthesize these bacteriocins is 
widely distributed among gastrointestinal bacteria (14,15). 
1.1.2 THE INTESTINAL MUCOSAL BARRIER 
The host immune system must tolerate the microbiota, whilst remaining effective 
against threats posed by the microorganisms. The challenge is complicated by the 
dynamic nature of the microbiota composition, which is influenced by a wide variety 
of factors, such as dietary changes (16), antibiotic treatment (17), as well as other 
pathogens in the GI tracts (18). 
To protect the host, the GI tract has developed several mechanisms, which can be 
broadly classed as anatomical containment and sensing the luminal environment.  
1.1.2.1 Anatomical Containment 
Physical barrier 
The physical barrier consists of the mucous layer and the Intestinal Epithelial Cells 
(IECs) themselves. Mucous is the first line of defence against pathogens in the 
intestine. It is a viscous gel-like fluid, secreted by goblet cells, and it is enriched by 
mucin glycoproteins that form large net-like polymers. There is evidence that mucous 
secretion is regulated by intestinal microbes or their metabolites (19–22). 
The mucous has slightly different properties across the GI tract. In the small intestine, 
the mucous consists of one layer, but in the colon, it is composed of two layers; a 
slightly looser outer layer, and an inner layer that is firmly attached to the IECs. The 
thickness of the mucous increases distally towards the distal colon (Figure 1-1) (23). 
Notably, whilst the outer layer contains large number of intestinal microbes, the inner 
layer is normally sterile in healthy individuals (24). 
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Figure 1-1 – Mucous thickness measured throughout the gastrointestinal tract 
of rat – Adapted from Atuma et al (25) 
 
Chemical barrier 
In the small intestine, Paneth cells produce Anti-Microbial Proteins (AMP) and 
defensins and RegIIIγ that are thought to be responsible for protection of mucous 
from invasion of pathogens (26,27). Secretory IgA is produced by plasma cells, and 
is released in the lumen after transcytosis (28). However, there are no Paneth cells 
in the healthy colon, and it is unclear what molecules are responsible for protection 
of the inner layer of mucous in the large intestine. There is recent evidence that a 
protein called Lypd8 may play a vital role in the colon. Lypd8 is anchored to the IECs, 
and constitutively released into the mucous, binding flagellated bacteria, such as 
Escherichia, Proteus and Helicobacter, inhibiting their invasion of the IECs (29). 
1.1.2.2 Mucosal immune system of the large bowel 
The mucosal immune system is in direct contact with the external antigenic 
environment. This section is primarily concerned with the mucosal immune system 
in the large bowel. The mucosal immune system consists of several parts: the 
immune effector, and the immune inductive sites. The immune effector site is made 
up of the intraepithelial lymphocytes (IELs) and immune cells within lamina propria 
(see below). The immune inductive sites, also known as GALT (Gut associated 
lymphoid tissue), are organised lymphoid structures consisting of B-cell follicles with 
germinal centres surrounded by a T-cell zone.  
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1.1.2.2.1 Gut Associated Lymphoid Tissue 
GALT follicles sometimes exist as aggregated forms, such as Peyer’s patches in the 
small intestine, caecal and colonic patches. There are also hundreds of isolated 
lymphoid follicles scattered throughout the small intestine and colon (30). 
Follicle-associated epithelium and M cells 
GALT receives its supply of antigens from the mucosal surface across the overlying 
intestinal epithelium called, ‘follicle-associated epithelium’ (FAE) (31). FAE has 
several unique features when compared with other intestinal epithelial cells, to enable 
its function, enabling close association with luminal bacteria and antigens. FAE is 
almost devoid of goblet cells and has few Paneth cells in the crypts surrounding FAE. 
Moreover, the expression of the IgA-transporting polymeric immunoglobulin receptor 
is low on enterocytes in and around the FAE. A particularly unique feature of FAE is 
the presence of M cells. M cells are highly active in phagocytosis and transcytosis, 
and thereby take up luminal bacteria and antigens and deliver them to DCs in the M-
cell pocket for initiation of mucosal immune responses. M cells have low lysosomal 
activity, suggesting they  able to transfer intact antigens to DCs in lamina propria, 
which then process and present the antigens (32). 
1.1.2.2.2 Intraepithelial lymphocytes (IELs) 
IEL are a subset of T lymphocytes that reside interspersed between epithelial cells. 
These cells are separated from adjacent enterocytes by a 10 to 20 nm space, and 
these lymphocyte-epithelial cell contacts have no junctional structure (33).  
Hayday and colleagues propose classifying IELs into two cell types: a and b. Type a 
includes TcRαβ+ cells that primarily recognize antigens presented by conventional 
MHC class I and II, and are primed within the systemic circulation. Type b cells 
includes TcRαβ+ CD8αα+ IEls and TcRγδ+ IELs, that respond to antigens not 
restricted by conventional MHC. Type b cells do not recognise antigens presented 
by MHC on professional antigen presenting cells, and it is thought that they are 
primed by epithelial cells in situ (34). 
1.1.2.2.3 Lamina Propria (LP) and the draining Mesenteric Lymph Nodes (MLNs) 
The LP is the layer of connective tissue between the epithelium and the muscularis 
mucosa. It is made up of smooth muscle cells, fibroblasts, lymphatics and blood 
vessels (35). Cells from both innate and adaptive immune system populate the LP. 
During healthy state, the LP is primarily populated by ILCs, lymphocytes, 
mononuclear phagocytes, as well as a small neutrophil and mast cell population. 
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Innate Lymphoid Cells (ILCs) are a group of innate immune cells and belong to the 
lymphoid lineage. ILCs play an important role in control of intestinal homeostasis by 
producing cytokines in response to stimuli (36). ILCs produce IL-22 and promote 
homeostasis and healing during infection in the gut (37,38). IL-22 can kill targeted 
Gram-positive bacteria by inducing production of RegIIIα by epithelial cells (39). 
There is also evidence that IL-22 can stimulate production of AMP (40). In addition, 
IL-6 derived from ILCs enhances IEC proliferation and contributes to healing from 
mucosal injury (41). When activated, ILCs can produce cytokines such as IFN-γ to 
protect epithelial cells from injury (42,43). 
 
 
Figure 1-5 – Overview of intestinal immune system in health and UC. (a) During 
healthy state, the epithelial cells and the mucous produce a physical barrier to entry 
of luminal pathogens. This is reinforced by chemical barrier that is composed of 
antimicrobial chemicals such as IgA and RegIIIy. Dendritic Cells (DCs) migrate to 
mesenteric lymph nodes (MLNs) where they imprint the resident lymphocytes with 
gut-homing molecules and trigger naïve T-cells to develop into tolerogenic regulatory 
T cells (Treg). (b) In UC, damage to the mucosal allows luminal pathogens to enter 
and initiate an inflammatory response. Adapted from Ungaro et al (44)  
(b) (a)Mucosal injury and inflammationHealthy state
(a) (b)
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Resident Intestinal Mononuclear Phagocytes 
Resident intestinal mononuclear phagocytes (iMNP), as part of the innate immune 
system, are the first line of defence against invading pathogens. iMNPs have 
developed efficient mechanisms to clear bacterial encroachment, as well as 
maintaining epithelial and mucosal homeostasis, whilst orchestrate the host’s 
immune response towards pathogenic organisms. 
Historically, iMNPs have been divided into three cell types: monocytes, Dendritic 
Cells (DCs) and macrophages, with distinct but complementary functions. There is 
increasing understanding and acceptance that this division of cell-type and roles is 
too simplistic (45). 
Intestinal macrophages orchestrate the innate and adaptive immune responses, via 
pattern recognition receptions (TLRs and NOD-like receptors) and various signalling 
pathways (46) . Bone marrow-derived monocytes, which are recruited to the intestine 
from the blood, are the precursors to intestinal macrophages (47). At the beginning, 
these monocytes are pro-inflammatory, before signals from the intestinal mucosa 
modifies them into inflammation anergic resident intestinal macrophages (48). 
Macrophages have incredible plasticity and can adapt their phenotype and function 
based on the signals from their environment. Macrophages positioned just beneath 
the surface epithelium are more tolerogenic than those positioned more deeply in LP, 
and unlike macrophages in other tissues, intestinal macrophages do not have a pro-
inflammation response to microbial stimulation (49,50). Interestingly, despite being 
phagocytic, intestinal macrophages, lack respiratory burst activity (51) or generation 
of nitric oxide (52). Intestinal macrophages also promote the proliferation of epithelial 
progenitor cells through production of produce Prostoglandin E2 (53). 
Another class of iMNPs are DCs, which like the intestinal macrophages, are also 
classed as Antigen-Presenting Cells (APCs). However, unlike intestinal 
macrophages, intestinal DCs continuously migrate to MLNs, where they modulate 
the adaptive immune response, though the mechanism regulating this migration to 
MLN is poorly understood (54). Here, the DCs play two important functions. DCs 
imprint naïve lymphocytes to express gut-homing molecules, α4β7 and CCR9 (55), 
and are also able to drive differentiation of naïve CD4 T-cells into regulatory T-cells 
(Tregs) (56,57). Several mechanisms seem to be responsible in supply of luminal 
antigens to DCs in healthy state. Goblet cells have been proposed to act as a conduit 
of that deliver antigens to DCs (58). Another proposed mechanism is that 
macrophages may acquire antigens by extending transepithelial dendrites, and then 
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transferring the luminal antigens to DCs via gap junctions (59). Whilst there is some 
evidence for this in mice (60,61), it is not known whether human intestinal 
macrophages can also sample luminal antigens in the same way. However, there is 
also evidence that DCs themselves can extend their dendrites through the epithelial 
tight junctions to sample the luminal antigens (62). Interestingly given that DCs 
express tight-junction proteins such as occludin, CLDN1 and ZO-1, the extension of 
their dendrites through the epithelial cells may not compromise the integrity of the 
epithelial barrier. 
Recent evidence suggests that macrophages also regulate the adaptive immune 
response in the gut. Macrophages that are directly positioned beneath the epithelial 
surface are known to be more tolerogenic. This may in part be due to their exposure 
and take up antigenic material, including food and bacterial particulates, as it 
emerges from the basolateral epithelial surface (63). Given their high levels of MHCII 
expression, intestinal macrophages are also considered as APCs (64). Indeed, there 
is evidence that intestinal macrophages drive differentiation of naïve CD4+ T-cells to 
Treg (65). However, there is some debate over how macrophages achieve this, as in 
healthy state, naïve T-cells are absent from the mucosa (66) and intestinal 
macrophages cannot activate naïve T-cells or migrate to MLNs (67). One possibility 
is that intestinal macrophages drive maintenance and expansion of Treg cells that 
have migrated from MLN to mucosa through production of IL-10 (68,69). 
Interestingly, production of IL-10 by intestinal macrophages is increased after 
bacterial stimulation (70,71), with evidence that this is dependent on presence of the 
commensal bacteria in the gut lumen (72). Another possible mechanism, as 
mentioned above, is that macrophages may transfer antigens to DCs, which in turn 
migrate to MLNs. 
Resident Lymphocytes 
In addition to iMNPs, the intestinal LP also contains T-cells and B-cells. Upon 
reaching the intestinal endothelial venules, the gut-imprinted, α4β7 and CCR9 
expressing lymphocytes engage locally expressed MAdCAM, leaving the circulation 
to enter the intestinal LP.  
There are phenotypic and functional differences in lymphoid cells between small 
intestine (SI) and large intestine (LI), which may be due to differences in nutrient 
adsorption and luminal bacterial content (73–75). However, these differences have 
not been fully delineated. For example, there is evidence that in mice, in contrast to 
the small intestine, B-cells are the predominant lymphocyte present in the LP of the 
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large intestine (76). Furthermore, there are variations in the functional state of the 
lymphocytes; for examples, IL-4 producing T-cells have been detected in SI but not 
in LI, and the percentage of IL-2 producing cells was higher in SI than LI as well (77). 
Further differences between SI and LI have been noted in isolated lymphoid follicles 
(ILFs), develop after birth in the small and large intestines (SI and LI) and represent 
a dynamic response of the gut immune system to the microbiota. Unlike ILF in the 
SI, the microbiota inhibits ILF development in the colon (78). The importance of ILFs 
in the LI is related to their ability to produce IgA, which is one of the most important 
molecules in the regulation of intestinal homeostasis. Whilst it has been known that 
B-cells in SI Peyer’s patches produce IgA, it is now recognised that B-cells in ILFs 
carry the same function in the LI. Interestingly, ILF density is inversely proportional 
to CD25+ Treg population (78). 
 
1.1.2.3 Controlling the permeability and homeostasis 
Tight Junctions (TJs) 
In addition to the other functions described above, the IECs also play an essential 
role in intestinal permeability properties and homeostasis, by controlling active 
transcellular and passive paracellular (intercellular) routes. The coordination 
between these two pathways serves as the mechanism that creates cell polarization 
and ensures fluid and solute movement across. 
It is well-established that TJ control paracellular permeability (79–81). TJs are 
complex, charge-selective pores that encircles the apical and lateral surfaces of 
adjacent cells, controlling the paracellular permeability properties (79), with up to 40 
proteins in their structure (82). TJs have four main structural proteins: occludins, 
junctional adhesion molecules (JAM), tricellulin and claudins (CLDN). These 
transmembrane proteins in TJs are connected to the cellular cytoskeleton via their 
PDZ domains, which bind to adaptor proteins such as zonula occludens-1-3, (ZO-1, 
ZO-2, ZO-3), MAGI-1, or MUPP-1 (83,84). ZO molecules directly bind the actin 
cytoskeleton (85) (Figure 1-2). 
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Figure 1-2 – Schematic diagram of a tight junction (TJ). TJs consist of primarily 4 
groups of transmembrane proteins (JAM-1, claudins, occludin and tricellulin). Of 
these, claudins are thought to control the charge-selective properties of TJs. These 
molecules interact with the cellular cytoplasmic structures, such as actin via adaptor 
proteins such as ZO-1 to ZO3, MUPP-1, MAGI and cingulin. 
 
Of the four components of TJs, tricellulin forms a barrier to macromolecules in 
tricellular tight junctions without affecting ion permeability (86), whilst TJ integrity and 
characteristics are independent of occludin (87). Occludin knockout mice have 
normal functioning TJs; however, these mice have significantly reduced chief and 
parietal cells in the gastric mucosa, suggesting that occludin plays a role in cell 
differentiation in certain organs (87). 
Claudins (CLDNs) 
CLDNs are the primary components that control the paracellular permeability 
characteristics of TJs (88–90). So far, 27 members of the CLDN family have been 
identified in mammals (91). CLDNs have a molecular weight between 22-27 kDa and 
are highly conserved across species (90). CLDNs are tetraspan membrane proteins, 
with two extracellular loops. CLDNs controls the charge selectivity of TJs through 
their first loop which contains several charges amino acids, which vary across 
different CLDN molecules (92). The second extracellular loop forms dimers with 
CLDNs on opposing cell membranes (93). The intracellular carboxy-terminal tail, 
which contains a PDZ-interacting domain, has the most heterogeneity amongst 
CLDNs (94). 
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Figure 1-3 – Schematic representation of a CLDN molecule. CLDNs are tetraspan 
molecules with 4 transmembrane domains (TM1 to TM4), two extracellular (EL1 and 
EL2) loops, and carboxy-terminal tail which contains a PDZ-interacting domain. 
Modified from Lal-Nag, et al. (95) 
 
The coding sequences of most mammalian claudin messenger RNAs (mRNAs) are 
encoded by only one exon. However, coding sequences of claudins 1, 7, 10, 11, 15, 
16, 18, 19, and 25 are composed of several exons. For some of these mRNAs, splice 
variants have been reported that result in different protein isoforms. 
The function and role of CLDNs in the intestine are poorly understood. CLDNs have 
been divided into two functional groups of “tight” or sealing CLDNs, and “leaky” or 
pore-forming CLDNs, based on changes to electrical resistance of cultured epithelial 
monolayers after changes to expression of individual CLDNs (see 56 for detailed 
review). The overall properties of the TJ, however, are dependent on the complement 
of other claudins expressed in the TJ. Claudin-1 has barrier-forming properties, and 
important in the TJ integrity (97). Claudin-2 increases paracellular permeability to 
sodium and water (98). Claudin-3 has been classified as barrier forming in the 
intestine, but the converse effect has been reported in lung alveolar epithelia (99). 
Claudin-5 appears to have barrier forming properties (100), whilst evidence for 
Claudin-7 functions is conflicting, and reports of Claudin-7 have been made as an 
anion pore or cation barrier in kidney. In the intestine, Claudin-7 appears to contribute 
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to barrier function, as loss of Claudin-7 increases paracellular movement of small 
organic solutes (101). Claudin-8 reduces permeability to monovalent cations (102). 
Table 1-1 summarises current understanding of the properties of the colonic CLDNs.  
Barrier Cation 1 (103), 3 (104), 4 (105), 5 (106), 8 (102,107,108) 
 Anion 7 (109–111) 
Pore Cation 2 (112,98,113), 12 (113) 
 
Table 1-1 – List of CLDNs expressed in the human large bowel, and their effect 
on the permeability of the TJs 
 
In the intestine, the composition of epithelial claudins varies spatially, both along the 
length of the GI tract as well as in the crypt–luminal axis (114,115), (Figure 1-4). 
However, the mechanism that control this spatiotemporal expression are not 
currently understood. So far, CLDNs 1, 2, 3, 4, 5, 7, 8, and 12 have been described 
in the large intestine (115). 
 
 
Figure 1-4 – Schematic representation of reported claudin expression in the GI 
tracts. (A) Along the intestinal tract. (B and C) Crypt–luminal axis of small and large 
intestine. (D) Membrane distribution in the TJ or in the lateral membrane of intestinal 
epithelial cells. (Cldn, claudin; IECs, intestinal epithelial cells.) – reproduced from 
Garcia-Hernandez et al (115) 
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In addition to their role in controlling barrier function, CLDNs also appear to regular 
epithelial homeostasis, proliferation and differentiation (116,117). The mechanisms 
by which CLDNs influence this homeostasis is poorly understood. It is clear that 
CLDNs respond to intra-cellular and extra-cellular stimuli. Inflammatory mediators, 
such as TNF-α and IFN-γ, regulate CLDN expression. During active inflammation 
there is up-regulation of expression of CLDN2 (118–122), and CLDN12 (118), whilst 
CLDN7 and CLDN8 are down-regulated (119). Reports on CLDN3 and CLDN4 are 
conflicting (119,122,123). Changes in expression levels of various CLDNs have bene 
reported in patients with intestinal inflammation. During an active episode of UC, 
there is up-regulation of expression of CLDN2 (118–122), and CLDN12(118), whilst 
CLDN7 and CLDN8 are down-regulated (119). Reports on CLDN3 and CLDN4 are 
conflicting (119,122,123). Mice models of colitis are more consistent, with reported 
up-regulation of CLDN-2 (124), and down-regulation of CLDN1 (124,125), 3 
(124,125), 5 (124), 7 (124), 8 (124,125). CLDN expression also appears to be 
influenced by inflammatory cytokines such as TNF-α and IFN-γ that are grossly 
elevated in colitis patients (120,121,126). 
Limited information is available on the transcriptional programs that control CLDN 
gene expressions. Almost all CLDNs contain a PDZ binding motif, which associates 
with sub-membrane plaque proteins containing PDZ domains and serve to organise 
TJ structure. However, the mechanisms that control the association between different 
claudins with specific plaque proteins are poorly understood. 
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1.2 ULCERATIVE COLITIS 
Inflammatory bowel disease (IBD) encompasses a collection of chronic relapsing-
remitting inflammatory diseases predominantly affecting the gastrointestinal tract. 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two principal sub-types, the 
aetiologies of which remain poorly understood. 
1.2.1 EPIDEMIOLOGY 
1.2.1.1 Prevalence and Incidence 
The incidence of ulcerative colitis is 1.2 to 20.3 cases per 100,000 persons per year, 
and its prevalence is 7.6 to 246.0 cases per 100,000 per year, as compared with an 
incidence of 0.03 to 15.6 cases and a prevalence of 3.6 to 214.0 cases per 100,000 
per year for Crohn’s disease (127). The highest incidence and prevalence of 
inflammatory bowel disease are seen in the populations of Northern Europe and 
North America (128), and lowest in continental Asia (129), and the incidence and 
prevalence has been raising globally over the last few decades (128). 
No sex predominance exists in UC (130–132), and the peak age of onset is in the 
third decade of life, with a second peak in the sixth decade (132,133). Both the 
prevalence and incidence of UC has been increasing world-wide over the last century 
(128), with the highest incidents in northern and western Europe, Canada and 
Australia (128,130,134). The risk of developing ulcerative colitis in children of 
migrants from low-incidence to high-incidence countries is similar to non- immigrants 
(135–137). The trend is also reported in Asia, Middle East and South America (138–
141); however, this may be confounded by increasing awareness of UC in these 
countries. 
1.2.2 PATHOGENESIS 
Existing literature often describes the pathogenesis of UC and CD together, although 
important differences exist. The current prevailing hypothesis for pathogenesis of UC 
is that an abnormal innate immune response in genetically susceptible individuals, 
combined with environmental factors, result in excessive activation of the adaptive 
immune system within LP (142,143). 
1.2.2.1 Genetic features 
There is evidence that differences exist between ethnic populations (144), with higher 
incidents of UC in Caucasians (145) and the Ashkenazi Jewish Population (146). The 
concordance rate of UC is 15.4% in monozygotic twins and 3.9% in dizygotic twins 
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(147). There is a genetic susceptibility, with first-degree relatives of patients with UC 
at higher risk of developing the disease (148,149).  
Genome-wide association studies (GWAS) have so far identified 163 risk 
susceptibility loci in patients with IBD, of which 110 are shared between UC and CD, 
and 23 are specific to UC (150). A number of these loci specific to UC are implicated 
in barrier function and epithelial restitution. These genes include CDH1 (cadherin 
type 1, a major component of the adherens junction and an important mediator of 
intercellular adhesion and mucosal repair (151), LAMB1 (laminin-β1 subunit, 
expressed in the intestinal basement membrane (152), HNF4A (hepatocyte nuclear 
factor-4α, a transcription factor which regulates expression of key components of the 
cell-cell junction). Several risk loci linked to other immune system–mediated diseases 
are associated with ulcerative colitis, particularly HLA-DR and genes involved in 
helper T-cell types 1 and 17 (Th1 and Th17) differentiation, such as IL-10, IL-7R, IL-
23R, and IFN-γ (153). 
NOD2 
The first genetic variant significantly associated with CD was discovered in the gene 
encoding nucleotide-binding oligomerization domain 2 (NOD2), located on 
Chromosome 16q12 (154,155). Individuals heterozygote for one of the NOD2 
variants have a two- to four-fold risk of developing CD, whilst individuals’ homozygote 
or compound heterozygote have a 20-40 fold risk (156). What is striking is that whilst 
NOD2 frameshift mutations confer a higher risk of developing CD (Odds Ratio 5.576, 
p value < 1.62 x 10-10), it confers protection against developing UC (OR 0.8332, p 
value = 0.2365) (157). Even though this did not reach statistical significance in UC, it 
highlights important differences in pathophysiology between CD and UC. 
1.2.2.2 Environmental features 
In addition to genetic variations between ethnic populations, it is now well established 
that the incidence increases with a westernised lifestyle and diet (158–160). Smoking 
confers protection against UC, with patients having milder disease, reduced need for 
medication and hospital admission (161). Appendisectomy also confers protection if 
performed early in life (162).  
1.2.2.3 Dysbiosis 
Dysbiosis, the imbalance of the gut microbiome, may disturb the delicate balance of 
commensal-host homeostasis, and either result or predispose to inflammation (163). 
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Dysbiosis is present in patients with IBD as characterised by a higher ratio of 
pathogenic to commensal bacteria (164), and there is evidence that the density of 
microbiota is greater in patients with UC or CD than in healthy control subjects (165). 
While the gut microbiota in healthy subjects show little temporal change, the gut 
microbiota in IBD patients appear to be unstable (166). The composition of the gut 
microbiota also differs between active and quiescent stages. A longitudinal study of 
the gut microbiota in UC patients, conducted for one year, demonstrated that the gut 
microbiota was unstable in patients with UC even in remission (167). Before relapse 
of UC, normal anaerobic bacteria such as Bacteroides, Escherichia, Eubacterium, 
Lactobacillus and Ruminococcus are decreased and the gut microbiota is also 
reduced (168). 
Moreover, medication also affects the composition of the gut microbiota. Mesalazine, 
for example, reduces the total bacterial number to almost half (169). A recent study 
of intense Faecal Microbiota Transplantation (FMT) in patient with UC showed some 
clinical efficacy (27% steroid-free in FMT group vs 8% in placebo group) (170). In 
patients with CD there is also ample evidence that modulation of bacteria with 
antibiotics such as ciprofloxacin is beneficial (171). 
Currently, whether dysbiosis is a cause of effect of inflammation and medication in 
patients with IBD is unclear. 
1.2.2.4 Epithelial barrier defect 
The epithelial cells in the colon (colonocytes) and the mucous are strongly implicated 
in the pathogenesis of UC. The colonocytes in patients with UC have reduced 
expression levels of PPAR-g, a negative regulator of NF-kB-=dependent 
inflammation (172,173). These patients also have depleted goblet cells in their colon 
(174). This is consistent with a reported reduction in trefoil factors, a family of goblet 
cell derived proteins that are produced in response to mucosal injury and are thought 
to play a part in mucosal barrier integrity (175,176). 
Whilst the inner mucous layer in colon is sterile and impenetrable to bacteria in 
healthy individuals, in patients with UC, bacteria can penetrate and reach the 
epithelial cells (174), suggesting a fundamental reduction in barrier function of the 
epithelial cells and the mucous in patients with UC. This is in keeping with evidence 
of increased permeability in colon of patients with UC, even during the quiescent 
state (177,178). The evidence that abnormal permeability may trigger inflammation 
has been supported by animal studies as well (179). 
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1.2.2.5 Aberrant immune response 
There is increasing evidence that UC and CD develop from different immune 
abnormalities.  
In a series of studies, Professor Segal has demonstrated impaired influx of 
granulocytes into skin windows and intestine of patients with CD, suggesting that CD 
may in fact result from an initial weak inflammatory response to clearance of faecal 
matter in the intestine (180). Impaired recruitment of neutrophils to skin windows 
injected with heat killed Escherichia coli (HkEc) in patients with quiescent CD (181), 
provided further evidence that CD is a systemic disease involving the innate immune 
system and not a gut-specific disease. Notably, impaired bacterial clearance was 
evident for high, but not low, bacterial doses – an observation that may explain why 
CD predominantly afflicts the gut. The patients' neutrophils responded normally to in 
vitro exposure to known chemoattractants. However, following activation with 
bacterial antigens, macrophages derived from blood monocytes of CD secreted 
significantly reduced levels of proinflammatory cytokines and chemokines necessary 
for recruiting neutrophils, most notably TNF-α (181,182). This evidence suggests that 
CD may be a macrophage primary immunodeficiency disease.  
The immune system defects in UC have not been studied as well as in patients with 
CD. However, current evidence suggests that in contrast to CD, patients with UC 
have a prolonged acute inflammatory response with concurrent elevation of CXCL10 
in circulation. The increased expression levels of CXCL10 have been observed in the 
colonic mucosa of patients with active UC (183), as well as in response to bacterial 
stimulation with HkEc (184). CXCL10 is secreted by a number of cell types, including 
monocytes and epithelial cells in response to both IFN-g and IFN-a/b (185), and plays 
a key role in the integrin activation and migration of cells, including activated T cells 
(186,187). This abnormal response appears to be due to an aberrant TLR-4 
signalling pathway in macrophages of patients with UC, resulting in the over-
expression of molecules associated with leukocyte recruitment and activation (PMID: 
20360984). Eldelumab is an anti-CXCL10 (also known as IFN-g-inducible protein 10 
[IP-10]) is in clinical trials for patients with IBD (188,189). 
1.2.3 PRESENTATION 
1.2.3.1 Clinical presentation 
Clinical presentation of UC and CD can be very similar with abdominal pain and 
diarrhoea. However, a hallmark of UC is per rectal bleeding, which is very rare in CD. 
 34 
On the other hand, patients with CD can suffer from perianal disease (e.g. anal 
fissures, anorectal abscess), and fistulas, which do not affect patients with UC. UC 
is a disease of the large bowel and does not affect the rest of the GI tract; CD, on the 
other hand, can affect any part of GI tract from mouth to anus, though the highest 
incidence is in the terminal ileum (TI). 
Patients with UC usually present with frequent bowel movements, which can be small 
in volume because of rectal inflammation. Associated symptoms include colicky 
abdominal pain, urgency, tenesmus, and incontinence (190).  
The onset of symptoms is usually gradual and may be preceded by a self-limited 
episode of rectal bleeding that occurred weeks or months earlier. 
Patients may also suffer from systemic symptoms such as fatigue, and weight loss, 
as well as joint pains, eye problems such as uveitis and episcleritis, and skin issues 
such as erythema nodusum and pyoderma gangrenosum. Some patients may also 
develop primary sclerosing cholangitis (PSC), an autoimmune condition affecting the 
biliary tree. 
1.2.3.2 Endoscopic and Histopathological Evaluation 
In UC, the inflammatory changes invariably start at the rectum, and then extend in a 
proximal, continuous and circumferential fashion to involve other parts of the colon. 
The inflammation in UC is superficial, affecting the mucous. This is different to CD, a 
condition in which the inflammation is transmural, affecting the full thickness of the 
bowel. The endoscopic findings in patients with UC include loss of vascular markings 
due to engorgement of the mucosa, mucosal granularity, petechiae, exudates, 
erosions, friability, and spontaneous bleeding, depending on the severity of 
inflammation.  
Histological abnormalities in UC include crypt distortion and atrophy (191,192), 
increased lymphocytes and plasma cells in the LP (basal plasmacytosis), reduction 
in number of goblet cells or depleted mucin within cells (191), and Paneth cell 
metaplasia (193,194) 
Paneth cells are extremely uncommon in the healthy state of the distal colon (distal 
to sigmoid). However, in UC, there is significant increase in number of Paneth cells, 
known as Paneth Cell Metaplasia, which is related to epithelial regeneration and 
repair (195). 
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1.2.3.3 Increased risk of colorectal cancer 
UC patients, as well as CD patients with colonic disease, are at an increased risk of 
developing colorectal cancer (CRC) (196,197). Over time, and with treatment, the 
risk has decreased and may be approaching that of the general population; however, 
certain populations are still at an increased risk of developing CRC, such as those 
with increased duration of disease, involvement of longer colon segment, 
uncontrolled inflammation, and those with PSC (198,199). The reasons for this 
reduction in risk of developing CRC are not completely clear. However, it may be at 
least partially related to the bowel cancer screening program (200). 
1.2.4 CURRENT TREATMENT OPTIONS IN UC 
Currently, there is no cure for either UC or CD, and the primary goal of treatment is 
to induce and maintain remission, with the long-term aim of preventing complications, 
which in the case of UC include colectomy and CRC. Despite the differences between 
CD and UC, currently the current treatment options for both overlap, with the aim of 
reducing the chronic inflammation. 
During acute or severe inflammation, steroid therapy, oral or intravenous depending 
on severity, is the mainstay. Close monitoring of the inflammatory response (using 
markers such as C-reactive protein and direct visualisation of the mucosa using 
endoscopy) is crucial as some patients require step-up treatment to stronger 
immunosuppressant medication such as cyclosporine or biologic agents, such as 
infliximab (201). 
In patients with mild-moderate disease, first line therapy is the 5-aminosalicylates (5-
ASA) drugs, either orally or topically (suppositories or enema). Whilst the mechanism 
of action of 5-ASAs has not been delineated, there is evidence of reduction of the 
total luminal bacterial number in patients on 5-ASA drugs (202). Immunomodulators, 
such as thiopurines (azathioprine or 6-mercaptopurine) may be required in patients 
who have repeated bouts of flare-up whilst taking 5-ASAs (201). 
Anti-TNF-α drugs, such as infliximab and adalimumab, are biologic drugs that are 
effective at inducing and maintaining remission in moderate to severe disease (203–
206). Vedolizumab, is another biologic agent, which blocks the adhesion molecule 
α4β7 integrin and is approved for moderate to severe ulcerative colitis (207). The 
α4β7 integrin is expressed on T cells and specifies the recruitment of T cells to the 
intestinal mucosa by interacting with its ligand MAdCAM-1 (208) 
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Despite advances in medical therapy, the life time risk of surgery in UC remains at 
30-40% (209). Whilst colectomy offers a “cure” for UC, it is not without significant risk. 
The most commonly performed surgery for ulcerative colitis is restorative 
proctocolectomy with ileal pouch-anal anastomosis (IPAA). Following IPAA, 
postoperative complications can occur in up to 33% of patients (210). 
Other components of the inflammatory response are being targeted by the newer 
agents, with up to 27 new drugs for UC in either active clinical trials, or recently 
completed trials (211). These include agents targeting pan-Janus Kinase Inhibitor, 
monoclonal antibody blocking the β7 subunit of the heterodimeric integrins α4β7 and 
αEβ7, and an anti-α4 integrin therapy (AJM300) (212). 
1.3 ANIMAL MODELS OF COLITIS 
Mice are the most commonly used animal model for experimentation. However, 
unlike humans, mice do not develop IBD. Hence, several models of colitis have been 
developed in mice, each causing inflammation through a different pathway, and none 
perfectly mimics the human disease. Since the aetiology of IBD is still unknown, these 
varied mouse models of colitis are helpful in studying the varying possible 
mechanisms, from the effect of epithelial cells, to the role of innate or adaptive 
immune system. Here, the different models of colitis in mice are summarised and 
discussed. 
1.3.1 MODELS OF COLTIS IN MICE 
1.3.1.1 Chemical Induction 
1.3.1.1.1 Dextran Sodium Sulphate (DSS) 
DSS is a synthetic sulfated polysaccharide composed of dextran and sulfated 
anhydro-glucose unit that is added to the drinking water of rodents at concentrations 
of 1-5% (213). The resultant inflammation has many of the features of UC in humans 
(214), including weight loss, diarrhoea and blood in the stools. Histological changes 
in DSS-colitis include mucin depletion and epithelial degeneration leading to the 
formation of cryptitis and crypt abscesses.  
The precise mechanism of inflammation in DSS-colitis is not known. There is 
differential susceptibility to developing colitis by DSS across different mouse strains 
(215) suggesting a genetic element. DSS is thought to induce colitis in mice partly by 
forming nano-lipocomplexes with medium-chain-length fatty acids in the large bowel 
that can fuse with epithelial cell membranes (214). However, even in C57/BL6 mice 
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which are known to be susceptible to DSS, germ free mice develop significantly less 
severe colitis than Specific Pathogen Free (SPF) mice. It has also been shown that 
after exposure to DSS, the inner layer of the mucous in the large bowel that is 
normally sterile becomes permeable to bacteria (216). Taken together, these results 
suggest that a major contributor of the inflammation in DSS-colitis are the commensal 
bacteria in the gut, and that one major contribution of DSS to development of 
inflammation is the effect it has on the properties of the mucous, and the effect on 
epithelial layer. DSS-colitis is the most widely used model of colitis in animals. 
1.3.1.1.2 2,4,6- Trinitrobenzene sulfonic acid (TNBS) 
TNBS is a hapten, which turns into an antigen when bound to tissue proteins, eliciting 
an immune response (217). Previous studies have shown that it can elicit the number 
of immunologic responses and represents both forms of IBD, predominantly CD 
(218). TNBS can be administered through a trocar needle using a rubber catheter 
inserted via the anus. The recommended dose of TNBS is 0.5–4.0 mg in 45–50 % 
ethanol intra-rectally, which varies between different mouse strains. For example, 
such as SJL and BALB/c mice are highly susceptible, whereas C57Bl/6 and 10 mice 
are resistant (219). Ethanol is required in a high concentration for the TNBS 
administration. Ethanol acts as a barrier breaker so that TNBS can enter the mucosa 
to induce colitis, where it covalently binds to the E-amino group of lysine and modify 
cell surface proteins (220). However, ethanol itself causes severe inflammation in the 
intestinal mucosa which makes it difficult to distinguish between the ethanol-induced 
inflammation and hapten-induced inflammation (221). 
1.3.1.1.3 Other chemicals used to induce colitis in mice 
Dinitrobenzene sulfonic acid (DNBS): DNBS is similar to TNBS in that they both 
bind to proteins, and act as a hapten, but unlike TNBS, animals treated with DNBS 
do not develop granulomas (222). 
Oxazolone: Oxazolone is another hapten that is administered intra-rectally with 
ethanol. The effect is a Th2-mediated acute colitis, and is limited to the distal part of 
the large bowel only (223). However, it has been suggested that oxazolone-induced 
colitis is dependent on invariant Natural Killer T-cells (NK-T cells) being produced in 
presence of IL-13 (224). 
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1.3.1.2 Bacterial induction of colitis 
1.3.1.2.1 Citrobacter rodentium induced colitis 
Like the human pathogens, Enteropathogenic and Enterohemorrhagic Escherichia 
coli (EPEC and EHEC, respectively), C. rodentium is an attaching and effacing (A/E) 
pathogen, which subverts innate immune system by effectors into infected 
enterocytes where they reprogram cell signalling (225). C. rodentium results in colitis 
in mice (226), initially colonising the caecum and then the entire large bowel, causing 
dysbiosis as a result of overgrowth of C. rodentium and reduction of intestinal 
microbiota diversity (227). C. rodentium has been used to investigate the innate 
mucosal responses to infection. 
1.3.1.2.2 Salmonella-induced colitis  
The gram-negative Salmonella typhimurium and Salmonella dublin are food-borne 
enteric bacterial pathogens that can result in intestinal inflammation. The 
inflammation has similar phenotype to human UC, including epithelial crypt loss, 
erosion and neutrophilic infiltration (228). However, given the acute nature of 
bacterial infections, it is likely that S. typhimurium infection is not a good model to 
study the chronic nature of human UC. 
1.3.1.2.3 Adherent–invasive E. coli  
The commensal Adherent–Invasive Escherichia Coli (AIEC) adheres to both small 
and large intestinal epithelial cells with equal affinity (229). The phenotype of the 
inflammation resembles UC (230,231). However, induction of inflammation using 
AIEC in animals requires mild epithelial damage, such as low-dose DSS treatment, 
during the entire course of the infection. 
1.3.1.3 Genetically engineered models of colitis 
In genetically engineered models, an existing gene is activated (or “knocked-out”). 
These can be either complete knock-out, in the whole animal, or conditional knock-
outs, in selected organs. Over the years, many genetic models have been developed, 
highlighting the complex interplay of different cells in pathogenesis of colitis. Whilst a 
full review is out of the scope of this chapter, a of these mouse models have been 
summarised below. 
1.3.1.3.1 IL-10-Knock out 
IL-10-/- deficient mice develop spontaneous colitis (232). IL-10 plays an important 
physiologic role in intestinal inflammation by maintaining a check on the pro-
inflammatory responses to normal antigens and intestinal microbiome (233). 
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1.3.1.3.2 TGF-β-Knock out 
TGF- β-/- mice develops multi-organ dysfunction due to macrophage hyper-activation 
and reduced regulatory T cell activity, including severe colitis. These mice die within 
4–5 weeks (234,235). Whilst the exact role of TGF- β in the intestine remains unclear, 
it appears to be involved in increased production of IL-10 and down-regulation of IL-
12 receptor expression (236). 
1.3.1.3.3 IL-2-Knock out 
IL-2-/- deficient mice develop inflammation in the large intestine that resembles UC 
by the time they are 8-9 weeks old (237). 
1.3.1.3.4 Atg16l1-Knock out 
Mice with Atg16l1 deletion in IECs spontaneously develop transmural ileitis in an age-
dependent manner (238). 
1.3.1.4 Adaptive transfer models of colitis 
In these models, intestinal inflammation is induced by selective transfer of certain cell 
types to immunocompromised host animals. These models have contributed new 
insights into the predominant role of T cells for mucosal immune regulation. 
1.3.1.4.1 CD45RB High Transfer 
Adaptive transfer of CD4+CD45RBhigh T-cells (naïve T cells) from healthy wild-type 
(WT) mice into recipients that lack T and B cells induces a pan-colitis and small bowel 
inflammation 8-9 weeks after T-cell transfer (239,240). 
1.4 THE THESIS 
1.4.1 OUTLINE OF THESIS 
The purpose of the investigations in the current study is to elucidate the role CLDN8 
plays in the pathogenesis of inflammation in UC. 
In this thesis, the transcriptomic data of patients with UC and healthy controls from 
an earlier dataset performed by Dr Smith in our lab was examined.  
I then characterised and studied Cldn8 deficient mice, investigating a range of 
parameters including bowel permeability and transcriptomic profiling, in naïve state 
and in response to DSS-induced colitis. In this set of experiments, DSS was used to 
induce colitis for several reasons. Firstly, as described above, DSS causes pan-colitis 
with histologic similarity with human UC. Secondly, the lab has extensive experience 
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in using DSS, and finally, a preliminary study in early generations of the Cldn8-/- had 
shown promising results. Backcrossing Cldn8 deficient mice on other transgenic mice 
(see above) was not feasible given the funding and time limitations of study.  
The hypotheses investigated were: 
• Cldn8 plays a protective role against intestinal inflammation 
• Loss of Cldn8 decreases intestinal permeability 
• Cldn8 plays an important role in keeping the inner layer of mucous sterile 
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2 Materials and Methods 
2.1 UC PATIENTS AND HEALTHY CONTROLS 
Human studied were performed by Dr Phil Smith. Patients with UC were recruited 
from the IBD clinic or endoscopy department at University College London Hospital 
(UCLH). Healthy control (HC) patients were recruited from the endoscopy 
department at UCLH undergoing routine colonoscopy; all had macroscopically and 
microscopically normal endoscopy (241). All subjects were between 18 and 75 years 
of age. Patients were included in the studies if they had a definite clinical and 
histological diagnosis of quiescent UC. All patients where on either no or minimal 
treatment; no patient was on steroids or biologic therapy, with some patients on 5-
ASA. 
Written informed consent was obtained from all participants. Patient details and 
clinical information were recorded in an encrypted, password protected database, 
registered and covered by the Data Protection Act, 1998. Access to this database, 
and the process of obtaining informed consent from the subjects, was restricted to 
named individuals with up to date certificates in Good Clinical Practice. Clinical 
details included were name, date of birth, hospital number, duration of disease, 
treatment, phenotype based on Montreal classification, comorbidities, current and 
past medication, smoking status, and family history. 
Ethical approval was obtained from the Joint UCL/UCLH Committee for the Ethics of 
Human Research (project number 02/0324) and the NHS National Research Ethics 
Service, London-Surrey Borders Committee (project number 10/H0806/115). 
Paired mucosal pinch biopsies were obtained from macroscopically normal mucosa 
of the terminal ileum (TI), ascending colon, descending colon, and rectum. Where 
possible biopsies were taken from all locations. One biopsy was stored in RNAlater 
stabilization reagent (Qiagen, Germany) at -80°C, and the other placed in 4% 
formaldehyde (CellPath, Newtown, UK) for histological evaluation by specialist 
histopathologists. Blood samples were taken from the study participants at the time 
of endoscopy.  
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2.2 Cldn8-KNOCK OUT AND WILD-TYPE MICE  
2.2.1 CLDN8-KO MICE 
Animal studies were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 and European Directive 2010/63/EU on the 
protection of animals used for scientific purposes. 
The Cldn8-Knock Out (KO) mice were generated by Lexicon Genetics Corporation. 
The Cldn8 gene consists of 1 exon and is on Chromosome 21. The target vector, 
pKOS-53 with LacZ/Neo cassettes, was targeted to the Cldn8 gene by homologous 
recombination. A schematic diagram of the targeting strategy, including the expected 
sizes of the PCR products for the Cldn8-KO mice are depicted in Figure 4-4. The line 
was reconstituted from frozen embryos from the Mutant Mouse Regional Resouces 
Centers (MMRRC) (https://www.mmrrc.org). Embryonic stem cells were re-derived 
from 129/SvEvBrd-derived embryonic stem cells. Cldn8 heterozygote mice were 
therefore bred to C57BL/6J albino mice to generate F1 heterozygous animals. These 
were intercrossed to generate F2 wild type, heterozygous, and homozygous mutant 
progeny. We took delivery of the F2 progeny.  
All earlier experiments in our laboratory, as well as the majority of literature on 
experimental colitis in mice have been performed on C57BL/6 black mouse strain. 
Therefore, the Cldn8-KO transgenic mice (F2) were backcrossed on to C57BL/6 
black WT mice to generate Cldn8-KO mice with a C57BL/6 black genetic 
background. Briefly, the process involved crossing the Cldn8-KO mice with non-
pedigreed non-sibling C57BL/6 black WT mice (C57BL/6NCrl strain code 027, 
bought from Charles River laboratories) for several generations. This backcrossing 
process is essential to generate congenic strains of mice, where they differ 
genetically in only one locus (Figure 4-5). 
Due to naturally occurring genetic drift, a mouse strain will diverge into a genetically 
distinct sub-strain if its breeding colony is separated from the parental breeding 
colony. To minimise this potential confounding factor, every 10 generations, the 
Cldn8-KO C57BL/6 black mice were crossed on to non-pedigreed non-sibling 
C57BL/6 black WT mice to prevent genetic drift. 
  
 43 
2.2.2 MOUSE GENOTYPING 
Mouse genomic deoxyribonucleic acid (gDNA) was extracted from ear clips. The ear 
clips were incubated over night at 55ºC in 95 µl of gDNA extraction buffer containing 
5 µl of 4mg/ml proteinase K (Qiagen). The samples were vortexed at 1400rpm at 
55ºC for 10 min in an Eppendorf Thermomixer Comfort (ThermoFisher, MA, USA) 
then centrifuged (ThermoFisher) at 28,000 g for 10 minutes to pellet the hair. 
Samples were subsequently transferred to clean new tubes and boiled at 95 ºC for 5 
minutes. 
Genotyping was performed by polymerase chain reaction (PCR) of the isolated gDNA 
amplified with Cldn8 gene specific primers. For WT mice, DNA266-28 and DNA266-
24 primers were used for genotyping (expected size 418bp). For Cldn8-KO mice, 
DNA-266-26 and GT-ires primers were used for genotyping (expected size 351bps) 
(see Appendix 1 – List of Primers). 
The PCR reaction volume was made up of 12.5 µl HotStar Taq Mastermix, 1 µl 
forward primer, 1 µl reverse primer, 1 µl gDNA, made up to 25 µl with RNase-free 
water. The final concentration in the reaction volume was 2.5U HotStar Taq DNA 
polymerase, 1xPCR buffer containing 1.5mM MgCl2, 200 µM of each dNTP, 0.4 µM 
of each primer and a variable amount of gDNA. PCR was carried out on a DNA 
Engine Tetrad 2® Peltier Thermal Cycler (Bio-Rad, CA, USA) using the conditions in 
table 2.2 below for 28 cycles. 5 µl Orange J was added to each 25 µl reaction mix 
and 15 µl was run on a 1% agarose gel and viewed with a ChemiDocTM Imager (Bio-
Rad). 
 Temperature Time 
Activated 95 ºC 15 minutes 
Denatured 95 ºC 45 seconds 
Annealed 60ºC 45 seconds 
Extended 72ºC 45 seconds (28 cycles) 
Extended 72ºC 10 minutes 
Cooled 4ºC Ad infinitum 
 
Table 2.2: PCR conditions for genotyping Cldn8-KO and WT mice. 
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2.2.3 OTHER MICE STRAINS 
C57BL/6 mice (C57BL/6NCrl strain code 027) were brought from Charles Rivers 
laboratories. On transfer of mice into the animal unit at UCL, mice were rested for 7 
days before experimentation in order to minimise the effect of stress compromising 
results. 
 
2.2.4 MICE HUSBANDRY 
Colonies were generated from WT and Cldn8-KO breeding pairs. Mice were bred 
and maintained under specific-pathogen free (SPF) conditions till 20 months of age, 
Biological Sciences Unit, UCL and Royal Free Hospital. Animal rooms were 
temperature controlled (21 ± 1°C) and with a 12 h light/dark cycle (lights on at 
07:00h). Mice were housed 3-5 per cage, with free access to food and water. Cages 
were cleaned once a week as part of the animal room routine. The conditions were 
monitored by the Named Animal Care and Welfare Officer (NACWO) in animal 
facility. Mice were fed with Harlan 2018 Teklad Global 18% protein rodent diet. 
Normal tap water was used. Routine health screens for infection were carried out for 
parasites and opportunistic infections. Mice between the ages 6 and 12 weeks were 
used for experimentation. They were matched for age, sex and weight for each study. 
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2.2.5 METABOLIC CAGE EXPERIMENTS 
Metabolic cages were used to analyse the micturition and faeces production in a 
controlled environment, whilst enabling measurement of animal’s food and water 
consumption in a set period of time. Mice were placed individually in metabolic cages 
(UNO BV, Netherlands) and allowed to acclimatise for 5 days. Measurements were 
taken for 24 hours, after which the animals were culled. The metabolic cage consists 
of a stainless-steel cage with metallic-mesh flooring placed over a funnel to allow 
collection of urine and faeces. Within the funnel, there is a trap to capture the faeces, 
whilst allowing the urine to flow in a small container underneath (see Figure 4-13 for 
detailed description). 
 
2.2.6 MICE FAECAL WATER CONTENT MEASUREMENT 
Mice were given free access to water and food. Individual mice were transferred to a 
cage with no bedding (to prevent any water absorption from the faeces by the 
bedding material). Spontaneously defecated stools were collected every 15min into 
pre-weighed eppendorf tubes (Eppendorf, Germany) to minimise atmospheric water-
loss. The faeces were then dehydrated in an oven overnight. The eppendorf tubes 
containing the faeces were weight pre- and post-dehydration to calculate the water 
content of the faeces.  
 
2.2.7 MICE FAECAL NA+ AND K+ CONCENTRATION MEASUREMENTS 
Faecal Na+ and K+ concentration was measured using a Corning-400 flame 
photometer (Corning, USA). To do so, dehydrated faeces were reconstituted in 1 ml 
of distilled water, and mixed with a plunger and then a needle, to ensure all salts in 
the faeces had dissolved in the distilled water. To sediment the faecal debris, the 
tubes were centrifuged at 22,000 g (ThermoFisher) and the supernatant was 
removed. The supernatant was put through the flame photometer at a dilution of 
1:800. To measure the Na+ and K+ concentration, the flame photometer was set using 
a “standard” solution with known concentration of sodium (0.2mM) and potassium 
(0.24 mM). 
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2.3 DSS-INDUCED MOUSE COLITIS MODEL 
Dextran Sodium Sulphate (DSS) was used to induce colitis in mice. DSS is a powder 
with a molecular weight of 36-50 kDa (MP Biomedicals, UK) that is dissolved in water 
and the DSS-water is provided to mice instead of normal drinking water. 
 
Acute Colitis: Male and female mice (6-8 weeks old) were provided regular drinking 
water (control) or DSS water for 7 days, as described previously (U.42). On day 3, 
the bottles were re-filled with freshly made DSS solution. On day 7, the DSS solution 
was replaced with normal drinking water. 
 
Chronic Colitis: Mice were provided with DSS water for 7 days as described above. 
After 14 days on normal drinking water, one group of mice were subjected to a 
second bout of DSS for 7 days. A separate group of mice were subjected to a second 
bout of DSS for 7 days, after 36 days on normal drinking water. 
Throughout the experiment (acute and chronic phases), the mice were weighed daily, 
and percentage weight change was calculated using the following formula: 
 
 (“Body weight on a given day” – “Original body weight”) 
 “Original body weight 
 
Faeces were scored for diarrhoea (0=normal consistency, 3=pasty stools, 5=watery 
stools) and blood (0=no blood, 1=blood). Presence or absence of blood was checked 
using a faecal occult blood test kit able to detect small amounts of blood in the faeces 
using Hema-screen (alpha laboratories, UK). On completion of the study, animals 
were culled, and large bowels were removed and assessed for length, and histology. 
  
x 100 
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2.4 CYTOKINE ASSAYS 
Mouse serum IL-2, INF-γ, IL-4, IL-10, IL-1b, IL-5, KC/GRO (IL-8), IL-6, TNF-⍺ and IL-
12p70 levels were determined using the MSD® Mouse Pro-Inflammatory 7-Plex Ultra-
Sensitive Kit (Meso Scale Discovery, US) and read on a SECTOR® Imager 6000 
(Meso Scale Discovery). 
2.5 RNA PREPARATION AND ANALYSIS 
2.5.1 RNA EXTRACTION  
Human biopsy samples 
Studies in humans were carried out by Dr Phil Smith. To harvest total RNA from each 
biopsy (~25 mg), samples were lysed using RNeasy Fibrous Tissue kit (Qiagen) RLT 
buffer and 0.14 M β-mercaptoethanol (β-ME) (Sigma-Aldrich, St. Louis, USA), and 
then homogenised by centrifugation at 10,000 g through a Qiashredder column 
(Qiagen), according to the manufacturer protocol. To remove protein, samples were 
incubated for 10 minutes at 55°C with 10 μl Proteinase K (20 mg/ml) (Qiagen). Total 
RNA was extracted using the RNeasy® Mini Kit (Qiagen) and eluted to 30μl of RNase 
free water (Qiagen). 
RNA concentration was measured using a NanoDrop ND-1000 spectrophotometer 
(ThermoFisher Scientific) measuring OD260/OD280 and OD260/OD230 to assess protein 
and solvent contamination respectively. Samples were included if they had an optical 
density ratio reading of 1.8-2.0 OD260/OD280 and >1.8 OD260/OD230. 
Mouse LI tissue samples 
To harvest total RNA, tissue samples were measured to ~25 mg. For RNA extraction, 
a mechanical disruption method was used to break down tissue samples using a 
bead, in the presence of b-ME-RLT buffer, at 50 Hz for 5 min in the TissueLyser LT 
(Qiagen). The solution was centrifuged down at 22,000 g for 5min and the 
supernatant used for RNA extraction, using the RNeasy Mini kit (Qiagen) according 
to the manufacturer protocol. To remove protein, samples were incubated for 10 
minutes at 55°C with 10 μl Proteinase K (20 mg/ml) (Qiagen). 
RNA concentration was measured using Qubit™ RNA HS Assay Kit (ThermoFisher), 
as per manufacturer instructions. 
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2.5.1.1 Microarray hybridisation 
Human samples 
Microarray expression studies in humans were carried out by Dr Phil Smith. For each 
sample, 500 ng of total RNA was amplified using the Illumina TotalPrep-96 RNA 
Amplification kit (Ambion, UK) and normalised to 150 ng/µl. For each sample, 750 ng 
was hybridised to Illumina HumanWG-6 v3.0 Expression BeadChips (Illumina, CA, 
USA) for 16 hours at 58oC. Following hybridisation Beadarrays were washed, stained 
with streptavidin-Cy3 (GE Healthcare, UK) and scanned using the Beadarray reader. 
The image was then processed with GenomeStudio® data analysis software 
(Illumina). 
Mouse samples 
For each sample, 500 ng of total RNA was amplified using the Illumina TotalPrep-96 
RNA Amplification kit (Ambion, UK) and normalised to 150 ng/µl. For each sample, 
750 ng was hybridised to Illumina MouseWG-6 v2.0 Expression BeadChips (Illumina) 
for 16 hours at 58oC. Following hybridisation Beadarrays were washed, stained with 
streptavidin-Cy3 (GE Healthcare, UK) and scanned using the Beadarray reader. The 
image was then processed with GenomeStudio® data analysis software (Illumina). 
2.5.2 CDNA CONVERSION AND QUALITATIVE PCR  
mRNA was converted to cDNA by oligo-d(T) priming and reverse transcription using 
the Promega reverse transcription kit, as per manufacturer’s instructions. qRT-PCR 
was performed using QuantiFast® SYBR® Green PCR (Qiagen), as per 
manufacturer’s instructions in triplicates on a Mastercycler® ep realplex (Eppendorf). 
Normalized mean gene expression values ± SD were determined from triplicate cycle 
threshold (Ct) values for each gene and the housekeeping gene peptidylprolyl 
isomerase A/cyclophilin A (PPIA) or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Relative transcript levels were determined by the 2−ΔΔCt method (242) 
(see Appendix 1 – List of Primers). 
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2.6 FLUORESCENCE-ACTIVATED CELL SORTING (FACS) 
2.6.1 MURINE LI LP CELL ISOLATION 
Following dissection, mouse LI were cut longitudinally and washed in ice cold PBS 
containing 100 U/ml penicillin, 100µg/ml streptomycin to remove faeces. Epithelial 
cells were removed by incubation of each large bowel in warmed 20 ml of pre-
digestion solution [Hanks balanced salt solution, (HBSS) (GIBCO, ThermoFisher 
Science) containing 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin and 2mM 
ethylenediaminetetraacetic acid, (EDTA)] at 37°C, agitated at 250 rpm for 30 min. 
The remaining LP tissue was diced into 1mm pieces and washed with ice cold PBS 
to remove EDTA. LP tissue was incubated in warm 20 ml digestion solution [HBSS 
containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 30mg collagenase 
(Sigma, USA), 1.6 mg DNase I (Sigma) and 15 mg Dispase II (Sigma)] at agitated at 
37°C, 250 rpm for 30 minutes, and vortexed for 20s at the start, middle and end of 
incubation. Finally, LP cells were passed through a 70 μm filter, washed with ice cold 
PBS. 
2.6.2 MURINE LI LP CELL LABELLING WITH ANTIBODIES 
Murine bowel LP cells were incubated with the LIVE/DEAD® fixable blue cell stain 
kit (Invitrogen L23105), blocked in CD16/CD32 Fc block (eBioscience 16-0161; 
1:500) prior to staining with CD45 PerCP-Cy™5.5 (BD 550994; 1:200), CD11b V450 
(BD 560455; 1:400), CD11c APC (BioLegend 117309; 1:400) and Gr1 PE (BD 
553128; 1:400), F4/80 FITC (eBioscience 11-4801; 1:800), CD3 PE-Cy™7 (BD 
560591; 1:800), MHCII AF700 (eBioscience 56-5321; 1:400) antibodies. The cells 
were fixed in 1% formaldehyde after staining. Cells were run on BD LSR II flow 
cytometer (BD 338301) after optimization with compensation beads (BD 552845). 
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2.7 IMMUNOBLOT 
To optimise the process of western blotting technique, four methods were used to 
prepare the epithelial whole cell lysates. 
Method 1: Mouse large bowel was removed, and washed with ice-cold PBS solution 
(Life technologies, CA, USA) to remove faecal material, and agitated at 250 rpm for 
30min at 37oC in Hank’s balance salt solution (Life technologies) with 2mM EDTA 
(Life technologies), 10% faecal calf-serum (Sigma) and 5% Pencillin-Streptomycin 
(Sigma) to dislodge the epithelial cells. The bowel tissue was removed, and the cell-
suspension was spun at 500 x g for 10min at 4oC to pellet the epithelial cells. Up to 
1-2 x 106 cells were transferred to 100 µl Laemmli sample buffer containing b-ME 
(Sigma), protease inhibitor (Roche, Switzerland) and phosphatase inhibitors (Sigma). 
Method 2: The epithelial cells were harvested as described in Method 1. However, 
the cells were transferred to RIPA buffer instead of Laemmli buffer. 
Method 3: 2cm of tissue was frozen on dry-ice, and powdered using a pestle and 
mortar. RIPA buffer, containing protease inhibitor (Roche) and phosphatase 
inhibitors (Sigma) was added to the powdered tissue and the solution was agitated 
for 1 hour at 4oC, before being spun down at 22,000 g for 10 min at 4oC. The 
supernatant was transferred to a fresh Eppendorf tube, sample buffer was added, 
and the solution was boiled at 98oC for 5min.  
Method 4: 2cm of tissue was frozen on dry-ice, and slowly thawed on ice. Whole cell 
lysis buffer, containing protease inhibitor (Roche) and phosphatase inhibitors (Sigma) 
was added and the tissue was mashed in the Eppendorf tube using a small pestle. 
The mashed tissue was incubated on ice for 10min before being spun down at 22,000 
g for 10 min at 4oC. The supernatant was transferred to a fresh Eppendorf tube, 
sample buffer was added, and the solution was boiled at 98oC for 5min.  
Samples were run on SDS-PAGE gels and transferred onto Hybond-P PVDF 
membranes (Amersham, GE Healthcare). Membranes were blocked in 5% non-fat 
milk for 1 hour then probed with primary antibody overnight at 4°C. Membranes were 
washed in Tris-buffered saline Tween-20 (TBST) then probed with HRP-linked 
secondary antibody for 1 hour at room temperature. Bound antibody was detected 
using ECL Plus/Prime (Amersham), exposed to Hyperfilm ECL (Amersham). 
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2.8 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
2.8.1 HISTOLOGY OF MOUSE LI 
Mouse large bowel tissue was fixed in 10% neutral buffered formalin (CellPath) 
overnight then paraffin-embedded using a Leica TP1050 tissue processor. 5µm 
sections were cut, underwent automated dewaxing and endogenous peroxidase was 
blocked using 3-4% (v/v) hydrogen peroxide. The tissue was blocked with 5% Goat 
Serum (Sigma G67G7) (diluted in distilled water) and stained in VFM Harris’ 
hematoxylin (CellPath), differentiated in 0.2% acid alcohol and stained in Eosin Y 
(VWR) using a Leica ST4040 linear stainer and mounted in Pertex (Leica).  
Immunohistochemical (IHC) analysis for Cldn8 detection were carried out using the 
automated Bond-Max system (Leica Biosystems Newcastle, Ltd.) using on board 
heat-induced antigen retrieval (Bond epitope retrieval solution ER2 for 30 min). 
Endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide for 5 
min. The histological specimens were incubated with the Primary Antibody for 60 min 
at room temperature. Before the application of the Polymer reagent, the sections 
were incubated for 30 min at room temperature with 5% Goat Serum (Sigma G67G7). 
The blocking reagent were diluted with distilled Water. The slides were incubated 
with Goat Anti-rabbit Poly-HRP-IgG (Polymer reagent) for 60 minutes at room 
temperature. The reactions were developed using a Bond polymer refine detection 
kit and followed by colour development with 3,3′-diaminobenzidine tetrahydrochloride 
as a chromogen for 10 min. During the optimisation process, four different 
commercially available anti-Cldn8 antibodies were used (Invitrogen; GeneTex; Santa 
Cruz; IBL) at different concentrations (1:100, 1:200, 1:400, 1:800). Slides were 
imaged with a Hamamatsu NanoZoomer 2.0-HT C9600 (Hamamatsu, UK). 
2.8.2 IN SITU HYBRIDIZATION AND MUCOUS IMMUNOSTAINING 
Mouse bowel was stained with DAPI (to stain DNA), anti-MUC2 antibody (to visualise 
the mucous), and EUB338 (to visualise the luminal bacteria). See Appendix 1 – List 
of Primers for EUB338. 
For in situ hybridisation of bacteria and mucous staining, bowel sections were fixed 
in methacarn, a water-free fixative, to preserve the mucous. Mouse intestine was cut 
around the most distal faecal pellet. A water-free paraffin embedding process was 
used to preserve the mucous (Dry methanol 2x 30 min, Absolute ethanol 2x15 min, 
1:1 Absolute ethanol/Xylene15 min, Xylene 2x15 min). Paraffin sections were initially 
dewaxed. The process of dewaxing involved incubating the slides in xylene substitute 
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twice, 10 min each, followed by 5 min in 100% ethanol, followed by 5 min in 95% 
ethanol, before air-drying the slides. The process was performed at 60oC. For 
hybridisation, 500-800 ng of EUB338 probe (Sigma, conjugated with Cy5.5) was 
added to 100 µl pre-warmed hybridization solution. 50 µl probe-hybridization solution 
was added to the sections before being covered with glass and incubated over night 
at 50oC in a humidity chamber. The slides were then washed for 5 min at 50oC using 
pre-warmed wash solution. 
Immunostaining was carried out at 4oC. The slides were rinsed with cold PBS, 
solutions added as a drop on the sample, and blocked in 5% FCS in PBS for 1h at 
4°C, before being incubated with primary antibody (anti-MUC2, Santa Cruz sc-
13312) diluted in 5% FCS (1:50) in a humid chamber at 4oC overnight. The slides 
were then wash 3 times in cold PBS, before being incubated with secondary antibody 
(conjugated with a fluorophore) diluted in 5% FCS (1:2000), dark at 4°C overnight 
(ThermoFisher, A-21088, conjugated Alexa Fluor® 680). DAPI (ThermoFisher) was 
added to the slides for 5 min, to stain for DNA, before being washed with PBS and 
mounted in a small volume of Prolong Anti-fade (Molecular Probes, P36930), and left 
to set at room temperature overnight. 
2.9 MICE IN VIVO COLONIC PERMEABILITY STUDIES 
Female Cldn8-KO and WT mice were anaesthetized with an intraperitoneal injection 
of Ketamine 100mg/kg mixed with xylazine 10mg/kg and maintained at 37oC on a 
thermostatically controlled heating blanket (Harvard Apparatus Ltd, Edenbridge, 
Kent, UK). The peritoneal content were exposed, ensuring no damage to the intestine 
during the procedure. A two-centimetre-long self-contained segment of large bowel 
was created. To create a self-contained segment of the bowel, two cuts were made 
in the bowel, and both ends tied with a string. The distal cut was made in the most 
distal part of the large bowel that could be reached in the pelvis without damaging 
other organs; the distal end of the segment was therefore within 1-cm of the rectum 
(see Figure 4-1 for graphical representation). Cuts in the bowel were made only to 
part of the lumen, and not the full width, to avoid damaging the mesentery and its 
blood supply (Figure 4-1-c). The lumen was cannulated from the proximal end with a 
fine plastic tube attached to a syringe. The segment was then flushed with warm 
0.9% saline to remove any faecal material, followed by air to remove the saline. A 
uptake buffer containing 3H-mannitol (0.037 MBq) and FITC-Dextran (50mg/ml) was 
instilled into the lumen and the segment tied off. The volumes instilled into the lumen 
was 90µl and was chosen in order to fill the intestinal segment whilst avoiding 
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distension. Care was taken to avoid instilling air into the lumen. Blood (0.5 ml) was 
collected after 30 min by cardiac puncture and centrifuged at 1500 g for 10 min to 
obtain plasma. The segment of intestine was removed, and the length and dry weight 
(after drying over-night in oven) was recorded. The permeability of the intestine was 
calculated by measuring concentration of 3H-mannitol (PerkinElmer, MA, USA) and 
FITC-Dextran (Sigma FD40S) in plasma and stock solution, and factoring the dried 
weight of the segment, and the animal’s weight (as a surrogate marker for the blood 
volume). To measure the radioactivity, 50 ml of the plasma, and 50 ml of stock 
solution (diluted 1:10 in uptake buffer) were made up to 5 ml in UltimaGoldTM 
(PerkinElmer). The radioactivity was measured in the final solution using Tri-Carb 
2900TR Liquid Scintillation Analyzer (Packard BioScience, MA, USA). The final 
measurement is expressed as a percentage of radioactivity absorbed. To measure 
fluorescence from FITC-Dextran, FLUOstar Omega (BMG Labtech, Germany) was 
used to measure fluorescence of FITC; for the measurements, 50 ml of stock solution 
was used for the standard curve, diluted in naïve serum; and 50 ml of serum from the 
mouse under experiment. 
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2.10 REAGENTS 
2.10.1 BUFFERS 
DNA extraction buffer: 
1 ml 1 M Tris pH8 (VWR 103156X), 100 µl 0.5M EDTA (Sigma E6511), 2 ml 1 M 
NaCl (Sigma S7653) and 50 µl 1% SDS (Sigma L3771) were added to 6.85 ml of 
distilled water (dH2O). 
3x Laemmli sample buffer 
2.4 ml 1 M Tris-HCI pH 6.8 (VWR), 3 ml 10% SDS (Sigma), 3 ml 100% glycerol (BDH 
101186M), 1.6 ml 2-mercaptoethanol (Sigma 63689) and 0.006g bromophenol blue 
(Sigma B0126). Stored at 4oC. 
10x RIPA lysis buffer (250ml) 
25 ml NP-40 detergent, 12.5 ml 20% SDS, 125 ml of 1M Tris-HCL pH 7.4, 12.5 g 
Sodium Deoxycholate, 75 ml 5 M NaCl, 12.5 g Sodium Deoxycholate, 5 ml 0.5 M 
EDTA, 7.5 ml water 
10x Transfer buffer 
144 g glycine (Sigma G7126), 3.74 g SDS (Sigma L3771) and 30.25 g Tris (VWR 
103156X) were dissolved, using a magnetic stirrer, in dH2O and made up to 1 L with 
dH2O. 
10x Tris-buffered saline (TBS) 
800 g NaCl (Sigma), 20 g KCI (Sigma P4054) and 300 g Tris to dH2O, made up to 
10 litres dH2O, pH 7.4.  
TBS-Tween 0.1% 
5 ml of Tween-20 (Sigma P1379) were added to 500 ml of 10x TBS and made up to 
5L with dH2O, 
FACS buffer (PBS containing 1% BSA and 0.01% azide) 
5 g of bovine albumin (BSA)/albumin faction V (VWR 1120180100) was added to a 
new bottle of 500 ml PBS pH7.2 (Gibco 20012). 500 µl of 10% sodium azide in dH2O 
(Sigma S8032) was added to the 500 ml of PBS and stored at 4oC. 
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Uptake buffer 
12 µl of 3H-mannitol, and 60mg of FITC-Dextran, added to 1188 µl Hepes buffer. 
Hepes buffer (pH 7.4) 
16 mM Na-Hepes (2.08g), 140 mM NaCl (4.09g), 3.5 mM KCL (0.13g), 1 mM 
Mannitol (0.091g), in 500 ml distilled water 
Carnoy (methanol) fixation (Methacarn) 
60% Absolute methanol, 30% Chloroform, 10% Glacial acetic acid 
Hybridization solution 
20 mM Tris-HCl pH 7.4, 0.9M NaCl, 0.1% SDS (optional: can add 5-20% formamide 
if high background is a problem) 
Washing solution (for in situ hybridisation) 
20 mM Tris-HCl, pH 7.4, 0.9 M NaCl 
 
2.10.2 SDS-PAGE GELS 
Resolving and stacking gel were made up with 30% w/v Acrylamide/ProtoFLOWGel 
(SLS H16996), 1.5 M Tris-HCI pH8.8 (resolving gel), 1 M Tris-HCI pH6.8 (stacking 
gel), dH2O, 10% SDS (Sigma L3771), freshly made 10% ammonium persulphate 
(Sigma A7460) and TEMED (Sigma T9281) (added in the order listed with TEMED 
last, just prior to use). The gels were cast using Mini-PROTEAN® System (Bio-Rad) 
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2.11 STATISTICAL ANALYSIS 
Unless otherwise stated, all statistical calculations were performed using GraphPad 
Prism 6.00 software on Mac (GraphPad Software Inc, USA). A p-value < 0.05 was 
considered statistically significant. Unless otherwise stated, statistical significance 
was calculated using a paired or unpaired two-tailed t-test. For multiple comparison 
between groups, statistical significance was assessed by one-way ANOVA with 
Tukey-post-test. 
2.11.1 ANALYSIS OF TRANSCRIPTOMIC DATA 
Human data 
Expression data was normalised after log2 transformation within Genome Studio 
(Illumina, CA, USA) using a cubic spline normalisation. Data was exported without 
background subtraction. Detection p-values associated with each probe expression 
value were also exported. These procedures were all carried at the Wellcome Trust 
Sanger Institute (Cambridge, UK). Probes that reached a minimum detection p-value 
of p<0.01 in at least two biopsies were included in the subsequent analyses. Data 
was normalised for chip effects using ComBat normalisation using R statistical 
programming software, an established algorithm for preventing batch effects in 
microarray (243). The transcriptomic data from Dr Phil Smith has been deposited in 
the Gene Expression Omnibus (GEO) with accession no. GSE48634 
Mouse data 
Expression data was normalised after log2 transformation within Genome Studio 
(Illumina, CA, USA) using a cubic spline normalisation. Data was exported without 
background subtraction. Detection p-values associated with each probe expression 
value were also exported. These procedures were all carried at the UCL Genomics 
Institute. Probes that reached a minimum detection of uncorrected p-value < 0.01 
were included in the subsequent analyses. Correction for multiple testing was 
performed using the False Discovery Rate (FDR) method. Due to the design of 
samples on the chips, data could not be normalised using ComBat normalisation. 
Differentially expressed genes between groups were computed using 
MultiExperiment Viewer (MEV) TM4 Microarray Software suite version 4.8 (Dana-
Farber Cancer Institute, Boston, USA) (244). Probes were identified that reach a 
minimum raw fold change of 1 between groups. Principle component analysis (PCA) 
was performed on the initial microarray dataset to determine if mucosal gene 
expression profiles could be separated according to mouse genotype and stage of 
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inflammation. PCA is a mathematical technique to reduce the dimensions of a 
datasets by calculating the principle components (directions) along which variation in 
a dataset is maximal. PCA was performed using the PCA tool of MeV TM4 Microarray 
Software suite, with default settings. 
FACS Data 
All FACS results analysed using FlowJo X 10.0.7 on Mac (Tree Star Inc, USA). 
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3 Transcriptomic analysis of human colonic biopsy from 
patients with UC and healthy controls 
3.1 INTRODUCTION 
As described in Chapter 1.2, UC is a chronic relapsing-remitting inflammatory 
disease predominantly affecting the gastrointestinal tract. However, the aetiology of 
UC is not well understood. Studies of twins have demonstrated am elevated 
concordance rate of UC is 15.4% in monozygotic twins, compared to 3.9% in 
dizygotic twins (245). GWAS studies have so far identified 163 risk susceptibility loci 
in patients with IBD, of which 110 are shared between UC and CD, and 23 are 
specific to UC (150). However, the identified genetic risk factors only account for 
7.5% of disease variance in UC (150). This highlights the role of environmental 
factors in pathogenesis of UC, and the possibility that epigenetics may partially 
account for the “hidden heritability” in UC (246). 
Epigenetic factors, such as DNA methylation, could mediate gene-environment 
interactions involved in pathogenesis of diseases (247,248). In addition to the effect 
of epigenetic factors on the phenotype of the individual, there is evidence of 
inheritability of epigenetic modifications. Studies in mice have highlighted the effect 
of dietary intake during pregnancy on the epigenetic reprogramming step in offspring 
during early development, resulting in an increased susceptibility of the off-springs to 
DSS-induced colitis (249).  
The transcriptomic analysis of the mucosa from patients with UC can therefore 
potentially identify genes that may be abnormally expressed as a result of germline 
mutations, environmental factors, or secondary to the pathogenic process itself. 
A number of transcriptomic analyses have been conducted in tissue (either via 
endoscopic biopsy or surgical resections) of patients with UC (250–256). However, 
in most of these studies, samples were obtained from inflamed tissue (253,255–257). 
This raises the possibility that the changes in gene expression signatures may be 
due to tissue damage and repair, as well the inflammatory cell infiltrates. 
In an attempt to identify molecules which could be causally related to the 
development of the disease, Dr Smith, a PhD student with Prof Segal analysed the 
transcriptomic profile of macroscopically non-inflamed mucosa from patients with UC 
in clinical remission, as compared to healthy controls (241). All patients where on 
either no or minimal treatment; no patient was on steroids or biologic therapy, with 
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some patients on 5-ASA. The focus of analyses in this chapter is the analysis of this 
data with an emphasis on prominent genes involved in epithelial homeostasis.  
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3.2 RESULTS 
3.2.1 PATIENT COHORT AND SAMPLE COLLECTION 
Endoscopic pinch biopsies were obtained from around the bowel (Figure 3-1) by Dr 
Philip Smith from 29 patients with histologically confirmed diagnoses of UC and 31 
healthy control (HC) patients undergoing routine colonoscopy, aged 18-75 years old 
at University College London Hospital (UCLH). HC patients were attending for routine 
endoscopic investigation of gastrointestinal symptoms and all had macroscopically 
normal colonoscopies and histologically normal biopsies. Samples were collected in 
two separate cohorts – an initial cohort and then a verification cohort (5 patients with 
UC and 4 new HC at a later time point; median, 22 months; range, 21–23 months). 
Phenotypic and demographic information for the patients are presented in Table 3-1. 
 
 
 
Figure 3-1 – Location of the biopsies collected during colonoscopy. Paired 
endoscopic pinch biopsies were obtained from macroscopically normal mucosa of 
the terminal ileum, ascending colon, descending colon, and rectum. Where possible 
samples were taken from all locations in each subject. One sample was placed in 
RNA-later stabilization reagent mRNA preparation, and the other was placed in 4% 
formaldehyde for histological evaluation. 
  
Ascending
colon
Descending
colon
Sigmoid	 colon
Rectum
Terminal	Ileum
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Table 3-1 – Demographics table for initial patient biopsy cohort. Phenotypes 
based on Montreal classification – A = Age at diagnosis (A1 <16 years old, A2 17-40 
years old, A3 >40 years old), E = Extent of disease (E1 proctitis, E2 left sided colitis, 
E3 pan-colitis); SEM, Standard error of the mean; 5-ASA, 5-aminosalicylates; AZA, 
azathioprine; 6-MP, 6-mercaptopurine; IBD, Inflammatory Bowel Disease; COBH, 
change in bowel habit; UC, ulcerative colitis; HC, healthy control – Adapted from Dr 
Phil Smith et al (241)  
 
  
UC HC
Number	of	patients 24 27
Gender	 Male		
Female
16
8
15
11
Age	(years)	 (+/-SEM) 48.3	(+/-3.5) 45.3	(+/-2.9)
Average	 age	 at	
diagnosis	(years)	
(+/-SEM)
30.7	(+/-3.6) -
Duration	of	disease	
(years)	 (+/-SEM)
17.54	(+/-2.8) -
Treatment	 (%) No	treatment
5-ASA	alone
AZA	alone
5-ASA	plus	AZA
5-ASA	plus	6-MP
5	(20.8%)
15	(62.5%)
0	(0%)
3	(12.5%)
1	(4.2%)
-
Phenotype A1	
A2	
A3	
4
16
4
E1
E2
E3
2
11
11
Smoking	status	(%) Current	 smoker
Ex-smoker
Never	 smoked
3	(12.5%)
5	(20.8%)
16	(66.7%)
3	(11.1%)
4	(14.8%)
19	(74.1%)
Family	history	of	IBD	
(%)
5	(20.8%) 3	(11.1%)
Indications	(%) Establish	IBD
IBD	assessment
IBD	surveillance
Rectal	bleeding
Exclude	IBD
Diarrhoea
Surveillance
COBH
0	(0%)
8	(33.3%)
16	(66.7%)
0
0
0
11	(40.7%)
1	(3.7%)
7	(25.9%)
2	(11.1%)
5	(18.5%)
Bowel	preparation	
(%)
Senna	and	Citramag
Phosphate	enema
Kleen-prep
No	preparation
21	(87.5%)
3	(12.5%)
0	(0%)
0	(0%)
19	(74.1%)
7	(25.9%)
0
0
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3.2.2 CLDN8 HAS ONE OF THE LARGEST FOLD-CHANGE REDUCTIONS OF ANY GENE IN 
PATIENTS WITH UC 
In our cohort of patients with UC, CLDN8 was found to be the second most common 
under-expressed gene, compared to HC patients (Figure 3-2). 
 
Figure 3-2 – Heatmap of under- and over-expressed genes in patients with UC, 
compared to HC patients. Results are from transcriptomic analysis of pinch 
biopsies obtained from the rectum. The table shows genes with fold change of £ -1 
or ³ 1. Arrow highlights CLDN8 is downregulated in patients with UC with the second 
biggest fold change. Data from 24 UC and 27 HC patients. UC, ulcerative colitis; HC; 
healthy controls – figure adapted from Dr Phil Smith 
  
Under-expressed	genes	in	the	Rectum
Gene	 Fold	change p	value Adj.	p	value
HOXD11 -2.69 5.24E-7 0.00204
CLDN8 -2.50 0.000105 0.04829
HOXD10 -1.94 3.67E-8 0.00053
HOXD13 -1.75 8.20E-7 0.00269
CLCNKA -1.73 9.54E-5 0.04555
CHRNA1 -1.72 7.15E-5 0.04095
UGT2A3 -1.71 5.44E-7 0.00204
CLCNKA -1.67 7.64E-5 0.04095
PCK1 -1.65 0.000108 0.04887
FAM5C -1.58 1.24E-7 0.00082
KIF5C -1.55 4.64E-5 0.03481
TNNC1 -1.51 0.00011 0.04898
NPY -1.50 1.72E-5 0.02454
PCK1 -1.47 3.71E-5 0.03092
KIAA1715 -1.43 4.01E-8 0.00053
FAM5C -1.41 4.92E-7 0.00204
CHRNA3 -1.36 3.77E-5 0.03092
RBM24 -1.31 6.32E-6 0.01510
FAM3C -1.30 8.18E-5 0.04214
CMAH -1.29 7.59E-5 0.04095
GNPTAB -1.28 2.90E-5 0.03049
ACAT1 -1.27 1.77E-5 0.02454
GNE -1.27 5.49E-5 0.03793
ZNF423 -1.23 2.07E-5 0.02497
ATRN -1.19 1.24E-7 0.00082
GPR177 -1.19 7.98E-5 0.04193
CMTM4 -1.18 1.26E-5 0.02232
NCRNA00173 -1.13 1.48E-5 0.02432
SLC25A12 -1.13 7.45E-6 0.01631
FAM38B -1.13 8.79E-5 0.04440
BTF3 -1.09 3.75E-5 0.03092
Over-expressed	genes	in	the	Rectum
Gene	 Fold	change p	value Adj.	p	value
ITLN2 2.74 2.78E-5 0.03047
TNFRSF6B 2.00 3.89E-5 0.03092
PITX1 1.82 1.10E-5 0.02213
MYEOV 1.71 3.27E-6 0.00859
S100P 1.68 6.24E-5 0.04001
CYP2C18 1.58 6.48E-5 0.04053
LOC401115 1.57 2.12E-5 0.02497
PSMB9 1.56 8.98E-5 0.04447
C4BPB 1.54 4.16E-5 0.03216
CASP1 1.53 7.37E-5 0.04095
ACY3 1.44 3.11E-5 0.03092
C2 1.43 3.27E-5 0.03092
AZGP1 1.35 7.12E-5 0.04095
C10orf125 1.34 1.87E-5 0.02454
TMPRSS3 1.34 4.77E-5 0.03481
NFE2L3 1.33 7.13E-5 0.04095
SERPINA1 1.32 1.43E-6 0.00417
LOC100130298 1.30 1.28E-5 0.02232
MB 1.29 7.52E-5 0.04095
TRIM29 1.29 3.76E-5 0.03092
TMEM16A 1.29 2.19E-5 0.02497
IRAK2 1.28 1.86E-5 0.02454
ANO1 1.25 3.36E-5 0.03092
GRIP2 1.25 9.86E-5 0.04624
NPY6R 1.24 5.46E-5 0.03793
CASP4 1.20 5.93E-5 0.03990
LOC729086 1.12 9.37E-5 0.04555
CABP4 1.07 6.25E-5 0.04001
HC UC
Under-expressed	genes in	the	Descending	colon
Gene Fold	change p	value Adj.	p	value
FAM5C -1.64 4.31E-8 0.00113
FAM5C -1.43 4.62E-7 0.00607
HC UC
HC UCLOW HIGH
Log2	
Expression
Under-expressed	genes	in	the	Rectum
Gene	Fold	changep	valueAdj.	p	value
HOXD11-2.695.24E-70.00204
CLDN8-2.500.0001050.04829
HOXD10-1.943.67E-80.00053
HOXD13-1.758.20E-70.00269
CLCNKA-1.739.54E-50.04555
CHRNA1-1.727.15E-50.04095
UGT2A3-1.715.44E-70.00204
CLCNKA-1.677.64E-50.04095
PCK1-1.650.0001080.04887
FAM5C-1.581.24E-70.00082
KIF5C-1.554.64E-50.03481
TNNC1-1.510.000110.04898
NPY-1.501.72E-50.02454
PCK1-1.473.71E-50.03092
KIAA1715-1.434.01E-80.00053
FAM5C-1.414.92E-70.00204
CHRNA3-1.363.77E-50.03092
RBM24-1.316.32E-60.01510
FAM3C-1.308.18E-50.04214
CMAH-1.297.59E-50.04095
GNPTAB-1.282.90E-50.03049
ACAT1-1.271.77E-50.02454
GNE-1.275.49E-50.03793
ZNF423-1.232.07E-50.02497
ATRN-1.191.24E-70.00082
GPR177-1.197.98E-50.04193
CMTM4-1.181.26E-50.02232
NCRNA00173-1.131.48E-50.02432
SLC25A12-1.137.45E-60.01631
FAM38B-1.138.79E-50.04440
BTF3-1.093.75E-50.03092
Over-expressed	genes	in	the	Rectum
Gene	Fold	changep	valueAdj.	p	value
ITLN22.742.78E-50.03047
TNFRSF6B2.003.89E-50.03092
PITX11.821.10E-50.02213
MYEOV1.713.27E-60.00859
S100P1.686.24E-50.04001
CYP2C181.586.48E-50.04053
LOC4011151.572.12E-50.02497
PSMB91.568.98E-50.04447
C4BPB1.544.16E-50.03216
CASP11.537.37E-50.04095
ACY31.443.11E-50.03092
C21.433.27E-50.03092
AZGP11.357.12E-50.04095
C10orf1251.341.87E-50.02454
TMPRSS31.344.77E-50.03481
NFE2L31.337.13E-50.04095
SERPINA11.321.43E-60.00417
LOC1001302981.301.28E-50.02232
MB1.297.52E-50.04095
TRIM291.293.76E-50.03092
TMEM16A1.292.19E-50.02497
IRAK21.281.86E-50.02454
ANO11.253.36E-50.03092
GRIP21.259.86E-50.04624
NPY6R1.245.46E-50.03793
CASP41.205.93E-50.03990
LOC7290861.129.37E-50.04555
CABP41.076.25E-50.04001
HCUC
Under-expressed	genesin	the	Descending	colon
GeneFold	changep	valueAdj.	p	value
FAM5C-1.644.31E-80.00113
FAM5C-1.434.62E-70.00607
HU
HCUC LOWHIGH
Log2	
Expression
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3.2.3 EXPRESSION OF CLDN8 AROUND HUMAN COLON IN HC AND PATIENTS WITH UC 
As UC is a disease of the large bowel, the expression pattern of CLDN8 was 
assessed across the large bowel in patients with UC (n=24) and healthy controls 
(n=26). 
Transcription profiles from the bowel of patients with quiescent (macroscopically 
normal looking mucosa) UC undergoing surveillance colonoscopies were compared 
with HCs (241). 
CLDN8 expression steadily increases distally in the large bowel, with the highest 
level expressed in rectum, in patients with UC as well as HCs. However, patients with 
UC has a significant reduction in expression throughout the colon when compared to 
HCs (Figure 3-3). Despite having macroscopically normal mucosa, approximately 
30% of the biopsies had evidence of microscopic inflammation. The drop in CLDN8 
expression is more marked in patients with histological evidence of UC. 
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Figure 3-3 – CLDN8 expression around the large bowel. (a) CLDN8 expression 
levels increase distally in the colon of HCs (b), but patients with UC have significantly 
lower CLDN8 levels compared to healthy controls (** p ≤ 0.01 using 1- way Anova 
test) In these experiments, biopsies were taken throughout the colon, in patients with 
quiescent UC, and from macroscopically normal mucosa. Green dots represent UC 
patients with no histologic evidence of inflammation. Red dots represent UC patients 
with histologic evidence of inflammation. (UC, ulcerative colitis; HC, healthy control, 
TI, terminal ileum; Asc. col, ascending colon; Desc. col, descending colon) – Adapted 
from Dr Phil Smith 
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3.2.4 EXPRESSION OF CLDN8 IN HUMAN TISSUE 
In order to validate the abnormal expression of CLDN8 in patients with UC, TaqMan® 
real time quantitative PCR was performed. The relative expression of patients with 
UC were quantified in comparison to HCs. Results were normalised to expression 
levels of the housekeeping gene PPIA, which has been evaluated as a suitable 
reference gene for normalisation in human samples. The patients with UC had a 
lower expression levels of CLDN8 as compared to tissue samples from HC patients 
(Figure 3-4). 
 
Figure 3-4 – CLDN8 expression is down-regulated in patients with UC. qPCR 
verification of CLDN8 expression in the rectal biopsy tissue of tissue of patients with 
UC as compared to HC (*** p ≤ 0.001 using unpaired t-test) UC, ulcerative colitis; 
HC, healthy control (PCR performed by Dr Jenny Dunne) 
 
 
 
  
UC patients 
HC patients 
***
R
el
at
iv
e 
ex
pr
es
si
on
 o
f m
R
N
A
 
 66 
3.2.5 EXPRESSION LEVELS OF UC-SPECIFIC GENES IDENTIFIED IN GWAS STUDIES  
GWAS studies have so far identified 163 risk susceptibility loci in patients with IBD, 
of which 110 are shared between UC and CD, and 23 are specific to UC (150). Of 
the 23 UC specific genes identified so far in GWAS studies, in our dataset, only 10 
genes showed statistically significant differences in expression between patients with 
UC and HC (Figure 3-5). 
Figure 3-5 – UC-specific genes identified in GWAS studies. Only genes that 
reached statistical significant between UC vs HC in our dataset have been shown     
(* p ≤ 0.5, ** p ≤ 0.01 using paired t-test). UC, ulcerative colitis; HC, healthy controls 
 
A number of UC-specific loci are implicated in barrier function and epithelial 
restitution, including CDH1, LAMB1 and HNF4A. The expression levels of these 
genes were analysed in our cohort of patients with UC and compared with HCs. 
CDH1 (cadherin type 1) is a major component of the adherens junction and an 
important mediator of intercellular adhesion and mucosal repair (151). Like CLDN8, 
expression of CDH1 increases distally in humans towards the rectum. However, 
unlike CLDN8, in patients with UC, the expression levels are slightly elevated. 
LAMB1 (laminin-β1 subunit) is expressed in the intestinal basement membrane and 
implicated in a wide variety of biological processes including cell adhesion, 
differentiation, migration, and signalling (152) and HNF4A (hepatocyte nuclear factor-
4α) is a transcription factor that regulates expression of key components of the cell-
cell junction. Of these, only the expression level of CDH1 was affected in our cohort 
of patients with UC (Figure 3-6). CDH1 expression levels were increased in our 
cohort. 
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Figure 3-6 – CDH1 expression around the large bowel. CDH1 levels are higher in 
the distal section of the colon, with slight increase in patients with UC compared to 
healthy controls (* p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001, using 1-way Anova test); (UC, 
ulcerative colitis; HC, healthy control; TI, terminal ileum; Asc. col, ascending colon; 
Desc. col, descending colon) 
 
 
 
Figure 3-7 – LAMB1 expression around the large bowel. LAMB1 levels are highest 
in TI, and then drop in colon, with slight increase in rectum. There was no statistically 
significant difference between patients with UC and HCs. (** p ≤ 0.01; *** p ≤ 0.001, 
using 1-way Anova test); UC, ulcerative colitis; HC, healthy control, TI, terminal ileum; 
Asc. col, ascending colon; Desc. col, descending colon 
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Figure 3-8 – HNF4A expression around the large bowel. HNF4A levels are highest 
in the proximal section of the colon, with a drop in expression distally towards rectum. 
There was no statistically significant difference between the patients with UC 
compared to HCs (*** p ≤ 0.001, using 1-way Anova test); UC, ulcerative colitis;      
HC, healthy control; TI, terminal ileum; Asc. col, ascending colon; Desc. col, 
descending colon 
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3.2.6 CORRELATION OF CLDN8 EXPRESSION WITH KNOWN MARKERS OF MUCOSAL 
INFLAMMATION  
 
To examine the relation of CLDN8 with inflammation, CLDN8 expression levels 
where correlated with expression levels of some of the known inflammatory markers, 
defensins, ITLN2, IL-8 and S100A8 (Figure 3-9). Defensins are small peptides and 
are active against bacteria, fungi and many enveloped and non-enveloped viruses, 
and their expression levels are increased in patients with UC (258), and are markers 
of chronic inflammation. CLDN8 significantly correlates with DEFA1B, DEFA5, 
DEFA6 and ITLN2 (p < 0.0001), but not with IL-8 and S100A8. 
 
 
Figure 3-9 - Correlation of CLDN8 with some known markers of inflammation in 
the rectum of patients with UC (n=21). r2 correlation coefficient and p-values shown 
for each analysis – figure from Dr Phil Smith 
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3.2.7 CORRELATION OF CLDN8 AND OTHER CLDNS IN THE RECTUM OF PATIENTS WITH 
UC 
Overall, 15 different CLDNs are expressed in the rectal samples of patients with UC, 
based on the transcriptomic data. These CLDNs are: -1, -2, -3. -4. -5. -7, -8. -11, -12, 
-14, -15, -16, -18, -19, and -23. Expression levels of these CLDNs were compared 
with CLDN8 expression (Figure 3-10). Of these, the expression levels of 5 CLDNs (-
1, -2, -12, -15, -18) were inversely proportional to CLDN8 expression, suggesting that 
these may either compensate for the loss of CLDN8, or are involved in the same 
physiologic process that results in loss of CLDN8. 
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Figure 3-1 Correlation of 
CLDN8 with other CLDNs 
expressed in the rectum of 
patients with UC (n=21). Only 
CLDNs with significant 
correlation have been shown. r2 
correlation coefficient and p-
values shown for each analysis 
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3.3 DISCUSSION 
As described above, in an attempt to identify molecules which could be causally 
related to the development of IBD, Dr Smith, a PhD student with Prof Segal analysed 
the transcriptomic profile of colonic tissue from patients with UC, as compared to HCs 
(259).  
In this dataset, of the top 4 under expressed genes, 3 belong to the homeobox family 
of genes (HOXD11, HOXD10, HOXD13), and one (CLDN8) is a TJ molecule, with 
the second largest fold change of all under expressed genes. 
It has previously been noted that CLDN8 is under expressed in patients with UC. In 
a meta-analysis of a number of transcriptomic studies of colonic tissue of patients 
with UC, CLDN8 had the largest reduction in expression of all genes (252). However, 
as described in section 3.1, in most of these studies, samples were obtained from 
inflamed tissue (253,255–257), raising the likelihood that any observed changes in 
gene expression may be due to cellular damage and repair processes. The finding 
that CLDN8 is also under expressed in our dataset is intriguing given that in this 
unique dataset, the tissue was collected exclusively from macroscopically non-
inflamed mucosa and from patients that were either on no treatment or minimal 
treatment. These findings raise the possibility that CLDN8 may play an important role 
in the pathogenesis of UC.  
It is also interesting to note that in our dataset, CLDN8 appears to be the only TJ 
molecule with a significant fold change in its expression of ≤ -1 or ≥ 1, after correcting 
for multiple testing. CLDN8 expression levels are inversely proportional to the 
expression levels of a number of CLDNs expressed in the large bowel, all of which 
show an increase in expression levels. Of these, only CLDN1 has similar properties 
to CLDN8 as a “barrier forming” CLDN and reduce the paracellular permeability; 
CLDN2 and CLDN12 are known to increase paracellular permeability and the 
function of CLDN15 and CLDN18 are not yet understood. Taken together, these 
suggest that the changes in expression levels of CLDNs in the large bowel are 
unlikely to be simply a response to compensate for the loss of CLDN8.  
Interestingly, of all the CLDNs expressed in the large bowel, only CLDN8 expression 
levels increase significantly from proximal large bowel towards rectum; all other 
CLDNs are expressed unifor mly throughout the large bowel (data not shown). This 
is intriguing, especially given the anatomical pattern of disease in UC, where the 
inflammation extends up for a variable distance from the rectum.  
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3.4 CONCLUSION 
The finding that reduced CLDN8 expression mirrors the disease pattern in quiescent 
UC may suggest a central role for reduced CLDN8 expression in the pathogenesis 
of UC. CLDN8 may play an important role in the physical strength of TJs, where the 
weaker TJs may allow microscopic physical trauma to the mucosa by formed faeces 
to set off an already abnormal immune response, thus explaining the distal 
distribution of the disease. The reduction of CLDN8 levels may also play a role in the 
increased epithelial permeability in UC patients, known to permit elevated levels of 
inflammatory stimuli to enter the tissue. CLDN8 prevents sodium paracellular back-
leakage (260), and may play a role in diarrhoea. This may partly explain the efficacy 
of corticosteroids in reducing symptoms of diarrhoea in patients with UC. CLDN8 
could therefore be an attractive prognostic and therapeutic target in clinical practice.  
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4 Development and characterisation of the Cldn8-Knock Out 
Mouse 
4.1 INTRODUCTION 
As discussed in Chapter 1.3, a number of animal models have been developed to 
investigate bowel inflammation. These include genetically modified animals, 
chemical and bacterial models to induce colitis. Whilst none of these models can 
replicate the complex pathology of human IBD, they provide tools to investigate 
particular molecules involved in the inflammatory process and pathway. 
To date, the function of Cldn8 has only been investigated in vitro. These studies have 
reported that Cldn8 forms a barrier to cations (including Na+ and K+), ammonium and 
bicarbonate ions (102,108,120). However, these studies are limited and are unable 
to assess the wider potential role of Cldn8 in the animal’s homeostasis. The use of 
gene specific knock out animal models enables selective examination of the action 
of individual molecules in vivo.  
Mice are the most commonly used animals for in vivo experiments, and many of their 
immunological pathways and processes are shared with humans, despite differences 
having been reported (261). These factors, in addition to practical reasons that mice 
are relatively small and have a short gestation period, have resulted in mice 
becoming an important model for investigation of the inflammatory pathways, and 
therefore, the mouse immune system is well characterised. Another important 
physiological similarity between humans and mice is that both have a prenatal sterile 
gut which is colonised with commensal bacteria during and following birth. We 
therefore decided to use a mouse model of colitis to investigate the role of Cldn8 in 
intestinal inflammation by acquiring a Cldn8-Knock Out (Cldn8-KO) mouse. 
Prior to inducing colitis, it was important to accurately characterise the Cldn8-KO 
mice. The parameters that were measured are detailed in the results section below. 
These included verification of deletion of Cldn8 gene, fertility and growth curves, 
normal physiological functions such as urination and defecation, histological 
evaluation of the intestine, serum cytokine measurement, as well as LP composition 
of inflammatory cells. In addition, intestinal permeability to small sugars, and mucous 
permeability to bacteria were measured in naïve animals. 
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4.1.1 INTESTINAL PERMEABILITY 
The role of various CLDNs in controlling paracellular permeability in the bowel is well 
established. The CLDNs are traditionally grouped according to their effect on 
paracellular permeability properties of the epithelial cells, as either having “barrier 
forming”, “pore forming” or “ambiguous function” (88). CLDN8 has been reported to 
form a barrier to cations, ammonium and bicarbonate ions (102,108,120). 
Changes in permeability have been reported in patients with UC. There is evidence 
from animal models that changes in permeability may trigger inflammation in the 
bowel. Mice that are IL-10 deficient, develop spontaneous colitis within 12 weeks, 
and there is evidence that this is preceded by changes in intestinal permeability from 
a young age (179,232). Importantly, these mice do not develop inflammation in germ-
free conditions. These observations suggest that increased penetration of luminal 
antigens due to increased permeability is the trigger for inflammation. Similarly, 
deletion of Cldn7 in mice enhances paracellular permeability in mice. These mice 
also spontaneously develop colitis (101). 
Various techniques have been used to measure intestinal permeability in mice. The 
most common technique includes oral or rectal gavage of different sugars, either 
mannitol, lactulose or dextran (262,263). Different factors, however, influence the 
uptake of these sugars from the intestinal lumen. These include GI motility, diet, 
gastric emptying, mucosal blood flow, as well as renal clearance of any tracers used. 
These factors affect the measurements of permeability, and give rise to false-positive 
or false-negative results (264,265). 
There is evidence that CLDN8 affects the paracellular permeability to acidic and 
basic ions (H+, NH4+, HC3-) (108), and also acts as a barrier to monovalent cations 
including Na+ and K+ (102). This raises the possibility that differences in the local 
concentration may exist between Cldn8-KO and WT mice; this may affect the function 
of the intestinal smooth muscle, which in turn may affect gut motility. Therefore, the 
basic gavage technique was not appropriate, as it would have been impossible to 
conclude if any observed variation in experiments between Cldn8-KO and WT mice 
were due to changes in intestinal permeability or motility. Therefore, a different 
technique was used to measure the intestinal permeability in vivo that controlled for 
any changes in intestinal motility. 
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In vivo permeability studies 
Female Cldn8-KO and WT mice were anaesthetized and maintained at 37oC on a 
thermostatically controlled heating blanket. The peritoneal content were exposed, 
ensuring no damage to the intestine during the procedure. A self-contained segment 
of large bowel was created. The distal cut was made in the most distal part of the 
large bowel that could be reached in the pelvis without damaging other organs; the 
distal end of the segment was therefore within 1-cm of the rectum (Figure 4-1-a and 
–b). Cuts in the bowel were made only to part of the lumen, and not the full width, to 
avoid damaging the mesentery and its blood supply (Figure 4-1-c). A transfer buffer 
containing 3H-mannitol and FITC-Dextran was instilled into the lumen before the 
segment was tied off. Blood was collected after 30min by cardiac puncture. The 
concentration of 3H-mannitol and FITC-Dextran were measured in plasma, and 
factoring the dried weight of the segment, and the animal’s weight (as a surrogate 
marker for the blood volume). There were two reasons for using the dried weight of 
the segment of intestine, instead of its length. First, as will be discussed in next 
chapter, large bowel shrinks in mice suffering from DSS colitis, and therefore, using 
the bowel length can introduce an error in calculation. Second, is that when dissecting 
the segment away from the mesentery, it is possible to stretch the segment (See 
Section 2.9 for full details). 
This experiment involved delicate micro-surgery on mice. The main challenge 
involved minimal handling of the intestines to prevent damage to blood vessels, and 
to the epithelial cells, which could have given rise to false-positive results. Other 
challenges included occasional spillage of the buffer into the peritoneal cavity, and 
taking care not to instil air into the lumen after the buffer. 
The two sugars, 3H-mannitol and FITC-Dextran were chosen as small and 
intermediate sized molecules to investigate permeability. 3H-mannitol has a 
molecular size of 182 kDa and is approximately 4Ǻ is size, which is the same size as 
the paracellular pore created by CLDNs (79), and FITC-Dextran has a molecular size 
of 4,000 kDa, is approximately 14Ǻ. 3H-mannitol is neutral and FITC contributes 
partial negative charge to Dextran at normal pH. 
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Figure 4-1 – In vivo Permeability Studies in Mice (a) Schematic diagram of the 
mouse GI tract. The highlighted area represents the self-contained segment of the 
large bowel (b) The segment remains connected to the mesentery and its blood 
vessels. (c) The bowel is cut only partially to prevent damage to blood vessels in the 
mesentery. 
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4.1.2 MUCOUS PERMEABILITY TO LUMINAL BACTERIA 
There is evidence that whilst commensal bacteria penetrate the outer layer of the 
mucous, the inner layer remains sterile (24,174,266). It has been shown that MUC2 
mucin plays an essential role in keeping the inner mucous sterile (24).  
However, the effect of CLDNs has not been investigated in relation to the mucous 
permeability to bacteria. In the large bowel, aldosterone promotes absorption of 
water, through its effect on absorption of sodium from the luminal side of colonic 
epithelial cells by simultaneously inducing epithelial sodium channels (ENaC) and 
CLDN8 expression (107) (Figure 4-2). Cldn8 expression levels may therefore affect 
the water content and viscosity of the mucous by controlling the luminal concentration 
of Na+. This in turn may affect the permeability of the mucous to luminal antigens. 
 
 
Figure 4-2 – Cldn8 expression levels may affect the mucous properties. Cldn8 
prevents back-leakage of Na+ through paracellular spaces into the lumen. 
Aldosterone stimulates expression of Cldn8 and epithelial Na+ channels (ENaC). 
Reducing the luminal concentration of Na+, may result in water content and viscosity 
of the mucous through osmotic effects of Na+. (ENaC - epithelial Na+ channels). 
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4.2 RESULTS 
4.2.1 COMPARISON OF HUMAN AND MOUSE CLDN8 AMINO ACID SEQUENCES 
Amino acid sequences for human and mouse CLDN8 were retrieved from Ensemble. 
CLDN8 has one transcript in both mice and humans, with one exon. The amino acid 
sequence for human CLDN8 was aligned to the mouse amino acid sequence for 
Cldn8 in SDSC biology work bench. Alignment analysis demonstrated that the amino 
acid sequence for CLDN8 is highly conserved between human and mouse with 83% 
homology (Figure 4-3).  
 
Figure 4-3 – CLDN8 is well conserved throughout species with 83% homology 
between human and mouse. The mouse and human CLDN8 amino acid sequences 
are aligned. (Ensemble; aligned in SDSC biology work bench). 
 
4.2.2 GENERATION OF Cldn8-KO MICE 
Cldn8-KO mice were generated by the Lexicon Genetics Corporation. The entire 
Cldn8 gene is encoded in 1 exon. To generate a KO mouse, the target vector, pKOS-
53 with LacZ/Neo cassettes, was targeted to the Cldn8 gene by homologous 
recombination (Figure 4-4). To genotype the mice, genomic DNA was extracted from 
the ear-punch biopsy, and submitted to PCR. The following primers were used for 
the PCR reaction: WT (DNA266-28 and DNA266-4), Cldn8-KO (DNA266-28, GT ires) 
- (see Appendix 1 – List of Primers). 
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Figure 4-4 – Generation of Cldn8-KO mouse (A) Schematic diagram of the 
targeting strategy for Cldn8-KO mutant mice. WT Cldn8 gene has 1 exon. The target 
vector, pKOS-53 with a LacZ/Neo cassette, was targeted to Cldn8 gene by 
homologous recombination. (B), primer DNA266-28, primer DNA266-4, and primer 
GT ires were used to distinguish WT alleles (418 bps) from mutant alleles (351 bps); 
(C) PCR verification of Mouse Cldn8 gene deletion, ear punch biopsy DNA was 
submitted to PCR analysis using primers DNA266-28, DNA266-4, and GT ires  
418	bp
351	bp
WT Het KO
c)
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4.2.3 Cldn8-KO MICE 
Cldn8 heterozygous mice had been generated using 129/SvEvBrd-derived embryonic 
stem cells. However, as discussed in section 1.3, genetic factors play an important 
role in the experimental colitis models in mice, and differences in susceptibility to 
experimental colitis have been identified among different strains of mice (215). Cldn8 
heterozygote mice were therefore bred to C57BL/6 albino mice to generate F1 
heterozygous animals. These were intercrossed to generate F2 wild type, 
heterozygous, and homozygous mutant progeny. We took delivery of the F2 progeny.  
All earlier experiments in our laboratory, as well as the majority of literature on 
experimental colitis in mice have been performed on C57BL/6 black mouse strain. 
Therefore, the Cldn8-KO transgenic mice (F2) were backcrossed on to C57BL/6 
black WT mice to generate Cldn8-KO mice with a C57BL/6 black genetic 
background. Briefly, the process involved crossing the Cldn8-KO mice with non-
pedigreed non-sibling C57BL/6 black WT mice for several generations. This 
backcrossing process is essential to generate congenic strains of mice, where they 
differ genetically in only one locus (Figure 4-5). 
Female mice reach sexual maturity in 6 weeks, and the time taken from conception 
to birth can be 3 weeks. It can therefore take up to 9-12 weeks for the next generation 
of mice to be born (taking into consideration the length of time taken to conceive). 
The results of experiments in this report are based on mice bred to generation 6 
(96.88% homozygosity). All experiments were performed at least once on litter-mate 
controls. Experiments investigating the acute response to DSS and in vivo 
permeability studies were repeated in generation 10 mice (99.80% homozygosity), to 
ensure reproducibility. 
 
Figure 4-5 – The effect of backcrossing on homozygosity throughout the 
process of generating congenic mice. The Cldn8-KO were backcrossed onto 
C57/B6 mice. With each backcross, there is an increase in percentage of C57B/6 
DNA that constitutes the genome of the offspring – Adapted from Chapter 1, The 
Laboratory Mouse (267) 
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4.2.4 VERIFICATION OF ABSENCE OF CLDN8 mRNA IN Cldn8-KO MICE 
In order to confirm that Cldn8 mRNA was not expressed in Cldn8-KO mice, PCR for 
Cldn8 was performed on tissue from kidney and bowel of the mice. Cldn8 mRNA was 
expressed in tissue obtained WT mice, but not in Cldn8-KO mice (Figure 4-6). Lack 
of expression of Cldn8 in tissue was confirmed using PCR with Gapdh as the 
housekeeping gene. 
 
Figure 4-6 – Genotyping of Cldn8-KO and WT mice. Confirmation of lack of 
expression of Cldn8 mRNA in large bowel of Cldn8-KO mice. Using Cldn8 primers, 
it was confirmed that Cldn8 mRNA is not expressed in Cldn8-KO mice, where as it is 
expressed in the large bowel tissue of WT mice. Genotyping was performed by PCR 
of gDNA isolated from mouse ear clips. (WT: wild-type, KO: knock out, Gapdh: 
Glyceraldehyde 3-phosphate dehydrogenase) 
 
4.2.5 VERIFICATION OF ABSENCE OF CLDN8 PROTEIN IN Cldn8-KO MICE 
Several attempts were made to identify CLDN8 protein using Western blot and 
immunohistochemistry. In total, 4 different available antibodies for CLDN8. For 
Western blot, different techniques were used for preparing cell lysate. However, none 
appeared to be specific to CLDN8 as they all stained a protein with the same weight 
in WT mice (Figure 4-7-a). Actin was used as a loading control and confirmed equal 
amounts of protein were present. 
The same was true for immunohistochemistry where the antibody appeared to bind 
the epithelium in WT mice, but non-specifically bound the tissue in the Cldn8-KO 
mouse. All these antibodies have been used in various publications for identifying 
CLDN8 (268–271).  
 
 
Cldn8
Gapdh
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Figure 4-7 – The antibody to Cldn8 binds non-Cldn8 molecules in a non-specific 
manner. (a) Western blot showing band at 25 kDa region in WT and Cldn8-KO mice 
(antibody from Invitrogen; 1:500); (b) Whilst staining with commercially available 
antibodies against Cldn8 was limited to epithelial layers in the WT mice, in the Cldn8-
KO mice the antibody binds non-specifically across the bowel tissue (GeneTex 
antibody; 1:400); WT, wild-type; KO, Cldn8-KO 
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4.2.6 OTHER Cldns DO NOT COMPENSATE FOR THE LOSS OF Cldn8 IN Cldn8-KO MICE 
There was no statistically significant difference in expression of various Cldns in the 
large bowel of Cldn8-KO and WT mice on transcriptomic analysis – please see 
chapter 6 for full details of the transcriptomic analysis. 
 
 
Figure 4-8 –Transcriptomic analysis of gene expression between Cldn8-KO and 
WT mice did not reveal any statistically significant changes in expression of 
other Cldns. (n=3 per group) 
 
4.2.7 CHARACTERISATION OF THE NAÏVE Cldn8-KO MOUSE 
In order to assess the feasibility of the Cldn8-KO mouse as an appropriate model for 
investigation of role of CLDN8 in intestinal inflammation, the phenotype of the Cldn8-
KO was characterised. 
No significant differences were detected during breeding or on physical examination 
and necropsy between naive Cldn8-KO and WT mice. Both are black mice with no 
characteristic markings. Loss of Cldn8-KO had no obvious impact on the health of 
mice maintained in SPF conditions. A handful of mice were kept for one year and did 
not develop any obvious phenotype, including no colitis phenotype 
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4.2.7.1 Cldn8-KO and WT mice follow similar growth curves 
Cldn8-KO (n=78) and WT (n=141) mice were weighed daily for the initial 21 days, 
and every 5-10 days thereafter for over 80 days. Both groups had the same growth 
curve for the first three weeks. After this point, the growth curve was separated for 
males and females, but similar in Cldn8-KO and WT groups, and no difference in 
weight was seen between naive age and sex matched Cldn8-KO and WT mice 
(Figure 4-9). 
 
Figure 4-9 – Cldn8-KO and WT mice follow similar growth curves. Both groups 
had the same growth curve for the first three weeks. After this point, the growth curve 
was separated for males and females, but similar in Cldn8-KO and WT groups, and 
no difference in weight was seen between naive age and sex matched Cldn8-KO 
(n=78) and WT mice (n=141) 
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4.2.7.2 Cldn8-KO and WT mice have similar size and gender ratio of their litter 
The breeding pattern of heterozygous parents followed a Mendelian pattern of 2 
heterozygous pups to 1 homozygous Cldn8-KO and homozygous WT pup. The 
breeding characteristics were also compared between Cldn8-KO mice and WT mice 
(Figure 4-10) from homozygous parents. Overall, 10 litters from each group were 
compared for litter size and gender ratio. There is no statistical difference between 
the two groups. The number and size of litters were comparable between knockout 
and wild type mice and the pups were born in expected Mendelian ratios. The mean 
percentage of males was 58.83% in Cldn8-KO mice and 48.75% in WT mice litter 
group. The mean litter size was 6.9 in Cldn8-KO mice and 7.6 in WT mice litter group. 
 
Figure 4-10 – Cldn8-KO mice have similar fertility phenotype to WT. There was 
no statistical difference in the (a) litter size and (b) gender ratio between Cldn8-KO 
and WT mice. 
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4.2.7.3 Faeces from Cldn8-KO mice has similar characteristics as that of WT 
mice 
Cldn8-KO mice were maintained in SPF conditions for up to one year. There was no 
sign of spontaneous colitis or any other adverse phenotype. Stool consistency was 
the same in Cldn8-KO and WT mice with fresh stool samples retrieved from both 
groups being fully formed with no evidence of PR bleeding. Stool cultures were 
performed by Deltagen and have been checked subsequently on numerous 
occasions by the vets at UCL animal services. There was no evidence of 
opportunistic infection in either strain. In particular, there was no evidence of 
Helicobacter species which may influence the susceptibility of mice to colitis. 
Faeces from Cldn8-KO mice (n=10) and WT mice (n=11) was analysed for water 
content, as well as sodium and potassium concentrations. There was no statistical 
difference in water content of the faeces between the two groups, expressed as % of 
the weight of faeces (Figure 4-11). There was also no statistical difference in the 
concentration of sodium and potassium between the two groups (Figure 4-12). 
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Figure 4-11 – The faeces from Cldn8-KO and WT mice has the same amount of 
water. Faeces of Cldn8-KO (n=10) and WT (n=11) mice was weighed initially when 
fresh, and then dried overnight in an oven and the dry weight measured again to 
calculate the weight (and volume) of water as a percentage of the content of faeces. 
 
 
 
Figure 4-12 – The faecal Na+ and K+ concentration is similar between Cldn8-KO 
and WT mice. The faeces of Cldn8-KO (n=10) and WT (n=11) mice was weighed 
initially when fresh, and then dried overnight in an oven and the dry weight measured 
again to calculate the weight (and volume) of water as a percentage of the content 
of faeces (meq/L – milliequivalents of solute per litre of solvent) 
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4.2.7.4 Comparison of food and water consumption, and micturition and 
defecation of Cldn8-KO and WT mice 
Metabolic cages were used to analyse the micturition and defecation in a controlled 
environment, whilst enabling measurement of animal’s food and water consumption 
in a set period of time (Figure 4-13). 
During the acclimatisation period, mice were provided the standard dry chow. 
However, by the following morning, the hard pellets had been powdered and 
scattered around, making it impossible to calculate how much of it was eaten by the 
mice. The powdered chow also fell into the funnel and mixed with urine, creating a 
thick, viscous material that trapped the faeces. Therefore, the measurements for 
food, urine and faeces were inaccurate. This was overcome by replacing standard 
dry chow with water-softened chow. One animal in the WT group appeared to have 
consumed significantly more water compared to other animals (Figure 4-14). This is 
likely due to insensible losses when the mouse tried to drink water and the water was 
scattered around. This was not the case for the other 5 mice, suggesting this was an 
issue with acclimatisation, and repeating the experiment with other mice will provide 
a more accurate reading. However, the animals appeared distressed on the metal 
mesh flooring of their cages after a few days, and it was felt that the experiment was 
unlikely to provide sufficiently accurate data to justify repeating the experiment with 
larger cohorts. Therefore, the metabolic cage experiments were performed only 
once, with three animals in each group, and not repeated after this. 
 
Figure 4-13 – Schematic drawing of the mouse metabolic cage. (a) Different 
component of an individual metabolic cage, (b) rack system of the metabolic cage. 
Mice were placed individually in metabolic cages and allowed to acclimate for 5 days. 
Measurements were taken for 24 hours, after which the animals were culled. 
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Figure 4-14 – Comparison of water consumption and urine production of Cldn8-
KO and WT mice. One animal (circled in graph above) in the WT group appeared to 
have consumed significantly more water compared to other animals. This is likely 
due to insensible losses when the mouse tried to drink water and the water was 
scattered around. This was not the case for the other 5 mice. Apart from this outlier, 
there was no statistical differences between the groups; however, this experiment 
was only performed once and on a small number of animals. 
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4.2.7.5 Macroscopic and Microscopic examination and comparison of colons 
from Cldn8-KO and WT mice 
Both macroscopic and microscopic examination of large bowel post mortem revealed 
no differences between the Cldn8-KO and WT mice. Large bowel from both groups 
was similar in weight and length (Figure 4-15-a). Histological examination of the GI 
tract (Figure 4-15-b) did not demonstrate any differences.  
 
Figure 4-15 – The macroscopic and microscopic appearances of the LI is similar 
in Cldn8-KO and WT mice (a) Length of large bowel is similar in both Cldn8-KO and 
WT mice. There is no statistical difference in the length of large bowel between 
Cldn8-KO and WT mice (n=10 per group) (b) Cldn8-KO mice do not exhibit any 
histological abnormality at baseline state. Histology examination of the naïve large 
bowel in
 
Cldn8-KO and WT mice reveals no obvious morphological abnormalities or 
evidence of inflammation on Hematoxylin & Eosin (H&E) staining; LI, large intestine 
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4.2.7.6 Baseline Serum Cytokines 
Baseline serum cytokine concentrations were measured in naïve state in Cldn8-KO 
or WT mice, using MSD® Mouse Pro-Inflammatory 7-Plex Ultra-Sensitive Kit, which 
measures IL-2, INF-γ, IL-4, IL-10, IL-1b, IL-5, KC/GRO (IL-8), IL-6, TNF-⍺ (Figure 
4-16). Unfortunately probe for IL-12p70 did not provide any readings.  
At resting, naïve state, IL-1b and IL-10 are expressed at higher levels in serum of 
Cldn8-KO as compared to WT mice. Expression levels of all other cytokines showed 
a larger variation in Cldn8-KO mice, but this did not reach statistical significant. 
The results in Figure 4-16 have been combined from two separate experiments, and 
therefore are expressed as relative concentrations as opposed to actual 
concentrations. 
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Figure 4-16 – Cldn8-KO have a higher serum concentration of IL-1b and IL-10 at 
baseline state compared to WT mice. Whilst there was no statistical difference in 
the remaining serum cytokine levels between Cldn8-KO and WT mice, there is higher 
variability in cytokine concentration levels in Cldn8-KO mice. The results have been 
combined from two separate experiments and are expressed as relative 
concentrations as opposed to actual concentrations. (* p ≤ 0.5 using paired t-test)  
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4.2.7.7 Baseline cell population in lamina propria (LP) of Cldn8-KO and WT 
mice 
Intestinal LP cells, isolated by collagenase digestion of large bowels from naïve 
Cldn8-KO and WT mice were analysed using Fluorescence-activated cell sorting 
(FACS). No statistically significant differences were identified between the two 
groups.  
Following optimisation of this method the average yield of live LP cells isolated was 
26.33%, of which 40.97% were found to be haemopoietic in origin (CD45+). Of these, 
2.67% neutrophils (GR1hi CD11b+ SSC-Ahi), 3.11% eosinophils (GR1hi CD11b+ SSC-
Aint), 26.02% were macrophages (F4/80+) and 9.09% were DCs (F4/80+ CD11c-). The 
gating strategy is presented in Figure 4-17. Comparison of each cells line between 
Cldn8-KO and WT mice is shown in Figure 4-18. 
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Figure 4-18 – There is no statistical difference in composition of inflammatory 
cells in LP of Cldn8-KO and WT mice; CD45+ is represented as percentage of total 
live cells; all other cells are represented as percentage of CD45+ cells  
Cldn8-KO WT
30
35
40
45
50
55
60
Pe
rc
en
ta
ge
 o
f l
iv
e 
ce
lls
CD45+ 
Cldn8-KO WT
0
2
4
6
8
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
MHCII- SSC-A(hi) - non-APC Macrophages
Cldn8-KO WT
0
1
2
3
4
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
DCs = MHCII+ CD11b+
Cldn8-KO WT
0
1
2
3
4
5
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
Eosinophils
Cldn8-KO WT
0
10
20
30
40
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
MHCII+ Macrophages
Cldn8-KO WT
0
2
4
6
8
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
MHCII- SSC-A(low) - non-APC Macrophages
Cldn8-KO WT
0.0
0.2
0.4
0.6
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
DCs = MHCII- CD11b+
Cldn8-KO WT
0
1
2
3
4
Pe
rc
en
ta
ge
 o
f C
D
45
+ 
ce
lls
Neutrophils
 96 
4.2.8 In naïve state, THERE IS NO DIFFERENCE IN INTESTINAL PERMEABILITY OF 3H-
MANNITOL AND FITC-DEXTRAN IN Cldn8-KO AND WT MICE 
Great care was taken to reduce any manual handling of the bowel. However, in some 
a few of the mice, the 2-cm segment of the large bowel had faeces within the lumen, 
requiring gentle manual handling to remove the faeces. The two groups were 
analysed separately, and the results confirm that any manual handling of the bowel 
results in false-positive results (Figure 4-19), due to damage to the delicate epithelial 
cells. Therefore, in experiments comparing Cldn8-KO and WT, only results of animals 
without any faecal pellets in the bowel segment were used. 
In naïve mice there is no difference in permeability of 3H-mannitol or FITC-Dextran 
between Cldn8-KO and WT mice (Figure 4-20). 
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Figure 4-19 – Manual handling of the intestine results in falsely elevated 
permeability readings. The permeability is higher in animals with faecal pellet in the 
lumen of bowel segment, which required manual handling to remove. All mice in this 
experiment were WT (****p ≤ 0.0001 using unpaired t-test) 
 
 
Figure 4-20 – There is no statistical difference in permeability of 3H-mannitol or 
FITC-Dextran between Cldn8-KO and WT mice in naïve state. 
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4.2.9 THE INNER LAYER OF MUCOUS IS STERILE IN Cldn8-KO AND WT MICE 
To investigate the permeability of inner layer of mucous, sections of the bowel where 
stained for bacteria luminal bacteria and epithelial DNA (the mucous staining – MUC2 
did not work). The inner layer of mucous is sterile in both Cldn8-KO and WT mice. 
 
 
 
Figure 4-21 – The inner layer of mucous is sterile in both Cldn8-KO and WT 
mice. The epithelial cell nucleus has been stained with DAPI (blue) and luminal 
bacteria have been stained with EUB338 (green). Sterile mucus layer is marked with 
a white arrow. 
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4.3 DISCUSSION 
In Chapter 3, the results of our unique transcriptomic dataset were analysed, and 
CLDN8 was found to have the second highest fold-change of all under expressed 
genes in patients with quiescent UC. Additionally, CLDN8 was the only TJ molecule 
with a significant fold change in its expression of ≤ -1 or ≥ 1, after correcting for 
multiple testing. Furthermore, CLDN8 expression levels increase significantly from 
proximal large bowel towards rectum, providing an intriguing possibility of link to the 
anatomical pattern of UC inflammation, where the inflammation extends up for a 
variable distance from the rectum. Therefore, the role of CLDN8 in inflammation was 
chosen for further investigations. 
In this chapter, CLDN8 was shown to be highly conserved at amino acid level 
between humans and mice. It is therefore highly probable that the function of CLDN8 
is conserved between humans and mice as well. After establishing deletion of Cldn8 
in the acquired Cldn8-KO mice, baseline characteristics of Cldn8-KO and WT mice 
were compared to fully assess the suitability of Cldn8-KO mice as an animal model 
to study the function of Cldn8 in intestinal inflammation.  
It was established that other Cldns do not compensate for the loss of Cldn8 in the 
Cldn8-KO mouse. Also, no difference in fertility, growth or survival were observed 
between Cldn8-KO and WT mice, and Cldn8-KO mice did display evidence of 
spontaneous colitis or systemic inflammation in the naïve state – five animals were 
housed for one year, but none developed any clinical signs of colitis, including 
diarrhoea, rectal bleeding or weight loss. 
Given the evidence that Cldn8 acts as a barrier to monovalent cations including Na+ 
and K+ (102), faecal water content faecal Na+ and K+ concentration, mucosal 
permeability to luminal bacteria and intestinal permeability to two differently sized 
sugars were investigated in the naïve state, and no differences found between Cldn8-
KO and WT mice. The inner layer of the mucous is also sterile in both Cldn8-KO and 
WT mice. 
FACS analysis did not demonstrate any statistical difference in the composition of 
the inflammatory cells in LP between Cldn8-KO and WT mice. However, 
unfortunately, some of the FACS experiments did not work. In particular, experiments 
to assess subsets of T-cells, including Treg did not work. This may be relevant given 
the findings of the cytokine concentrations (see below.) 
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The Cldn8-KO mice, however, had higher serum concentration levels of IL-1b and 
IL-10 in blood, compared to WT mice. Also, whilst there was no statistically significant 
difference between the other measured cytokines in the serum (TNF-⍺, INF-γ, IL-2, 
IL-4, IL-5, IL-6, KC/GRO between Cldn8-KO and WT mice, there was more variation 
in Cldn8-KO mice than WT. These findings were surprising given that Cldn-8-KO 
mice do not develop any abnormal phenotype, have normal intestinal permeability 
and normal inflammatory cell composition in their LI LP. Furthermore, the two 
cytokines with elevated concentrations in Cldn8-KO mice, IL-1b and IL-10 have 
opposing effects. IL-1b is a potent proinflammatory cytokine, inducing neutrophil 
influx and activation, T-cell activation and cytokine production, as well as B-cell 
activation and antibody production (272,273). IL-10, however, is an immune-inhibitor, 
and acts as an inhibitor of antigen presentation, inhibiting MHCII and upregulating 
co-stimulatory molecules CD80 and CD86, on DCs and macrophages (274). Mice 
lacking IL-10 spontaneously develop intestinal inflammation, preceded by changes 
in intestinal permeability (232). Recent evidence suggests that IL-10 is responsible 
for maintaining Foxp3 expression in Treg cells in inflammatory conditions (69). The 
molecular mechanisms by which IL-10 maintains Foxp3 expression are not yet clear. 
4.4 CONCLUSION 
The findings in this chapter are intriguing. The Cldn8-KO mice do not exhibit any 
gross phenotypical abnormalities, and no statistically significant difference was 
observed between any of the measured parameters in the intestine of Cldn8-KO and 
WT mice. Despite these findings, the elevated serum IL-1b and IL-10 serum cytokine 
concentration levels in Cldn8-KO mice raise the possibility of ongoing, low-level 
inflammation. In the next chapter, effects of chemically induced colitis in mice, using 
DSS, will be investigated.  
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5 Characterisation of the Cldn8-KO mouse using a chemical 
induced model of colitis, DSS 
5.1 INTRODUCTION 
In chapter 4, Cldn8-KO mice were characterised in naïve state, and found not to 
develop spontaneous colitis. Therefore, to investigate the role of Cldn8 in intestinal 
inflammation, colitis will be induced in the Cldn8-KO mice. 
As discussed in Chapter 1.3, given that mice do not develop the equivalent of human 
IBD, different models of colitis have been developed in mice.  
In this chapter, the effect of the chemically-induced colitis using DSS is investigated 
in Cldn8-KO mice. There were several reasons for choosing DSS to investigate the 
role of Cldn8 in intestinal inflammation.  
Firstly, the chemical toxin DSS is a widely used and published method to induce 
colitis in mice, and is added to the drinking water at concentrations of 1-5% for 3-7 
days (275). In response to DSS, mice develop a predominantly neutrophilic infiltrate 
with a continuous colitis which resembles UC in humans (214,276). Histological 
changes in DSS-colitis include mucin depletion and epithelial degeneration leading 
to the formation of cryptitis and crypt abscesses. A chronic colitis can be induced by 
recurrent challenges of DSS (276,277).  
Secondly, the current evidence suggests that, at least in part, the mechanism of 
action of DSS may be through its effect on the mucous layer. It has been shown that 
germ free mice develop significantly less severe colitis than SPF mice, and that in 
response to DSS exposure, the inner layer of the normally sterile inner mucous in the 
large bowel becomes permeable to bacteria (216). Taken together, these results 
suggest that luminal bacteria play a significant role in development of inflammation 
in DSS-induced colitis, and that one major contribution of DSS to development of 
inflammation is the effect it has on the properties of the mucous. Therefore, given 
that as discussed in chapter 4.1.2, loss of Cldn8 may affect the properties of the 
mucous, DSS-induced colitis was chosen as the model to investigate the effect of 
Cldn8 in intestinal inflammation. 
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5.2 RESULTS 
5.2.1 DSS DOSE RESPONSE 
In order to choose an appropriate dose of DSS to induce an experimental colitis, Dr 
O’Shea had previously performed a dose response study. For this, 25 wild type 
C57BL/6 male mice, 8-10 weeks old, were divided into 5 cages of equal numbers. 
Their drinking water was replaced with different concentrations of DSS (1%, 2%, 3%, 
5%) dissolved in drinking water for 7 days. One group of mice did not have DSS 
added to the water and acted as the control group. After 7 days, the DSS was 
replaced by normal drinking water. Weights were measured and stool samples 
collected daily. Mice that survived the DSS challenge were culled at D15. 
Mice exposed to 3-5% DSS developed severe bloody diarrhoea by day 5, lost >15% 
of their body weight by day 7 and all had to be culled by day 10 due to severe weight 
loss. In contrast mice exposed to 1% DSS lost very little weight and had minimal 
diarrhoea or rectal bleeding. 2% was deemed the ideal concentration of DSS to use 
for further experiments as mice lost <15% of their original weight which was maximal 
by day 10, but all had regained their baseline weight and normal stool consistency 
by the end of the experiment on day 15. 
 
Figure 5-1 – DSS results in a dose dependent weight loss in C57/B6 mice. DSS 
was dissolved in drinking water for 7 days at different percentages. Mice were 
weighed daily and plotted as a percentage of their original weight, error bars 
represent S.E.M. Dotted red line denotes 15% weight loss. Mice were litter mates, 
age, weight and sex matched, n=5 per group – figure from Dr O’Shea 
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5.2.2 CHARACTERISATION OF 2% DSS COLITIS IN WT C57BL/6 MICE 
In order to assess the suitability of DSS-induced mouse model of colitis for 
examination of the role of Cldn8 in intestinal inflammation, C57BL/6 WT mice were 
exposed to 2% DSS in their drinking water for 7 days, before being switched back to 
normal drinking water. The mice’s response to colitis was assessed, by measuring 
body weight and blood in the stool (including occult blood testing). Mice were 
sacrificed at days 0, 3, 9 and 21 from start of DSS and their large bowels were 
resected, measured and 5mm snips were taken from distal colon for qPCR 
measurement of Cldn8 mRNA levels. 
WT mice developed colitis, characterised with weight loss, diarrhoea, blood in their 
stool, and shortening of their large bowel (Figure 5-2). Similar to humans (see Section 
3.2.1), and as reported previously in colitis (120,124), Cldn8 levels dropped early on 
in the inflammatory process in Day 3. Interestingly, Cldn8 expression levels showed 
rebound on Day 9, 2 days after mice were swapped back onto normal drinking water. 
By Day 21, Cldn8 mRNA levels were back to baseline levels (Figure 5-2-d). 
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Figure 5-2 – Mice develop colitis in response to DSS. WT mice developed colitis 
in response to consuming 2% DSS in their drinking water for 7 days, before being 
switched back to normal drinking water and recovering. Day 0 is traditionally the first 
day that DSS is started. D21 is 2 weeks after DSS had been stopped. (a) Mice were 
weighed daily and plotted as a percentage of their original weight, error bars 
represent S.E.M. (n=12). (b) Mice developed blood in their stools during colitis. As 
colitis became more severe, some mice did not pass stools within 30min. (c) Length 
of bowel in mice correlates to the severity of intestinal inflammation. (d) Quantitative 
PCR of Cldn8 relative to house-keeping gene PPIA in the large bowel was performed. 
Cldn8 mRNA expression levels drop in response to inflammation; however, there is 
a rebound in mRNA expression levels of Cldn8 during early recover phase, and return 
to normal levels by day 21 (e) Representative image of H&E stained large bowel 
tissue (20× magnification, scale bar: 200 µm) on days 0,3, 9 and 21 after the DSS 
challenge demonstrates effects colitis in WT mice with increased cellular infiltration, 
crypt distortion, ulceration and goblet cell depletion on day 7. On day 21 there is 
histologic resolution of inflammation with normal tissue architecture. Error bars 
represent S.E.M; * p < 0.5, ** p ≤ 0. 01, *** p ≤ 0.001, using unpaired t-test 
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5.2.3 ACUTE COLITIS: 2% DSS-INDUCED COLITIS IN Cldn8-KO AND WT MICE 
Cldn8-KO and WT mice were cohoused in UCL animal facility. Mice were age, weight 
and sex matched. Diet, ambient temperature, light and living conditions were identical 
for the two groups. Prior to experimentation mice were rested in the animal facility for 
at least 7 days to acclimatize. 2% DSS was added to the drinking water on D0 for 
seven days and then this was replaced with normal drinking water. Mice were 
assessed for weighed daily, and stool samples were collected daily for assessment 
of consistency and presence of blood. Mice were sacrificed at days 0, 3, 6, 9, and 
14. Post mortem, blood was obtained from cardiac puncture for serum and bowels 
were resected for qPCR, FACS and histology. 
5.2.3.1 Clinical signs 
On examination both strains of mice became clinically unwell and developed a colitis 
during the seven-day exposure to 2% DSS. Clinical signs of diarrhoea, rectal 
bleeding and weight loss peaked at D9 in both strains.  
WT mice were more susceptible to 2% DSS induced colitis than litter mate Cldn8-KO 
mice. This was evident clinically by an increased and more rapid weight loss 
(p<0.0001) (Figure 5-3-a) with more severe clinical signs and earlier onset colitis with 
bloody diarrhoea. Stool from WT mice contains bloods earlier than stool from Cldn8-
KO mice, in response to DSS (Figure 5-4-a). The stool from both groups shows 
evidence of blood. However, the proportion of WT mice with blood in their stools is 
higher than Cldn8-KO mice within 2 days of DSS. Lack of stools is a feature of 
severity of colitis, due to reduction in peristalsis of inflamed bowel, and a higher 
proportion of WT mice did not defecate when compared to Cldn8-KO mice (ordinarily 
mice defecate every 3-5 minutes; in these experiments, “no stool” was defined as 
lack of defecation for 30 minutes).  
Interestingly, Cldn8-KO mice develop softer stool in response to DSS more rapidly 
than WT mice. However, the proportion of Cldn8-KO mice that develop severe 
diarrhoea is smaller than WT mice (Figure 5-4-b) 
Clinical improvement was seen in both strains from D10 onwards; mice regained their 
original weights and stool consistency returned to normal (Figure 5-3). 
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Figure 5-3 – Loss of Cldn8 results in reduced susceptibility to DSS induced 
colitis. Cldn8-KO and WT litter-mate mice exposed to 7 days of DSS. (a) Cldn8-KO 
mice do not lose as much body weight and are not clinical as unwell as the WT mice, 
(b) the large bowel in WT mice shrinks significantly more than the large bowel in 
Cldn8-KO (n=7 per genotype (c) Representative photographs of colons resected post 
mortem from Cldn8-KO and WT mice on day 9 post DSS. The colons from WT mice 
contained bloody stools, seen here in the shrunken caecum, and were significantly 
shorter than those from Cldn8-KO mice. Error bars represent S.E.M; * p < 0.5, ** p ≤ 
0. 01, *** p ≤ 0.001, **** p ≤ 0.0001 using unpaired t-test 
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Figure 5-4 – Rate of onset of colitis is faster in WT mice than in Cldn8-KO mice. 
(a) in response to DSS, blood appears in the stools of WT mice in a shorter time than 
in Cldn8-KO mice. (b) Cldn8-KO mice develop softer stool in response to DSS more 
rapidly than WT mice. However, the proportion of Cldn8-KO mice that develop severe 
diarrhoea is smaller than WT mice. Lack of stools is a feature of severity of colitis, 
due to reduction in peristalsis of inflamed bowel. 
 
5.2.3.2 Serum Cytokines 
During the course of the experiment cardiac puncture was performed on days 0, 3, 
6, and 9, in Cldn8-KO or WT mice, using MSD® Mouse Pro-Inflammatory 7-Plex 
Ultra-Sensitive Kit, which measures IL-2, INF-γ, IL-4, IL-10, IL-1b, IL-5, KC/GRO (IL-
8), IL-6, TNF-⍺ (Figure 5-5). Unfortunately probe for IL-12p70 did not provide any 
readings. The results in for D0 have been combined from two separate experiments, 
and therefore all the results, across multiple dates are expressed as relative 
concentrations and not actual concentrations.  
Table 5-1 summarises the findings. 
Days on DSS Findings 
0 (naïve) Higher IL-1b and IL-10 concentration levels in Cldn8-KO mice 
3 Higher IL-2 concentration levels in Cldn8-KO mice 
6 Higher IL-5 concentration levels in Cldn8-KO mice 
9 (post DSS) Higher IL-10 concentration levels in WT mice 
 
Table 5-1 – Summary of differences between cytokine concentration levels 
between Cldn8-KO and WT mice at different stages of DSS inflammation 
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Figure 5-5 – Serum cytokine concentration levels in Cldn8-KO and WT at 
different stages of DSS inflammation. D0 is naïve state, DSS was stopped on D7, 
and therefore D9 is 2 days post-DSS. In naïve state, Cldn8-KO mice have higher 
concentration of IL-1b and IL-10. On D3, only IL-2 is expressed at higher 
concentration in Cld8-KO, on D6 only IL-5 is expressed at higher concentration in 
Cld8-KO, and on D9, only IL-10 is expressed at higher concentration in WT mice. No 
other statistically significant difference was observed between the two groups at 
different stages of DSS-induced inflammation. The results have been combined from 
two separate experiments and are expressed as relative concentrations as opposed 
to actual concentrations. (* p < 0.5 using unpaired t-test) 
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5.2.4 MICROSCOPIC CHANGES IN RESPONSE TO DSS-INDUCED COLITIS 
Mice were culled on Day 0, 3, 7 and 9 to determine histological evidence of colitis. 
As previously discussed in no macroscopic or microscopic differences were observed 
in the colon of Cldn8-KO naïve mice compared with WT naïve mice. 
Consistent with clinical signs, both strains developed evidence of colitis on histology, 
with increased cell infiltration, crypt elongation, distortion and ulceration. Both groups 
had histologic signs consistent with severe colitis by day 7. However, there was no 
statistically significant difference in the histological scores between the Cldn8-KO and 
WT mice at any time point. (Figure 5-6). 
 
Figure 5-6 – There is no histological difference between Cldn8-KO and WT mice 
on DSS. (a) Representative image of H&E stained large bowel tissue (20× 
magnification) on days 0, 3, 7 and 9 after the DSS challenge demonstrates effects 
colitis in Cldn8-KO and WT mice with increased cellular infiltration, crypt distortion 
and goblet cell depletion and ulceration on day 7 (b) On days 0, 3, and 9, the 
histological score was 0 for Cldn8-KO and WT mice. On day 7, both groups had 
severe inflammation on histology 
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5.2.5 THE SEVERITY OF DSS-INDUCED COLITIS IS DIFFERENT BETWEEN MALE AND 
FEMALE MICE 
The severity of DSS-induced colitis is varied between male and female mice in WT 
mice but not in Cldn8-KO mice (Figure 5-7). Whilst both male and female WT mice 
develop colitis and lose weight, this is more pronounced in female WT mice, which 
lose significantly more weight than their male counterparts. The severity of colitis in 
male WT mice is similar to that of male Cldn8-KO mice. The male WT mice do not 
recover from colitis as rapidly as their Cldn8-KO mice, or even the female WT mice 
(Figure 5-7-a and Figure 5-7-c). The rate of recovery is similar in female WT and 
Cldn8-KO mice. 
 
 
Figure 5-7 – The severity of DSS-induced colitis is different between male and 
female mice. Female WT mice develop the most severe colitis. The severity of colitis 
in male WT mice is comparable to that of male and female Cldn8-KO mice. However, 
male WT mice do not recover as rapidly as the female WT mice, or the male or female 
Cldn8-KO mice. Error bars represent S.E.M; * p < 0.5, ** p ≤ 0. 01 using unpaired t-
test 
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5.2.6 CHRONIC COLITIS: REPEAT EXPOSURE OF Cldn8-KO AND WT MICE TO 2% DSS 
Cldn8-KO and WT mice were exposed to two consecutive 7-day challenges of 2% 
DSS. After each challenge a period of recovery was permitted; in one experiment, 14 
days recovery was permitted between the first and second challenge, and in another 
experiment, 28 days of recovery was permitted before the final 7 days of DSS. 
The period of rest from DSS provided to mice before a repeating the exposure to 
DSS affected the severity of colitis. Mice develop a relative resistance to developing 
a second episode of colitis if exposed to DSS within a short period after the first 
episode of DSS-induced colitis. The colitis in WT mice after 5 weeks of rest was as 
severe, and mice lost weight at the same rate, as they did during the first bout of DSS 
induced colitis (Figure 5-8-a). However, the WT mice that were exposed to DSS only 
after 2 weeks of break had significantly milder colitis (Figure 5-8-a). This 
phenomenon was repeated in Cldn8-KO mice as well (Figure 5-8-b). This suggests 
that even though both groups have recovered from their first episode of colitis, and 
phenotypically mice appear the same at week 2 or week 5 after the first exposure to 
DSS, important differences exist at molecular level that confer protection from 
developing another severe episode of colitis. The colitis that mice develop after being 
exposed to DSS only after 2 weeks of rest is markedly milder than even the colitis 
developed by Cldn8-KO after their first exposure to DSS (Figure 5-8-b). 
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Figure 5-8 – Mice develop resistance to repeated DSS-induced colitis. The 
period of rest from DSS provided to mice before a repeating the exposure to DSS 
affected the severity of colitis. Mice develop a relative resistance to developing a 
second episode of colitis if exposed DSS within 2 weeks of the initial insult (b) but 
lose this protection after 5 weeks (a) Error bars represent S.E.M – the 5 week DSS 
experiment in WT mice in (a) was performed by Dr O’Shea 
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5.2.7 ASSESSMENT OF CELLULAR INFLAMMATORY RESPONSE IN LP OF Cldn8-KO AND 
WT MICE 
As discussed in section 4.2.7.7, no difference was seen in the cellular composition 
within the colonic LP in naive Cldn8-KO mice compared with WT mice. There was no 
statistical difference in the number of cells in LP of Cldn8-KO mice compared with 
WT mice during DSS inflammation and immediate recovery period (Figure 5-9). 
 
 
Figure 5-9 – There is no difference in cellular response to inflammation in LP of 
Cldn8-KO mice compared with WT mice, Error bars represent S.E.M; n=3 per 
group 
 
FACS analysis of the colonic LP cell populations was performed for each genotype 
at day 0, 3, 6, 9, 14, following exposure to DSS, as well as second episode of DSS 
exposure on day 21, 24 and 28. By day 3, a lower proportion of neutrophils (GR1hi 
CD11b+ SSC-Ahi) were recruited to the LI in Cldn8-KO mice when compared with WT 
mice. Cldn8-KO has lower proportion of recruited neutrophils by day 6 as well, but by 
day 9, the proportion of neutrophils were comparable between the Cldn8-KO and WT 
mice (Figure 5-10-a and -b). On day 3, Cldn8-KO also had a lower proportion of 
macrophages (F4/80+ MHCII+) present in their LP than WT mice (Figure 5-11-a and 
–b). The differences in proportion of other cell types across different time points were 
not statistically significant.  
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Figure 5-10 – Cldn8-KO
 
mice have an attenuated neutrophilic infiltration into the 
colon following exposure to DSS. Representative FACS plots of isolated colonic 
LP cells in naïve mice (D0), 3 days (D3) and 6 days (D6) post DSS in Cldn8-KO and 
WT. The proportion of neutrophils (GR1hi CD11b+ SSC-Ahi) were determined using 
FACS analysis. The proportion of neutrophils in colonic LP are similar between the 
naive Cldn8-KO and WT mice (day 0), but the proportion of neutrophils in Cldn8-KO 
mice is lowers when compared with WT mice, on D3 and D6. The proportion of 
neutrophils did not significantly differ between the groups by Day 9 after initial DSS 
exposure. The mice were provided another DSS challenge on D21. However, 
neutrophils made up a significantly smaller proportion of cells on Day 28, than they 
did on Day 6. Results are expressed as the mean; *p<0.05 using unpaired t-test 
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Figure 5-11 – Cldn8-KO
 
mice have a lower proportion of macrophages in the 
colon LP following exposure to DSS. Representative FACS plots of isolated 
colonic LP cells in naïve mice on day 3 (D3) post DSS in Cldn8-KO and WT. The 
proportion of antigen-presenting macrophages (F4/80+ MHCII+) were determined 
using FACS analysis. The proportion of macrophages in colonic LP are similar 
between the naive Cldn8-KO and WT mice (day 0), but are lower in Cldn8-KO mice 
on D3 post DSS. The proportion of macrophages did not significantly differ between 
the groups by Day 6 after initial DSS exposure. The mice were provided another DSS 
challenge on D21. However, macrophages made up a significantly smaller proportion 
of cells on Days 21 and 28, than they did on Days 3 and 6. Results are expressed as 
the mean; *p<0.05 using unpaired t-test 
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5.2.8 INCREASED PERMEABILITY TO 3H-MANNITOL IS LESS PRONOUNCED IN Cldn8-KO 
MICE COMPARED TO WT MICE IN EARLY STAGE INFLAMMATION 
As discussed in chapter 4.2.8, no differences in permeability were observed in naïve 
state between Cldn8-KO and WT mice. Both groups have increased permeability to 
3H-Mannitol and FITC-Dextran by Day 3 of administration of DSS. However, the 
increased permeability to 3H-mannitol is less marked in Cldn8-KO mice as compared 
to WT mice (Figure 5-12-a). This reflects their less severe clinical response to DSS 
colitis. There is no difference in permeability of 3H-mannitol in both groups by Day 9 
on DSS. There is no difference in permeability of FITC-Dextran between Cldn8-KO 
and WT mice. Interestingly, whilst the permeability of 3H-mannitol remained abnormal 
by Day 9 in both animal groups, the permeability of FITC-Dextran returned to normal 
by Day 9 post initiation of administration of DSS.  
 
 
Figure 5-12 – Permeability of 3H-mannitol and FITC-Dextran is raised in both 
Cldn8-KO and WT mice by D3 of DSS. However, the increase in permeability of 3H-
mannitol is less pronounced in Cldn8-KO mice on D3 DSS; * p < 0.5 using unpaired 
t-test 
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5.2.9 THE INNER LAYER OF MUCOUS REMAINS STERILE AFTER 12 HOURS OF EXPOSURE 
TO DSS IN Cldn8-KO AND WT MICE 
To investigate the permeability of inner layer of mucous, sections of the bowel where 
stained for bacteria luminal bacteria and epithelial DNA (the mucous staining – MUC2 
did not work), in naïve state and after the animal was exposed to DSS for 12 hours. 
In both states (naïve as well as post-DSS), the inner layer of mucous was sterile in 
Cldn8-KO and WT mice. 
 
 
Figure 5-13 – The inner layer of mucous remains sterile in both Cldn8-KO and 
WT mice after the animals were exposed to DSS for 12 hours. The epithelial cell 
nucleus has been stained with DAPI (blue) and luminal bacteria have been stained 
with EUB338 (green). Sterile mucus layer is marked with a white arrow 
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5.3 DISCUSSION 
In Chapter 4, the Cldn8-KO mice were characterised in naïve state, and found to 
have no discernible physiological difference with the C57BL/6 WT mice. In this 
chapter, effect of DSS-induced colitis on Cldn8-KO mice were studied. 
DSS was used to induce colitis in mice. In response, Cldn8 was downregulated in LI 
in WT mice, returning to baseline as the colitis resolved. This response is similar to 
observations made by others (120,124).  
Interestingly, in WT mice, Cldn8 is overexpressed during the early phase after DSS 
insult is removed; this is when the bowel is recovering and epithelial injury is healing. 
The dynamic response of Cldn8 locally to intestinal inflammation would suggest that 
the molecule has a role in the cellular regeneration. This is in keeping with 
observations that Cldns may be involved in cell motility (278). 
Most intriguing was the observation that the DSS-induced colitis was significantly 
milder in Cldn8-KO mice than WT mice. This was characterised by reduced weight 
loss, and significantly healthier appearing LI macroscopically. The finding was 
mirrored in a smaller increase in the proportion of LI LP neutrophil and macrophage 
populations as well as smaller raise in intestinal permeability in Cldn8-KO, particularly 
during the early phase of the inflammation.  
This was a surprising finding, and contrary to the original hypothesis.  
With regards to intestinal permeability, the increase in permeability of 3H-mannitol 
was lower in Cldn8-KO as compared to WT mice. The same was true for FITC-
Dextran, though the difference did not reach statistical significance. Interestingly, 
whilst the permeability of 3H-mannitol remained abnormal by Day 9 in both animal 
groups, the permeability of FITC-Dextran returned to normal by Day 9 post initiation 
of administration of DSS. This is an interesting observation, given that the animals 
were switched back to normal water on Day 7. Taken together, this data suggests 
that permeability of 3H-mannitol (4Ǻ in size), is likely to be determined by properties 
of the paracellular spaces between epithelial cells; however, the permeability of 
FITC-Dextran is likely to be determined by breaks in the epithelial layer, which should 
start to close as the epithelial cells starts to regenerate after withdrawal of DSS. 
The attenuated clinical response of the Cldn8-KO mice to DSS was also evidence in 
the inflammatory cellular infiltrate to the LI LP. By day 3, a lower proportion of 
neutrophils and macrophages were recruited to the LI in Cldn8-KO compared to WT 
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mice. However, by day 9 the proportion of neutrophils were comparable between the 
Cldn8-KO and WT. Unfortunately, the FACS experiments investigating population of 
Treg cells did not produce any results. 
The precise mechanism of inflammation in DSS-colitis is not known. It is well 
established that the resultant inflammation has many of the features of UC in humans 
(214), including weight loss, diarrhoea and blood in the stools, and histological 
changes including mucin depletion and epithelial degeneration leading to the 
formation of cryptitis and crypt abscesses. Mice receiving DSS develop evidence of 
breakdown in the tight junction complex with a loss of tight junction proteins (279), 
and epithelial apoptosis (280) within the first 24 hours of DSS exposure. The directly 
toxic effect of DSS on epithelial cells is thought to be secondary to formation of nano-
lipocomplexes with medium-chain-length fatty acids in the large bowel that can fuse 
with epithelial cell membranes (214). The evidence for a directly toxic effect of DSS 
comes from studies in antibiotic treated (281), and germ free (282,283) mice, which, 
in response to DSS, developed a significantly less severe colitis than SPF mice with 
normal intestinal microflora. Further evidence into the pathogenesis of DSS comes 
from studies of mucous properties. In the LI, the inner layer of the mucous is normally 
sterile, and impenetrable to luminal bacteria. However, it has also been shown that 
after exposure to DSS, the inner layer of the mucous in the large bowel that is 
normally sterile becomes permeable to bacteria (216). 
As discussed in chapter 4.1.2, aldosterone promotes absorption of water, through its 
effect on absorption of sodium from the luminal side of colonic epithelial cells by 
simultaneously inducing epithelial sodium channels (ENaC) and CLDN8 expression 
(107) (Figure 4-2). This may therefore provide a mechanism for the relative protection 
against DSS witnessed in Cldn8-KO mice, where the mucous may be better hydrated 
and more resistant to the effects of DSS. To investigate this, investigations were 
performed to investigate the permeability of mucous in Cldn8-KO and WT mice in 
naïve state and after the animal was exposed to DSS for 12 hours. No differences 
were observed between Cldn8-KO and WT mice at either time point, and the inner 
layer of the mucous remained sterile after exposure of the animals to DSS for 12 
hours. The 12 hour time window was chosen based on previously published reports 
that the inner layer of mucous becomes permeable after exposure of the animal to 
DSS for 12 hours (174). It is worth noting that the authors Johansson et al had used 
3% DSS for their experiments, as opposed to 2% DSS used in experiments in this 
thesis. This might explain the reason that the inner layer of mucous remained sterile 
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even in WT mice in these experiments, and that a longer exposure time on 2% DSS 
may cause the inner layer of mucous to become permeable to bacteria. 
The serum concentration of a number of cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, 
KC/GRO, TNF-α, INF-y) was measured at different time points during inflammation, 
and shortly after, during recovery period. The finding that the IL-2, was increased in 
Cldn8-KO mice on day 2 was interesting. IL-2 is the major growth factor for T 
lymphocytes and plays an important role in stimulating the suppressor function of 
Tregs (284,285), as well as stimulating generation of effector and memory CD8+ T 
cells (285). IL-5, which had a higher serum concentration in Cldn8-KO mice on day 
5 post DSS-induced colitis, induces terminal differentiation of B-cells to 
immunoglobulin production. IL-5 is mainly produced by activated T helper (Th) 2 cells 
and mast cells. By day 9, WT mice had higher concentration levels of anti-
inflammatory cytokine IL-10 than Cldn8-KO mice. This, however, may represent the 
milder colitis in Cldn8-KO mice and faster recovery of their acute inflammatory 
response. What was particularly intriguing about the concentration of cytokines 
measured on day 9, was the comparison of concentration levels in Cldn8-KO mice 
on day 0 (naïve) and day 9 (recovery period post DSS). As discussed previously, in 
naïve state, the mice had a significantly more varied concentration level for most of 
the cytokines, and IL-10 and IL-1b in particular, appeared to be present at higher 
concentration in the serum. However, by day 9 (only 2 days after removal of DSS 
from the mice), IL-10 and IL-1b concentration were very low in Cldn8-KO mice, and 
comparable to the naïve state in WT mice. 
Another intriguing finding are the results of the chronic DSS model in mice, where 
animals were exposed to DSS again, after a variable length of time. When WT mice 
were exposed to DSS after 5 weeks of rest, they developed colitis as severe as the 
first bout of exposure. However, when mice were exposed to DSS only after 2 weeks 
of rest, they had a significantly milder colitis. This protective phenotype was observed 
in both Cldn8-KO and WT mice. In keeping with this finding, the neutrophils and 
macrophages made up a significantly smaller proportion of cells when the mice were 
challenged with DSS after 2 weeks, showing a clearly attenuated inflammatory 
response. 
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5.4 CONCLUSION 
Although DSS colitis resembles microscopic features of IBD, in particular UC, it does 
not truly reflect the pathophysiology of human IBD. However, in WT mice, Cldn8 in is 
downregulated in response to DSS-induced colitis, which is in keeping with the 
observation in patients with UC where CLDN8 has one of the highest fold changes 
of any downregulated gene. Cldn8-KO mice have an attenuated response to DSS-
induced colitis. These results suggest that CLDN8 does have a role in intestinal 
inflammation, and downregulation of CLDN8 may be a protective mechanism by the 
intestine. The finding that serum IL-10 levels are slightly elevated in naïve Cldn8-KO 
mice, may provide a possible mechanism for the protective phenotype observed in 
these mice. As discussed in chapter 4.3, IL-10 is an anti-inflammatory cytokine, and 
mice lacking IL-10 spontaneously develop intestinal inflammation (232). Recent 
evidence suggests that the IL-10 is responsible for maintaining Foxp3 expression in 
Treg cells in inflammatory conditions (69). This may represent a mechanism of action 
for reduced susceptibility of Cldn8-KO mice to developing colitis secondary to DSS. 
However, as described above, unfortunately, the set of FACS experiments 
investigating population of Treg cells did not produce any results. 
The following chapter uses transcriptomic analysis to investigate the molecular basis 
for the observed differences to DSS-induced colitis between Cldn8-KO and WT mice.  
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6 Transcriptomic analysis of Cldn8-KO and WT mice at naïve 
state and during DSS inflammation 
6.1 INTRODUCTION 
As discussed in chapter 1.2, UC is a very heterogeneous disease, and the aetiology 
is poorly understood. The current prevailing hypothesis for pathogenesis of UC is that 
an abnormal innate immune response in genetically susceptible individuals, 
combined with environmental factors, result in excessive activation of the adaptive 
immune system within LP (142,143). Abnormalities in mucous, epithelial 
permeability, immune system, as well as the microbiome have all been implicated. 
In chapter 3, data from transcriptomic analysis of our unique dataset of patient with 
quiescent UC was presented, and CLDN8 was identified as the only TJ molecule with 
a significant fold change in its expression of ≤ -1 or ≥ 1, after correcting for multiple 
testing. In chapters 4, no physiological differences were identified from the Cldn8-KO 
and the WT mice. Subsequently, in chapter 0, it was demonstrated that Cldn8-KO 
mice’s clinical response to DSS is significantly attenuated when compared with WT 
mic, and that there is a small (but statistically significant) difference in permeability to 
3H-mannitol by Day 3. 
In this chapter, a ‘hypothesis generating’ approach is taken to identify a molecular 
basis for the observed differences to DSS-induced colitis between Cldn8-KO and WT 
mice. Transcriptomic data were analysed using conventional group comparisons. 
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6.2 RESULTS 
6.2.1 QUALITY CONTROL OF MICROARRAY RESULTS 
To identify difference in expression between Cldn8-KO and WT mice, microarray 
analysis of genome-wide gene expression was performed, at naïve state (D0), D3 
(early-mid-point inflammation), D9 (early recovery phase), and D21 (post recovery). 
D21 is particularly interesting, because whilst the animals’ colitis has clinically 
recovered by day 21, both Cldn8-KO and WT mice display a protective phenotype 
against developing colitis in response to further bout of DSS, and this protection is 
only transient as it is lost within a few weeks (see Chapter 5.2.6 for details). 
Microarray analysis was performed using Illumina Mouse-WG6 v2.0 Expression 
BeadChips. Three animals were used per group, per time point (overall 24 animals). 
Expression data were log2 transformed with cubic spline normalisation (286) between 
arrays, by Dr Adam Levine (Figure 6-1). 21,555 out of the total of 45,282 probes 
(47.6%) were found to be expressed at detectable levels, as determined using the 
detection p-values associated with each probe (see Materials and Methods section 
0 and 2.11.1 for details). Unfortunately, Cldn8 probes (ILMN_2623145, 
ILMN_2681236) did not provide any reading for any of the samples (including WT 
naïve state mice). qRT-PCR was performed to confirm that Cldn8 was expressed in 
the original samples (see Figure 5-2 for qRT-PCR confirmation). This confirmed that 
Cldn8 was indeed expressed and that the probe on the BeadChip was faulty. 
 
Figure 6-1 – Cubic spine normalisation. Density plots of intensity of each array are 
superimposed on a single graph for a better comparison between arrays and for an 
identification of arrays with abnormal distribution. (a) is pre-normalised and (b) is 
post-Cubic spline normalised data. 
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6.2.2 DIFFERENTIALLY EXPRESSED GENES BETWEEN Cldn8-KO AND WT MICE 
Differentially expressed genes were identified using the Multiple Experiment Viewer 
(MEV) TM4 software suit (version 10.2), an established software package for 
statistical analysis of microarray datasets (244). Probes were identified that were 
significantly different between Cldn8-KO and WT mice at the four time-points, using 
an uncorrected p-value of p < 0.01 and a minimum fold change of ≤ -1 or ≥ 1 
compared to mean expression in either Cldn8-KO mice or the WT mice. See Figure 
6-2 for the volcano plots, and Table 6-2 for the list of genes with minimum fold change 
of ≤ -1 or ≥ 1. 
 
DSS Days Total no. of differentially 
expressed genes  
Differentially expressed genes 
with minimum Fc ≤ -1 or ≥ 1 
D0 (naïve) 188 10 
D3 144 2 
D9 (early recovery) 182 2 
D21 (protective 
period) 
549 16 
 
Table 6-1 – Number of differentially expressed genes between Cldn8-KO and 
WT mice at different stages of DSS-induced colitis. Whole genome microarray 
analysis of gene expression was performed using Illumina Mouse WG6.0 v2.0 
expression array. Differentially expressed genes were identified using a minimum 
fold change of ≤ -1 or ≥ 1 and p-value <0.01 (uncorrected for multiple testing). None 
of the genes remained statistically significant after correction for multiple testing. 
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Day 0 (Naïve) 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2935012 Anxa4 1.32 1.11E-04 
ILMN_2421925 Wdfy1 1.49 2.15E-05 
ILMN_2998658 Erdr1 1.88 5.50E-03 
Under-expressed genes (p value < 0.01, ≤ -1 fold change) 
ILMN_2514377 Cxadr -2.47 5.86E-07 
ILMN_1230696 IGL-V1  -2.08 5.17E-03 
ILMN_2693858 D14ERTD449E -1.68 2.45E-04 
ILMN_1225825 LOC100039175 -1.40 2.96E-05 
ILMN_1232435 Mmrn1 -1.40 6.40E-05 
ILMN_2710159 MGC41689  -1.27 1.04E-03 
ILMN_2896768 Cbr3 -1.19 2.95E-03 
 
 
 
 
Day 3 DSS 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2684053 Lpo 2.17 3.34E-04 
Under-expressed genes (p value < 0.01, ≤ -1 fold change) 
ILMN_2514377 Cxadr -2.28 6.70E-04 
 
 
 
 
Day 9 DSS 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2738369 Krt6a 1.08 3.32E-03 
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Day 21 DSS 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2958099 Adssl1 1.32 2.89E-03 
ILMN_2759371 Fgfbp1 1.27 7.28E-03 
ILMN_1245079 Adssl1 1.04 1.97E-03 
ILMN_2602938 Smpdl3b 1.03 8.83E-03 
Under-expressed genes (p value < 0.01, ≤ -1 fold change) 
ILMN_2684053 Lpo -2.37 1.34E-03 
ILMN_1222286 LOC666652 -1.77 3.99E-03 
ILMN_2909275 Slc46a1 -1.47 7.37E-03 
ILMN_1229197 Gm14446 -1.42 4.34E-04 
ILMN_2866267 F2rl1 -1.29 2.80E-03 
ILMN_2844353 AI747448 -1.27 8.47E-03 
ILMN_2592486 Pglyrp1 -1.25 4.03E-03 
ILMN_2784078 Mmp15 -1.21 2.12E-03 
ILMN_2854943 Gprc5a -1.16 1.09E-03 
ILMN_2828265 SEPT5 -1.12 4.82E-03 
ILMN_1246785 Gprc5a -1.11 1.90E-03 
ILMN_2589859 Duoxa2 -1.10 7.45E-03 
 
Table 6-2 – Differentially expressed genes between Cldn8-KO and WT mice at 
different stages of DSS inflammation. Whole genome microarray analysis of gene 
expression was performed using Illumina Mouse WG6.0 v2.0 expression array. 
Differentially expressed genes were identified using a minimum fold change of ≥ 1 or 
≤ -1 and p-value <0.01 (uncorrected for multiple testing). None of the genes remained 
statistically significant after correction for multiple testing. 
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6.2.2.1 qRT-PCR verification of gene expression 
As discussed above in section 6.2.2, after correction for multiple testing, no 
statistically significant differences were noted between Cldn8-KO and WT mice at 
any time point. However, without correction for multiple testing, some differences 
were noted at each time point between the Cldn8-KO and WT mice. Therefore, the 
expression of some of these genes was verified using qRT-PCR on the original 
samples used for microarray analysis, as technical controls. 
Cxadr 
The Illumina Mouse WG6.0 v2.0 expression array has three probes for Cxadr in mice, 
and one of the probes had shown a consistent difference in expression levels 
between Cldn8-KO and WT mice (Figure 6-3). In humans, CXADR is on chromosome 
21. However, in mice Cxadr is on chromosome 16, which is the same chromosome 
as Cldn8, and therefore, it is possible that during the deletion process of Cldn8, Cxadr 
may have been affected. The CXADR gene has two splice variants both in humans 
and mice. PCR primers were developed to cover both variants (see Appendix 1 – List 
of Primers). After PCR verification, no difference in expression levels were noted 
between Cldn8-KO and WT (Figure 6-3).  
 
 
Figure 6-3 – Cxadr expression on Illumina and qRT-PCR (a) The Illumina Mouse 
WG6.0 v2.0 expression array has three probes for Cxadr. (b) The qRT-PCR 
verification of Cxadr gene did not show any difference between the Cldn8-KO and 
WT mice.  
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Lpo and Duox2 
The Illumina Mouse WG6.0 v2.0 expression array has one probe for Lpo in mice and 
one probe for Duox2, which showed a difference in expression levels at day 3 and 
day 21 on DSS, respectively (Figure 6-4). 
Lactoperoxidase (Lpo) activates thiocynate and hydrogen peroxide (produced by 
Duox2) to hypothiocyanite, which has bactericidal properties. The increased activity 
of Lpo seen on the microarray data (Figure 6-4-a) represented a possible mechanism 
for the relative protection of Cldn8-KO to DSS induced colitis when compared to WT 
mice. 
However, qRT-PCR verification of Lpo did not show any difference between Cldn8-
KO and WT mice. Interestingly, Duox2 had a higher expression in WT on day 9 (2 
days after stopping DSS water) than in Cldn8-WT mice. 
 
 
Figure 6-4 – Lpo and Duox2 expression on Illumina and qRT-PCR (a) the Illumina 
Mouse WG6.0 v2.0 expression array probe expression levels for Lpo and Duox2 
suggested a difference in days 3 and 21 of DSS inflammation (b) The qRT-PCR 
verification of Lpo gene did not show any difference between the Cldn8-KO and WT 
mice. However, on day 9 of DSS induced colitis experiments, Duox2 had a lower 
expression in Cldn8-KO mice than in WT. 
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6.2.3 PRINCIPLE COMPONENT ANALYSIS 
Principle component (PCA) analysis was conducted to determine whether global 
Cldn8-KO and WT mice gene expression profiles could be separated on the basis of 
disease. PCA is a mathematical algorithm for reducing the dimensionality of datasets, 
by finding the principal components (directions) along which the variation is minimal. 
PCA plots of samples, where each data point represents expression values of all the 
expressed probes in the array, can be used to visually assess similarities and 
differences between samples and whether they can be grouped (287). 
Considering the combined datasets, principal components 1 and 2 accounted for 
66.94% and 9.15% of the data variability respectively. A further 4.84% of the variance 
was explained by principal component 3 (Figure 6-5). 
 
 
Figure 6-5 – Scree plot from principal component analysis. Eigenvalyes and 
cumulative variability of the principle components have been superimposed. A total 
of 24 components were detected in the PCA. 
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Figure 6-6 – Principal component analysis of Cldn8-KO and WT mice at different 
time points of DSS-induced colitis. Array expression data were log2 transformed 
and PCA analysis was performed using Multiexperiment Viewer TM4 microarray 
software suit. Scatter plots for principal components 1 and 2 are shown, with 
microarray results for each sample represented as a single point. Array samples 
colour coded by genotype and inflammatory state (K - Cldn8-KO; W - WT) 
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6.2.4 DIFFERENTIALLY EXPRESSED GENES AT DIFFERENT DSS TIME POINTS 
In this section, changes in gene expression will be analysed across time, in Cldn8-
KO and WT separately. Differences in changes in gene expression in Cldn8-KO and 
WT mice across time will then be compared. 
Differentially expressed genes between naïve animals and different times points 
during as well as after recovery from DSS-induced colitis were identified using the 
MEV TM4 software suit (version 10.2). Probes were identified that were significantly 
different at different time points, using an uncorrected p-value of p < 0.01 and a 
minimum fold change of ≤ -1 or ≥ 1 compared to mean expression in either Cldn8-
KO mice or the WT mice. Multiple correction testing was performed using false 
detection rate (FDR) method with a cut off value of < 0.01. 
 
6.2.4.1 WT Mice 
 
 
 
Figure 6-7 - Volcano plot of differentially expressed genes in WT mice, between 
D0 (naïve) mice and different stages of DSS-induced inflammation.   (a) Day 3 
(b) Day 9 and (c) Day 21 of DSS-induced inflammation. Whole genome microarray 
analysis of gene expression was performed using Illumina Mouse WG6.0 v2.0 
expression array. Genes differed in expression at an adjusted p-value < 0.01 are 
represented as blue and red dots (uncorrected for multiple testing). Genes with a 
minimum fold change of ≤-1 or ≥1 are represented as blue dots. Only genes 
expressed differently between day 9 and day 0 remained statistically significant after 
correction for multiple testing, using false detection rate (FDR) cut off value of < 0.01 
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WT – D9 vs D0 differentially expressed genes 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2772632 Saa3 6.84 2.24E-07 
ILMN_2712075 Lcn2 6.32 1.04E-05 
ILMN_2656504 Retnlg 6.09 4.45E-05 
ILMN_2803674 S100a9 6.00 2.93E-04 
ILMN_1223257 Ccl4 5.98 1.92E-04 
ILMN_2710905 S100a8 5.92 9.32E-04 
ILMN_2777498 Il1b 5.81 4.96E-04 
ILMN_1246800 Serpina3n 5.71 6.50E-06 
ILMN_2737685 Mmp13 5.44 2.80E-06 
ILMN_2619952 Mmp10 5.30 2.63E-05 
Under-expressed genes (p value < 0.01, ≤ -1 fold change) 
ILMN_1232533 Sycn -6.13 4.86E-05 
ILMN_1225061 NA -5.89 4.91E-07 
ILMN_1252131 Klk1b27 -5.01 5.30E-05 
ILMN_1238736 NA -4.95 1.57E-04 
ILMN_2980898 Mptx1 -4.89 1.60E-06 
ILMN_2731191 Klk1b5 -4.89 1.85E-04 
ILMN_2777363 Tgm3 -4.84 3.50E-06 
ILMN_1229177 Klk1b26 -4.77 1.41E-04 
ILMN_2760199 Klk1 -4.73 4.09E-04 
ILMN_1246145 Gsdmc3 -4.57 1.94E-07 
 
 
Table 6-3 – Differentially expressed genes in WT mice, between Day 9 on DSS 
and Day 0 (naïve). Overall, 2146 probes (out of 21,554) remained significant after 
correction for multiple testing using false discovery rate (FDR) cut off value of < 0.01. 
Only top 10 over-expressed and under-expressed genes are shown here. Whole 
genome microarray analysis of gene expression was performed using Illumina 
Mouse WG6.0 v2.0 expression array. Differentially expressed genes were identified 
using a minimum fold change of ≤ -1 or ≥ 1 and p-value <0.01 (uncorrected for 
multiple testing). 
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6.2.4.2 Cldn8-KO Mice 
 
 
 
Figure 6-8 - Volcano plot of differentially expressed genes in Cldn8-KO mice, 
between D0 (naïve) mice and different stages of DSS-induced inflammation.   
(a) Day 3 (b) Day 9 and (c) Day 21 of DSS-induced inflammation. Whole genome 
microarray analysis of gene expression was performed using Illumina Mouse WG6.0 
v2.0 expression array. Genes differed in expression at an adjusted p-value < 0.01 
are represented as blue and red dots (uncorrected for multiple testing). Genes with 
a minimum fold change of ≤-1 or ≥1 are represented as blue dots. Only genes 
expressed differently between day 9 and day 0 remained statistically significant after 
correction for multiple testing, using false detection rate (FDR) cut off value of < 0.01 
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Cldn8-KO – D9 vs D0 differentially expressed genes 
Probe ID Gene ID Fold Change p-value 
Over-expressed genes (p value < 0.01, ≥ 1 fold change) 
ILMN_2772632 Saa3 6.64 1.62E-06 
ILMN_2710905 S100a8 6.48 4.67E-06 
ILMN_2722616 Krt14 6.31 1.19E-06 
ILMN_2803674 S100a9 6.22 8.67E-06 
ILMN_1223257 Ccl4 6.08 9.31E-04 
ILMN_2777498 Il1b 6.06 2.26E-04 
ILMN_2712075 Lcn2 5.90 7.84E-05 
ILMN_2656504 Retnlg 5.84 4.03E-04 
ILMN_1246800 Serpina3n 5.80 9.62E-07 
ILMN_2754364 Ltf 5.63 2.75E-04 
Under-expressed genes (p value < 0.01, ≤ -1 fold change) 
ILMN_1225061 NA -5.82 5.70E-05 
ILMN_1252131 Klk1b27 -5.12 5.63E-05 
ILMN_1238736 NA -5.06 4.85E-05 
ILMN_2731191 Klk1b5 -4.93 1.51E-04 
ILMN_1229177 Klk1b26 -4.82 1.44E-04 
ILMN_2980898 1810030J14Rik -4.78 1.11E-05 
ILMN_2760199 Klk1 -4.71 1.61E-04 
ILMN_2727309 NA -4.57 1.47E-06 
ILMN_2601519 Abp1 -4.54 7.55E-04 
ILMN_2742426 Selenbp1 -4.42 6.97E-06 
 
 
Table 6-4 – Differentially expressed genes in WT mice, between Day 9 on DSS 
and Day 0 (naïve). Overall, 2216 probes (out of 21,554) remained significant after 
correction for multiple testing using false discovery rate (FDR) cut off value of < 0.01. 
Only top 10 over-expressed and under-expressed genes are shown here. Whole 
genome microarray analysis of gene expression was performed using Illumina 
Mouse WG6.0 v2.0 expression array. Differentially expressed genes were identified 
using a minimum fold change of ≤-1 or ≥1 and p-value <0.01 (uncorrected for multiple 
testing). 
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Figure 6-9 – Venn Diagram of differences in changes in gene expression 
between D9 and D0 (naïve) on DSS, in Cldn8-KO and WT mice. Whole genome 
microarray analysis of gene expression was performed using Illumina Mouse WG6.0 
v2.0 expression array. Differentially expressed genes were identified using a 
minimum fold change of ≤-1 or ≥1 and p-value <0.01, after correction for multiple 
testing using false discovery rate (FDR) method with cut off value of < 0.01. 
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6.2.4.3 Identification of the biological function of the differentially expressed 
genes at different time points during and after recovery from DSS-
induced colitis in WT and Cldn8-KO mice 
 
Over and under-expressed differentially expression probes on day 9 of DSS-induced 
colitis as compared to naïve animals was identified. Probes that remained statistically 
significant after correction for multiple testing, using false detection rate (FDR) cut off 
value of < 0.01 were analysed using DAVID Bioinformatics Resources v6.7 to 
determine gene ontology (GO) processes that were enriched within the probe list. 
The most significantly enriched GO processes were included antigen processing and 
presentation of peptide antigen, immune response, inflammatory response, oxidation 
reduction, and response to wounding (Table 6-5).  
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Table 6-5 – Functional analysis of differentially expressed genes for WT and 
Cldn8-KO mice, between days 9 and 0 in DSS-induced intestinal inflammation. 
Analysis of functional ontology of the differentially expressed genes between days 9 
and 0 on DSS-induced colitis was performed using DAVID Bioinformatics Resources 
v6.7. Only genes that reached significance after multiple testing correction based on 
a false discovery rate (FDR) of < 0.01 were included in analysis. The 20 most 
significantly enriched GO processes within (a) WT and (b) Cldn8-KO mice datasets 
are shown, with associated p-values. The number of genes in each GO process 
present in the dataset is also included.  
(a)
(b)
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6.3 DISCUSSION 
In this chapter, the global transcriptomic profile of Cldn8-KO and WT mice was 
interrogated, in naïve state, as well as during and post DSS-induced colitis, in an 
attempt to identify molecular differences responsible for the attenuated inflammatory 
response by Cldn8-KO observed in chapter 5. Although a number of differentially 
expressed genes were identified between Cldn8-KO and WT mice at each time point, 
none remained statistically significant after correction for multiple testing.  
Also, as discussed in chapter 5, for a short period after recovering from DSS-induced 
colitis, mice are protected from developing another bout of severe DSS-induced 
colitis. This protection was seen at 2 weeks after the first challenge, but is lost by 
week 5 (see chapter 5.2.6 for full details). In an attempt to identify molecular 
differences responsible for this protective mechanism, differentially expressed genes 
at different time points were interrogated within each genotype group (e.g. day 3 vs 
day 0 in WT mice). Although a number of differentially expressed genes were 
identified between each time point analysis, which could be of functional relevance, 
only differentially expressed genes between day 9 and day 0 (naïve) remained 
significant after correction for multiple testing. Many processes were common 
between Cldn8-KO and WT mice, involving inflammatory and recovery processes, 
suggesting that overall, Cldn8-KO and WT mice have similar functional ontologies at 
on day 9 of DSS-induced intestinal inflammation. 
Some of the observed variations in gene expression are likely to be due to limitations 
of Microarray technology (288). For example, the Illumina Mouse WG6.0 v2.0 
expression array has three probes for the Cxadr gene, and as discussed above, one 
of these probes had a significantly different expression profile between Cldn8-KO 
and WT mice (IMN_2514377). However, on qRT-PCR, there was no change in 
expression of Cxadr between Cldn8-KO and WT mice. It is likely that this finding is 
due to a SNP variation in WT mice. The same is true for the Lpo gene that was 
identified and verified with qRT-PCR. 
Microarrays have been crucial in science through their ability to simultaneously 
interrogate tens of thousands of transcripts, and identify differentially expressed 
genes. However, microarrays have several limitations. There is evidence that a 
proportion of probes on Illumina chips are unreliable and may fail (288), as was the 
case for Cldn8 probe in this study. Background noise and cross-hybridisation of 
transcripts with probes means that microarrays cannot distinguish between “low” 
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expression and “no” expression. During analysis, the microarray probe intensity is 
assumed to be proportional to the concentration of the transcript, but this is 
dependent on the affinity of the probe and transcript. Polymorophisms within the 
probe region and differences between mouse strains can influence the microarray. 
Splice variants present a challenge to microarray data analysis. If the short nucleotide 
probe on the chip targets a specific splice variant, then other variants of the same 
gene will be ignored. Another technique for investigating gene expressions is RNA-
Seq. RNA-Seq is the direct sequencing of transcripts by high-throughput sequencing 
technologies. RNA-Seq does not rely on genome annotation for prior probe selection, 
and has the potential to replace microarrays. RNA-Seq has a number of advantages 
over microarray, such as ability to detect novel transcripts, and avoiding the problems 
with splice variants. Unlike microarrays, RNA-Seq also does not suffer from 
background noise, and cross-hybridisation, and avoids problems with incorrect 
annotation of the probes (289). However, there are challenges associated with RNA-
Seq; in addition to being more expensive, it is also a relatively new technique, and 
therefore, the data-analytic tools are less developed than they are for microarray. 
6.4 CONCLUSION 
The finding that after correction for multiple testing, differentially expressed genes 
between Cldn8-KO and WT mice did not remain statistically significant at any time 
point, may suggest that the main reason for the observed differences between the 
different mice groups may be the loss of Cldn8. In the next, final chapter, a possible 
role for Cldn8 and future studies are proposed. 
  
 141 
7 General Discussions 
7.1 SUMMARY OF FINDINGS 
• In transcriptomic analysis performed on colonic pinch biopsies, CLDN8 was 
found to have one of the largest fold-change reductions of any gene in 
patients with quiescent UC 
• CLDN8 is the only TJ molecule with a differential expression across the large 
intestine. CLDN8’s expression increases distally towards the rectum, 
mirroring the pattern seen in UC inflammation 
• CLDN8 expression levels negatively correlate with markers of chronic 
inflammation, such as DEFA1B, DEFA5, DEFA6 and ITLN2 
• Cldn8-KO mice do not develop spontaneous signs of colitis 
• Cldn8-KO mice have comparable physiology to WT mice in naïve state 
• There is a reduction in expression of Cldn8 mRNA in WT mice in response to 
inflammation 
• The commercially available anti-CLDN8 antibodies in mice are not specific to 
CLDN8 
• There is a rebound expression of Cldn8 mRNA during the early phase of 
recovery 
• Loss of Cldn8 in Cldn8-KO mice results in reduced susceptibility to DSS 
induced colitis 
• Cldn8-KO mice, had smaller increase in intestinal permeability to 3H-mannitol, 
reduced neutrophils and macrophages in inflammatory cell infiltrate in LP 
during the early phase of inflammation. 
• The increased permeability to 3H-mannitol is less marked in Cldn8-KO mice 
as compared to WT mice, reflecting the less severe clinical response to DSS 
colitis in Cldn8-KO mice. 
• Whilst the permeability of 3H-mannitol remained abnormal by Day 9 in both 
animal groups, the permeability of FITC-Dextran returned to normal by Day 9 
post initiation of administration of DSS. Taken together, this data suggests 
that permeability to larger molecules is determined by gaps in the epithelial 
cells, but the permeability to small molecules (~4Ǻ in size), it is likely to be 
determined by properties of the paracellular spaces between epithelial cells. 
• There were no gross histologic differences during inflammation between 
Cldn8-KO and WT mice, suggesting that the differences between the two are 
very subtle 
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• There is an increase of serum IL-1b and IL-10 in serum of naïve Cldn8-KO 
mice. 
• For a shortly period after recovery from DSS-induced colitis, mice are less 
susceptible to developing another severe DSS-induced colitis. This protection 
was observed at 2 weeks after stopping DSS-water, and was lost by week 5. 
• Female mice are more susceptible to DSS-induced colitis, and lose more 
weight than their male counterparts. However, female mice also recover 
much more rapidly, reaching their pre-DSS-induced colitis weight sooner than 
their male counterparts. This is true in Cldn8-KO and WT mice 
• The inner layer of mucous is sterile in naïve Cldn8-KO and WT mice, and 
remains sterile after the animals have been exposed to DSS-water for 12 
hours 
• Transcriptomic analysis between Cldn8-KO and WT mice did not reveal any 
significant differences between the two groups at different time points. After 
correction for multiple-testing, no differentially-expressed genes remained 
7.2 DISCUSSION OF FINDINGS, IMPLICATIONS AND STUDY 
LIMITATIONS 
7.2.1 UC IS ASSOCIATED WITH EPITHELIAL AND MUCOSAL BARRIER ABNORMALITIES 
UC is a chronic relapsing IBD. Unlike CD, UC is a disease of the large bowel and 
does not affect the rest of the GI tract. Patients with UC usually present with frequent 
bowel movements, which can be small in volume because of rectal inflammation. 
Patients may also suffer from extra-intestinal manifestations of the disease, such as 
joint pains, eye problems such as uveitis and episcleritis, and skin issues such as 
erythema nodusum and pyoderma gangrenosum. Some patients may also develop 
primary sclerosing cholangitis (PSC), an autoimmune condition affecting the biliary 
tree. The aetiology of UC is complex, and the current prevailing hypothesis for 
pathogenesis of UC is that an abnormal innate immune response in genetically 
susceptible individuals, combined with environmental factors, result in excessive 
activation of the adaptive immune system within LP (142,143). 
The importance of colonic bacteria and abnormalities in mucous barrier are becoming 
better understood: 
• GWAS have identified a number risk loci that are specific to UC and involved 
in barrier function and epithelial restitution. 
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• Studies have also found increased permeability in colon of patients with UC, 
even during the quiescent state (167,168), though as we have found in our 
studies, even patients may have microscopic inflammation despite 
macroscopically normal colonic mucosa, and this may influence the results 
of these studies. 
There have been many observations on the response of Cldns to inflammation. It is 
generally accepted that during colitis, CLDN2 is upregulated (119,120,122,124), and 
CLDN8 is downregulated (120,124,290). However, evidence for other CLDNs is 
mixed. For example, some studies have found CLDN1 to be upregulated (290,291), 
downregulated (124,292), or not changed in expression (119,120,293). One 
significant problems so far, has been that given the large number of CLDNs 
expressed in the large bowel, investigators have been selective in the ones they have 
studied using qRT-PCR. As a result, the data has been patchy across different 
studies.  
However, there is now strong evidence from human transcriptomic analysis studies, 
both in inflamed tissue (252), and also from our own data set from patients with 
quiescent disease (241) that CLDN8 is likely to be the main TJ involved during 
inflammation. In these studies, not only has CLDN8 had one of the largest fold 
changes in expression of any identified gene, but CLDN8 has also been the only TJ 
gene with a significant fold change in expression levels.  
Despite the observations described above, there is very little evidence on the role of 
TJ molecules in intestinal inflammation. It has been shown that loss of Cldn7, one of 
the most prominent Cldns in intestine, in mice, will result in spontaneous intestinal 
inflammation (101), and that Cldn2 deficient mice are more susceptible to DSS-
induced colitis (294).  
CLDN8 has been reported to form a barrier to cations, ammonium and bicarbonate 
ions (102,108). Therefore, it had been proposed that the combined increased 
expression of “pore-forming” CLDN2 (98) and reduction in “barrier forming” CLDN8 
(102,108) may predispose to inflammation by increasing intestinal permeability to 
luminal antigens. The a priori hypothesis for this study was that reduced CLDN8 
expression would worsen the inflammatory response; instead it appears to be 
protective. 
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7.2.2 LOSS OF CLDN8 IS PROTECTS AGAINST DSS-INDUCED COLITIS 
The evidence presented in this thesis is that loss of Cldn8 confers relative protection 
against DSS-induced colitis in Cldn8-KO mice, compared with WT mice, as 
evidenced by clinical features such as reduced weight loss in Cldn8-KO mice. 
However, the differences were very subtle, and minimal, including minor differences 
in LP inflammatory cell infiltrates (neutrophils and macrophages) and differences in 
permeability to 3H-mannitol (and not larger FITC-Dextran) on Day 3 of DSS-induced 
inflammation only. 
7.2.3 POTENTIAL ROLE OF THE MUCOUS BARRIER 
Bacterial load increases towards the distal intestine, reaching a maximum in the 
colon, with 1013 organisms per gram of faeces. The first line of defense against these 
pathogens is the mucus layer, produced by the epithelial goblets cells. The thickness 
of the mucus layer steadily increases from the proximal to the distal large bowel 
(295,296), and is composed of an outer loosely adherent layer, and an inner more 
adherent layer (25), which is normally sterile (174,266,297).  
There is evidence that bacteria are able to penetrate the normally impenetrable 
impermeable inner mucus layer in the colon of patients with UC (216). Similarly, in 
mice, it has been shown that the inner mucus layer is impermeable to fluorescent 
beads with a diameter in the same size range as bacteria (2 µm), and that DSS 
changes the properties of the inner mucus layer such that it was thinner and 
permeable to bacteria (216).  
The main component of the mucus layer is MUC2 (297), which has an important 
protective mechanism; MUC2 knockout mice are susceptible to developing 
spontaneous colitis similar to UC, and have an increased susceptibility to DSS-
induced colitis (298–301). Whilst mucous thickness is normal in patients with 
quiescent UC (302), mucin 2 (MUC2) synthesis and secretion are decreased in active 
UC due to alterations in sulphation (303). 
In addition to MUC2, the mucous layer also contains positively-changed Anti-
Microbial Peptides (AMPs). The cationic character of AMPs result in electrostatic 
attraction to the negatively-charged phospholipids of microbial membranes, and their 
hydrophobicity subsequently aids integration into the microbial cell membrane, 
leading to disruption (304). Two main classes of AMPs are produced by the colonic 
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epithelium: defensins and cathelicidins. There is evidence of abnormality in b-
defensins may play a role in development of inflammation in CD and UC (305). 
As discussed above, Cldn2-KO develop a more severe colitis in response to DSS 
than WT mice (294), and increased expression of Cldn2 confers protection against 
DSS colitis (306). Also as described above, there is also evidence that during 
inflammation, Cldn8 expression is down-regulated whilst Cldn2 expression is up-
regulated (119,124).  
Cldn2 and Cldn8 have opposing characteristics (307). Whilst Cldn8 acts as a barrier 
to cations (102,108), Cldn2 induces cation-selective channels in tight junctions of 
epithelial cells (98). Cldn8 is also involved in sodium and water homeostasis in the 
colon (107), by preventing back-leakage of the former into the lumen. The changes 
in Cldn expression during inflammation may therefore be an attempt to strengthen 
the mucous barrier by increasing its water content and the defensins contained within 
it, thereby reducing exposure of the immune system to bowel microbiota. The 
additional protection could provide some relief towards the minor insults, but not 
sustained challenges such as continuous DSS-water for 7 days. Therefore, the 
results of experiments in this study, such as lower increases intestinal permeability 
in Cldn8-KO mice on day 3 post DSS, may represent a slight delay in the 
inflammatory process in Cldn8-KO mice as a result of slightly “stronger” mucous 
barrier. 
To investigate this possibility, permeability of the inner layer of mucous to bacteria 
was investigated, in naïve state as well as at 12 hours after exposure of the animals 
to DSS. However, in both points, the inner layer of mucous remained sterile in Cldn8-
KO and WT mice. DSS-induced colitis is significantly less severe in mice treated with 
antibiotics (281) or germ free mice (282,283). This, combined with evidence that DSS 
results in permeability of the inner layer of mucous to bacteria, is clear evidence of 
the invasion of luminal bacteria is an important, albeit not the sole, trigger for DSS-
induced colitis. Therefore, the findings that the inner layer of mucous remained sterile 
even in WT mice suggest that the duration of exposure of the mice to DSS was too 
short to show any discernible difference in mucous properties of the Cldn8-KO and 
WT mice. 
7.2.4 POTENTIAL ROLE OF CYTOKINES 
Evidence from these experiments suggest that there is an increase in serum 
concentration of IL-1b and IL-10 in serum of Cldn8-KO naïve mice. IL-10 has been 
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well established as an anti-inflammatory cytokine, and IL-10-KO mice have been 
known to spontaneously develop colitis (179,232). Treating IL-10-KO mice with 
normally sub-lethal doses of LPS can be fatal (308). Recent evidence suggests that 
the protective mechanism of IL-10 may be through its effect on maintaining Foxp3 
expression in Treg cells in inflammatory conditions (69). This may represent a 
mechanism of action for reduced susceptibility of Cldn8-KO mice to developing colitis 
secondary to DSS However, as described above, unfortunately, the set of FACS 
experiments investigating population of Treg cells did not produce any results. 
7.2.5 RECOVERY PERIOD 
Two further observations in this study are interesting, and would warrant further 
exploration. 
First, is the observation that there is rebound in expression levels of Cldn8 mRNA in 
the first few days after DSS-water has been stopped and the bowel is recovering. 
This is potentially important given the increasing evidence in the role of Cldns in cell 
motility, and their effect on intestinal morphology. For example, Cldn15 deficient mice 
are born and grow normally, but have an enlarged upper small intestinal phenotype, 
megaintestine (309). These Cldn15-KO mice showed enhanced proliferation of 
normal cryptic cells after weaning without diseased states such as polyps or cancer, 
resulting in megaintestine, in which the upper small intestine was approximately 2 
times larger than normal in length and diameter. 
Relatively little information in known about the role of Cldn8 in intestinal development. 
As shown in these studies, Cldn8-KO mice have normal intestinal appearances, both 
macroscopically and microscopically. 
However, Cldn8 has been associated with various malignancies, including prostate 
cancer (310), osteosarcomas (311,312), colorectal cancer (290,313,314). Apart from 
prostate cancer, where the expression of CLDN8 was found to be increased, in all 
other cancers, CLDN8 expression has been found to be downregulated.  
The findings that CLDN8 is downregulated in response to inflammation may, 
therefore, have a direct implication for human disease. As discussed in chapter 
1.2.3.3, patients with UC are at an increased risk of developing colorectal cancer 
(196,197). Over time, and with treatment, the risk has decreased and may be 
approaching that of the general population; however, certain populations are still at 
an increased risk of developing CRC, such as those with increased duration of 
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disease, involvement of longer colon segment, uncontrolled inflammation, and those 
with PSC (198,199). The reasons for this reduction in risk of developing CRC are not 
completely clear, and whist there is evidence that the bowel cancer screening 
program may be impacting cancer risk (200), the optimal surveillance period remains 
unclear. CLDN8 may, therefore, present an important opportunity for a marker for 
risk-stratification of patients with increased risk of developing colorectal cancer. 
Second, is the observation that for a short period after recovering from DSS-induced 
colitis, mice develop a relative resistance, and further challenges with DSS result in 
a significantly attenuated inflammatory response. This protection is lost after a short 
period. This is a potentially significant finding, which warrants further investigation. 
UC is a relapsing-remitting disease, with unpredictable flare-ups. A greater 
understanding of the potential protective mechanisms post-inflammation can 
potentially aid with better decisions on timing of initiation or escalation of therapy. In 
addition, clearer understanding of the intestine’s protective mechanisms may aid with 
development of novel therapies that can enhance the protective mechanisms and 
have a lower systemic side-effect profile compared to the strong immune-
suppressant agents currently used in treatment of UC. 
7.2.6 LIMITATIONS OF EXTRAPOLATING THE FINDINGS FROM MICE TO HUMANS 
CLDN8 mRNA expression is downregulated in response to inflammation in humans 
and mice. CLDN8 amino acid is also highly conserved between humans and mice. 
However, any conclusions drawn from mouse studies regarding human physiology 
and disease must be made cautiously due to limitations of animal models.  
The first cause for caution is that WT mice do not spontaneously develop colitis, and 
none of the models of colitis that have been developed in mice would be fully 
representative of human disease. Whilst the inflammatory pathways and processes 
overlap between the different models of mouse colitis, each model has a slightly 
different emphasis on different aspects of mouse physiology. Since the aetiology of 
IBD is still unknown, these varied mouse models of colitis are helpful in studying the 
varying possible mechanisms, from the effect of epithelial cells, to the role of innate 
or adaptive immune system. However, none perfectly mimics the human disease. In 
this study, DSS-induced colitis was chosen as the initial inflammatory model because 
of the evidence that DSS affects the permeability of the inner layer of mucous. DSS 
is also the only model that, similar to the pattern of disease in UC, results in a 
continuous colitis, whereas bacterial infection models produce a patchy colitis, which 
is more in keeping with CD. However, given the importance of bacterial invasion into 
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the inner layer of the mucous during UC, it would be worth performing experiments 
with C. rhodentium, which is an attaching and effacing (A/E) pathogen, and may also 
provide further insights into the mucous layer properties of Cldn8-KO mice, as it 
penetrates the mucous layer before reaching the epithelial cells. 
The second cause for caution in interpreting the results of investigations performed 
on mice is that whilst there are significant similarities between the mouse and human 
immunology, differences do exist, both systemically as well as in the intestine. For 
example, balance of lymphocytes and neutrophils in mice is quite different to 
humans; whereas human blood is neutrophil rich (50–70% neutrophils, 30 –50% 
lymphocytes), mouse blood is lymphocytes rich (75–90% lymphocytes, 10–25% 
neutrophils) (315). In addition, in humans, neutrophils are a rich source of leukocyte 
defensins, but defensins are not expressed by neutrophils in mice (316). 
7.3 CONCLUSION 
CLDN8 was identified as one of the genes with the most significant downregulation 
in expression on a transcriptomic analysis of patients with quiescent UC, raising the 
possibility that CLDN8 plays a fundamental role in intestinal inflammation. Loss of 
Cldn8 in Cldn8-KO mice results in a relative resistance to DSS-induced colitis. It is 
therefore plausible that downregulation of CLDN8 in patients with UC is a physiologic 
response by the intestine to increase local defences against luminal pathogens.  
7.4 FUTURE WORK 
Further work is now required to further ascertain the mechanism(s) by which Cldn8 
protects the intestine against inflammation. Also, additional work is necessary to 
better understand the protective mechanisms that exist for a short period of time after 
recovery from intestinal inflammation. 
7.4.1 PROPOSED STUDIES 
1- Study the effect of DSS on permeability of inner layer of mucous to luminal 
bacteria over a longer time course, allowing enough time for DSS to affect the 
permeability of mucous layer 
2- Study the Treg population in detail in Cldn8-KO mice, and its relation to IL-10 
3- Assess effect of loss of Cldn8 on cellular proliferation in the intestine using 
bromodeoxyuridine (BrdU) 
4- Detailed investigation of the effect of loss of Cldn8 on the renal physiology 
(whilst this is not directly related to intestinal inflammation, the Cldn8-KO 
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mouse would be an appropriate model to investigate the role of Cldn8 in renal 
homeostasis and pathophysiology) 
5- Using bacterial models of inflammation to assess the effect of loss of Cldn8 
on intestinal inflammation; in particular using C. rodentium to assess mucous 
layer properties in Cldn8-KO mice. 
6- Using cell lines, investigate the pathways controlling expression of CLDN8  
7- Produce an antibody to CLDN8 protein that is specific to more accurately 
assess the expression levels of CLDN8 than currently feasible with mRNA 
detection (this may not be feasible as CLDNs share significant portions of 
their amino acid sequence, and the main variations is in the EC1 and EC2 
and the intracellular C-terminus) 
8- Study effect of lack of Cldn8 on susceptibility of mice in developing CRC 
9- Investigate the transient protective mechanisms that result in an attenuated 
inflammatory response to repeat challenges of DSS shortly after recovery.  
7.4.2 HUMAN STUDIES 
Perform longitudinal studies in humans to measure variations in CLDN8 expression. 
This would help determine if patients can be stratified into more accurate risk groups 
for developing CRC.  
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9 Appendices  
 
APPENDIX 1 – LIST OF PRIMERS 
 
 
Primers used for Genotyping 
DNA266-28  5’-GTTGTGAGCACATTTCTACAGG 
DNA266-24  5’-GGATGGCTGTCATGAAAGCC 
GT ires  5’-CCCTAGGAATGCTCGTCAAGA 
 
 
Primers used for qRT-PCR 
Name Forward Primer Reverse Primer 
Cldn8 GACAGCCATCCTCGGAATGA  GCGGCTCTTCACGTTCTCA  
Lpo CCTCTGGTTCGAGGTCTGTT CCACAGAAAGCTCTCCAGGA 
Duox2 TCTGAACCTGCTCTCCTTGG CCTTGTCTACCTGCCCAGAA 
Cxadr CTGTCACAGGAAACGCAGAG CCAAGTCCCCAGTGAAGACT 
Ppia GGGCCGCGTCTCCTTT ATCCTTTCTCTCCAGTGCTCAGA 
Gapdh AAGGTCATCCCAGAGCTGAA CTGCTTCACCACCTTCTTGA 
 
 
EUB338 
Probe sequence (5′ to 3′) – GCTGCCTCCCGTAGGAGT - Cy5.5 conjugated 
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APPENDIX 2 – PUBLICATIONS 
PAPERS 
Provision of out-of-hours services for acute upper gastrointestinal bleeding in 
England: results of the 2014–2015 BSG/NHS England national survey, Frontline 
Gastroenterology Jan 2017, 8 (1) 8-12, Nedjat-Shokouhi B, Glynn M, Denton ERE, 
Greenfield SM (PMID: 28839878) 
Critical Role of the Disintegrin Metalloprotease ADAM-like Decysin-1 [ADAMDEC1] 
for Intestinal Immunity and Inflammation, O'Shea NR, Chew TS, Dunne J, Marnane 
R, Nedjat-Shokouhi B, Smith PJ, Bloom SL, Smith AM, Segal AW, J Crohns Colitis. 
2016 Dec;10(12):1417-1427. Epub 2016 May 25 (PMID: 27226416) 
The setting up and running of a cross-county out-of-hours gastrointestinal bleed 
service: a possible blueprint for the future, Shokouhi BN, Khan M, Carter M, et 
al, Frontline Gastroenterol. 2013 Jul;4(3):227-231 (“Editors Choice”), (PMID: 
28839729) 
BOOK CHAPTERS 
Gastroenterology and Hepatology, associate editor, Oxford Handbook of Acute 
Medicine, 4th edition, in print 
Lower GI and IBD associate editor, Oxford Handbook of Gastroenterology and 
Hepatology, 3rd edition, in progress 
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APPENDIX 3 – ORAL PRESENTATIONS 
 
2014 UCL PhD Seminars: Pathogenesis of Ulcerative Colitis: The role of 
Claudin-8 in epithelial barrier function and inflammation 
2014 UCLH lunch-time Gastroenterology seminar: Pathogenesis of 
Ulcerative Colitis: The role of Claudin-8 in epithelial barrier function 
and inflammation 
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APPENDIX 4 – COMMITTEE MEMBERSHIPS 
 
2013-2016 British Society of Gastroenterology: Trainee representative to IBD 
Committee 
2016 UCL Genetic Institute’s bioinformatics talk: Patient involvement in 
providing phenotype data – rewards and challenges 
2015 UCL Bright Ideas: judge for UCL Bright Ideas award 
2015 UCL Infection, Immunology and Inflammation Symposium: Poster 
judge 
2015 Digestive Disease Federation (DDF): Poster judge (IBD Section) 
 
